{ "documentInfo": { "documentType": "https://xbrl.org/2021/xbrl-json", "features": { "xbrl:canonicalValues": true }, "namespaces": { "ifrs-full": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "iso4217": "http://www.xbrl.org/2003/iso4217", "scheme": "http://standards.iso.org/iso/17442", "terveyst": "http://www.terveystalo.com", "xbrl": "https://xbrl.org/2021", "xbrli": "http://www.xbrl.org/2003/instance" }, "taxonomy": [ "http://www.terveystalo.com/7437001AEZHLL3UEX093-2025-12-31.xsd" ] }, "facts": { "fact-8": { "value": "1278900000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:Revenue", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00/2026-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-9": { "value": "1340000000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:Revenue", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2024-01-01T00:00:00/2025-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-10": { "value": "4000000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:OtherIncome", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00/2026-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-11": { "value": "3700000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:OtherIncome", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2024-01-01T00:00:00/2025-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-12": { "value": "509800000.0", "decimals": -5, "dimensions": { "concept": "terveyst:RawMaterialsAndConsumablesUsedAndServicesExpense", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00/2026-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-13": { "value": "549800000.0", "decimals": -5, "dimensions": { "concept": "terveyst:RawMaterialsAndConsumablesUsedAndServicesExpense", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2024-01-01T00:00:00/2025-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-14": { "value": "403500000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:EmployeeBenefitsExpense", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00/2026-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-15": { "value": "427800000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:EmployeeBenefitsExpense", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2024-01-01T00:00:00/2025-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-16": { "value": "100000000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00/2026-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-17": { "value": "106400000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2024-01-01T00:00:00/2025-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-18": { "value": "132100000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:OtherExpenseByNature", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00/2026-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-19": { "value": "143700000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:OtherExpenseByNature", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2024-01-01T00:00:00/2025-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-20": { "value": "137500000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:ProfitLossFromOperatingActivities", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00/2026-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-21": { "value": "116100000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:ProfitLossFromOperatingActivities", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2024-01-01T00:00:00/2025-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-22": { "value": "1800000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:FinanceIncome", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00/2026-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-23": { "value": "2100000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:FinanceIncome", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2024-01-01T00:00:00/2025-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-24": { "value": "23000000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:FinanceCosts", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00/2026-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-25": { "value": "28600000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:FinanceCosts", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2024-01-01T00:00:00/2025-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-26": { "value": "-21200000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:FinanceIncomeCost", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00/2026-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-27": { "value": "-26500000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:FinanceIncomeCost", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2024-01-01T00:00:00/2025-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-28": { "value": "-200000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:ShareOfProfitLossOfJointVenturesAccountedForUsingEquityMethod", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00/2026-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-29": { "value": "0.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:ShareOfProfitLossOfJointVenturesAccountedForUsingEquityMethod", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2024-01-01T00:00:00/2025-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-30": { "value": "116200000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:ProfitLossBeforeTax", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00/2026-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-31": { "value": "89600000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:ProfitLossBeforeTax", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2024-01-01T00:00:00/2025-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-32": { "value": "23500000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:IncomeTaxExpenseContinuingOperations", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00/2026-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-33": { "value": "18000000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:IncomeTaxExpenseContinuingOperations", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2024-01-01T00:00:00/2025-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-34": { "value": "92600000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:ProfitLoss", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00/2026-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-35": { "value": "71700000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:ProfitLoss", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2024-01-01T00:00:00/2025-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-36": { "value": "92600000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:ProfitLossAttributableToOwnersOfParent", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00/2026-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-37": { "value": "71700000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:ProfitLossAttributableToOwnersOfParent", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2024-01-01T00:00:00/2025-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-38": { "value": "3000000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00/2026-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-39": { "value": "-2000000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2024-01-01T00:00:00/2025-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-40": { "value": "0.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00/2026-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-41": { "value": "-100000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2024-01-01T00:00:00/2025-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-42": { "value": "3000000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:OtherComprehensiveIncome", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00/2026-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-43": { "value": "-2100000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:OtherComprehensiveIncome", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2024-01-01T00:00:00/2025-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-44": { "value": "95600000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:ComprehensiveIncome", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00/2026-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-45": { "value": "69600000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:ComprehensiveIncome", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2024-01-01T00:00:00/2025-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-46": { "value": "95600000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00/2026-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-47": { "value": "69600000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2024-01-01T00:00:00/2025-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-48": { "value": "0.73", "decimals": 2, "dimensions": { "concept": "ifrs-full:BasicEarningsLossPerShare", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00/2026-01-01T00:00:00", "unit": "iso4217:EUR/xbrli:shares" } }, "fact-49": { "value": "0.57", "decimals": 2, "dimensions": { "concept": "ifrs-full:BasicEarningsLossPerShare", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2024-01-01T00:00:00/2025-01-01T00:00:00", "unit": "iso4217:EUR/xbrli:shares" } }, "fact-50": { "value": "0.73", "decimals": 2, "dimensions": { "concept": "ifrs-full:DilutedEarningsLossPerShare", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00/2026-01-01T00:00:00", "unit": "iso4217:EUR/xbrli:shares" } }, "fact-51": { "value": "0.57", "decimals": 2, "dimensions": { "concept": "ifrs-full:DilutedEarningsLossPerShare", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2024-01-01T00:00:00/2025-01-01T00:00:00", "unit": "iso4217:EUR/xbrli:shares" } }, "fact-52": { "value": "96000000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:PropertyPlantAndEquipment", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2026-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-53": { "value": "87700000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:PropertyPlantAndEquipment", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-54": { "value": "189500000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:RightofuseAssets", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2026-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-55": { "value": "182700000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:RightofuseAssets", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-56": { "value": "838800000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:Goodwill", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2026-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-57": { "value": "829400000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:Goodwill", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-58": { "value": "80300000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:IntangibleAssetsOtherThanGoodwill", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2026-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-59": { "value": "82000000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:IntangibleAssetsOtherThanGoodwill", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-60": { "value": "200000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:InvestmentProperty", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2026-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-61": { "value": "300000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:InvestmentProperty", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-62": { "value": "7200000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:InvestmentAccountedForUsingEquityMethod", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2026-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-63": { "value": "0.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:InvestmentAccountedForUsingEquityMethod", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-64": { "value": "300000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:OtherNoncurrentReceivables", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2026-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-65": { "value": "300000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:OtherNoncurrentReceivables", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-66": { "value": "9300000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:DeferredTaxAssets", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2026-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-67": { "value": "7100000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:DeferredTaxAssets", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-68": { "value": "1700000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:OtherNoncurrentAssets", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2026-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-69": { "value": "700000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:OtherNoncurrentAssets", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-70": { "value": "1223400000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:NoncurrentAssets", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2026-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-71": { "value": "1190200000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:NoncurrentAssets", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-72": { "value": "7600000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:Inventories", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2026-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-73": { "value": "7200000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:Inventories", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-74": { "value": "124200000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:TradeAndOtherCurrentReceivables", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2026-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-75": { "value": "135000000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:TradeAndOtherCurrentReceivables", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-76": { "value": "700000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:CurrentTaxAssetsCurrent", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2026-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-77": { "value": "900000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:CurrentTaxAssetsCurrent", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-78": { "value": "75200000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:CashAndCashEquivalents", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2026-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-79": { "value": "65200000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:CashAndCashEquivalents", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-80": { "value": "207700000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2026-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-81": { "value": "208200000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-82": { "value": "10000000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2026-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-83": { "value": "0.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-84": { "value": "1441100000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:Assets", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2026-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-85": { "value": "1398400000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:Assets", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-86": { "value": "100000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:IssuedCapital", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2026-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-87": { "value": "100000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:IssuedCapital", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-88": { "value": "492800000.0", "decimals": -5, "dimensions": { "concept": "terveyst:ReserveForInvestedUnrestrictedEquity", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2026-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-89": { "value": "492800000.0", "decimals": -5, "dimensions": { "concept": "terveyst:ReserveForInvestedUnrestrictedEquity", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-90": { "value": "14800000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:TreasuryShares", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2026-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-91": { "value": "15200000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:TreasuryShares", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-92": { "value": "-4300000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:ReserveOfExchangeDifferencesOnTranslation", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2026-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-93": { "value": "-7300000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:ReserveOfExchangeDifferencesOnTranslation", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-94": { "value": "110400000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:RetainedEarnings", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2026-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-95": { "value": "77900000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:RetainedEarnings", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-96": { "value": "584200000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:EquityAttributableToOwnersOfParent", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2026-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-97": { "value": "548200000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:EquityAttributableToOwnersOfParent", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-98": { "value": "584200000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:Equity", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2026-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-99": { "value": "548200000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:Equity", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-100": { "value": "332300000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:LongtermBorrowings", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2026-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-101": { "value": "348500000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:LongtermBorrowings", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-102": { "value": "154300000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:NoncurrentLeaseLiabilities", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2026-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-103": { "value": "144500000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:NoncurrentLeaseLiabilities", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-104": { "value": "17600000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:DeferredTaxLiabilities", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2026-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-105": { "value": "18700000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:DeferredTaxLiabilities", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-106": { "value": "1600000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:NoncurrentProvisions", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2026-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-107": { "value": "3300000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:NoncurrentProvisions", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-108": { "value": "20400000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:NoncurrentPayables", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2026-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-109": { "value": "15500000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:NoncurrentPayables", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-110": { "value": "526200000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:NoncurrentLiabilities", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2026-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-111": { "value": "530500000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:NoncurrentLiabilities", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-112": { "value": "48800000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:ShorttermBorrowings", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2026-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-113": { "value": "29700000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:ShorttermBorrowings", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-114": { "value": "45400000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:CurrentLeaseLiabilities", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2026-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-115": { "value": "47300000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:CurrentLeaseLiabilities", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-116": { "value": "16500000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:CurrentTaxLiabilitiesCurrent", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2026-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-117": { "value": "9500000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:CurrentTaxLiabilitiesCurrent", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-118": { "value": "3100000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:CurrentProvisions", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2026-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-119": { "value": "2900000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:CurrentProvisions", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-120": { "value": "212400000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:TradeAndOtherCurrentPayables", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2026-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-121": { "value": "230300000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:TradeAndOtherCurrentPayables", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-122": { "value": "326200000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:CurrentLiabilitiesOtherThanLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2026-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-123": { "value": "319700000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:CurrentLiabilitiesOtherThanLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-124": { "value": "4600000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2026-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-125": { "value": "0.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-126": { "value": "856900000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:Liabilities", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2026-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-127": { "value": "850200000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:Liabilities", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-128": { "value": "1441100000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:EquityAndLiabilities", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2026-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-129": { "value": "1398400000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:EquityAndLiabilities", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-130": { "value": "116200000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:ProfitLossBeforeTax", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00/2026-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-131": { "value": "89600000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:ProfitLossBeforeTax", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2024-01-01T00:00:00/2025-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-132": { "value": "100000000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00/2026-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-133": { "value": "106400000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2024-01-01T00:00:00/2025-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-134": { "value": "-1300000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:AdjustmentsForProvisions", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00/2026-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-135": { "value": "100000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:AdjustmentsForProvisions", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2024-01-01T00:00:00/2025-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-136": { "value": "700000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:OtherAdjustmentsForNoncashItems", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00/2026-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-137": { "value": "-1500000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:OtherAdjustmentsForNoncashItems", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2024-01-01T00:00:00/2025-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-138": { "value": "-200000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00/2026-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-139": { "value": "-300000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2024-01-01T00:00:00/2025-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-140": { "value": "-21200000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:AdjustmentsForFinanceIncomeCost", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00/2026-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-141": { "value": "-26500000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:AdjustmentsForFinanceIncomeCost", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2024-01-01T00:00:00/2025-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-142": { "value": "8400000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00/2026-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-143": { "value": "4900000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2024-01-01T00:00:00/2025-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-144": { "value": "-400000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:AdjustmentsForDecreaseIncreaseInInventories", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00/2026-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-145": { "value": "-100000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:AdjustmentsForDecreaseIncreaseInInventories", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2024-01-01T00:00:00/2025-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-146": { "value": "-17700000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00/2026-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-147": { "value": "9600000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2024-01-01T00:00:00/2025-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-148": { "value": "500000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:InterestReceivedClassifiedAsOperatingActivities", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00/2026-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-149": { "value": "1000000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:InterestReceivedClassifiedAsOperatingActivities", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2024-01-01T00:00:00/2025-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-150": { "value": "20400000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00/2026-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-151": { "value": "12400000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2024-01-01T00:00:00/2025-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-152": { "value": "207000000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:CashFlowsFromUsedInOperatingActivities", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00/2026-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-153": { "value": "223700000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:CashFlowsFromUsedInOperatingActivities", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2024-01-01T00:00:00/2025-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-154": { "value": "30800000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00/2026-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-155": { "value": "27300000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2024-01-01T00:00:00/2025-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-156": { "value": "20800000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00/2026-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-157": { "value": "12300000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2024-01-01T00:00:00/2025-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-158": { "value": "600000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00/2026-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-159": { "value": "600000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2024-01-01T00:00:00/2025-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-160": { "value": "10700000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00/2026-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-161": { "value": "8400000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2024-01-01T00:00:00/2025-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-162": { "value": "100000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00/2026-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-163": { "value": "300000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2024-01-01T00:00:00/2025-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-164": { "value": "7000000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:OtherCashPaymentsToAcquireInterestsInJointVenturesClassifiedAsInvestingActivities", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00/2026-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-165": { "value": "0.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:OtherCashPaymentsToAcquireInterestsInJointVenturesClassifiedAsInvestingActivities", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2024-01-01T00:00:00/2025-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-166": { "value": "1000000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:OtherCashPaymentsToAcquireEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00/2026-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-167": { "value": "0.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:OtherCashPaymentsToAcquireEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2024-01-01T00:00:00/2025-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-168": { "value": "0.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00/2026-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-169": { "value": "300000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2024-01-01T00:00:00/2025-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-170": { "value": "0.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:DividendsReceivedClassifiedAsInvestingActivities", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00/2026-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-171": { "value": "0.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:DividendsReceivedClassifiedAsInvestingActivities", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2024-01-01T00:00:00/2025-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-172": { "value": "-69600000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:CashFlowsFromUsedInInvestingActivities", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00/2026-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-173": { "value": "-47400000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:CashFlowsFromUsedInInvestingActivities", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2024-01-01T00:00:00/2025-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-174": { "value": "0.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:ProceedsFromNoncurrentBorrowings", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00/2026-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-175": { "value": "200000000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:ProceedsFromNoncurrentBorrowings", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2024-01-01T00:00:00/2025-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-176": { "value": "-0.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:RepaymentsOfNoncurrentBorrowings", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00/2026-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-177": { "value": "145100000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:RepaymentsOfNoncurrentBorrowings", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2024-01-01T00:00:00/2025-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-178": { "value": "18100000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:ProceedsFromCurrentBorrowings", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00/2026-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-179": { "value": "9900000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:ProceedsFromCurrentBorrowings", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2024-01-01T00:00:00/2025-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-180": { "value": "15600000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:RepaymentsOfCurrentBorrowings", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00/2026-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-181": { "value": "100100000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:RepaymentsOfCurrentBorrowings", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2024-01-01T00:00:00/2025-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-182": { "value": "48800000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00/2026-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-183": { "value": "48400000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2024-01-01T00:00:00/2025-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-184": { "value": "0.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00/2026-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-185": { "value": "-3800000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2024-01-01T00:00:00/2025-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-186": { "value": "21100000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:InterestPaidClassifiedAsFinancingActivities", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00/2026-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-187": { "value": "23700000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:InterestPaidClassifiedAsFinancingActivities", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2024-01-01T00:00:00/2025-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-188": { "value": "1300000.0", "decimals": -5, "dimensions": { "concept": "terveyst:InterestReceivedClassifiedAsFinancingActivities", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00/2026-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-189": { "value": "300000.0", "decimals": -5, "dimensions": { "concept": "terveyst:InterestReceivedClassifiedAsFinancingActivities", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2024-01-01T00:00:00/2025-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-190": { "value": "60800000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:DividendsPaidClassifiedAsFinancingActivities", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00/2026-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-191": { "value": "38000000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:DividendsPaidClassifiedAsFinancingActivities", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2024-01-01T00:00:00/2025-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-192": { "value": "-126800000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:CashFlowsFromUsedInFinancingActivities", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00/2026-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-193": { "value": "-148800000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:CashFlowsFromUsedInFinancingActivities", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2024-01-01T00:00:00/2025-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-194": { "value": "10500000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:IncreaseDecreaseInCashAndCashEquivalents", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00/2026-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-195": { "value": "27500000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:IncreaseDecreaseInCashAndCashEquivalents", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2024-01-01T00:00:00/2025-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-196": { "value": "65200000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:CashAndCashEquivalents", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-197": { "value": "37700000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:CashAndCashEquivalents", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2024-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-198": { "value": "100000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00/2026-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-199": { "value": "-100000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2024-01-01T00:00:00/2025-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-200": { "value": "500000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:CashAndCashEquivalentsClassifiedAsPartOfDisposalGroupHeldForSale", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2026-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-201": { "value": "0.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:CashAndCashEquivalentsClassifiedAsPartOfDisposalGroupHeldForSale", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-202": { "value": "75200000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:CashAndCashEquivalents", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2026-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-203": { "value": "65200000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:CashAndCashEquivalents", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-204": { "value": "100000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:Equity", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:IssuedCapitalMember", "unit": "iso4217:EUR" } }, "fact-205": { "value": "492800000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:Equity", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "terveyst:ReserveForInvestedUnrestrictedEquityMember", "unit": "iso4217:EUR" } }, "fact-206": { "value": "-15200000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:Equity", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:TreasurySharesMember", "unit": "iso4217:EUR" } }, "fact-207": { "value": "77900000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:Equity", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:RetainedEarningsMember", "unit": "iso4217:EUR" } }, "fact-208": { "value": "-7300000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:Equity", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember", "unit": "iso4217:EUR" } }, "fact-209": { "value": "548200000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:Equity", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-210": { "value": "0.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:ProfitLoss", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00/2026-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:IssuedCapitalMember", "unit": "iso4217:EUR" } }, "fact-211": { "value": "0.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:ProfitLoss", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00/2026-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "terveyst:ReserveForInvestedUnrestrictedEquityMember", "unit": "iso4217:EUR" } }, "fact-212": { "value": "0.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:ProfitLoss", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00/2026-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:TreasurySharesMember", "unit": "iso4217:EUR" } }, "fact-213": { "value": "92600000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:ProfitLoss", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00/2026-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:RetainedEarningsMember", "unit": "iso4217:EUR" } }, "fact-214": { "value": "0.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:ProfitLoss", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00/2026-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember", "unit": "iso4217:EUR" } }, "fact-215": { "value": "92600000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:ProfitLoss", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00/2026-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-216": { "value": "0.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:OtherComprehensiveIncome", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00/2026-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:IssuedCapitalMember", "unit": "iso4217:EUR" } }, "fact-217": { "value": "0.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:OtherComprehensiveIncome", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00/2026-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "terveyst:ReserveForInvestedUnrestrictedEquityMember", "unit": "iso4217:EUR" } }, "fact-218": { "value": "0.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:OtherComprehensiveIncome", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00/2026-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:TreasurySharesMember", "unit": "iso4217:EUR" } }, "fact-219": { "value": "0.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:OtherComprehensiveIncome", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00/2026-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:RetainedEarningsMember", "unit": "iso4217:EUR" } }, "fact-220": { "value": "3000000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:OtherComprehensiveIncome", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00/2026-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember", "unit": "iso4217:EUR" } }, "fact-221": { "value": "3000000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:OtherComprehensiveIncome", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00/2026-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-222": { "value": "0.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:DividendsPaid", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00/2026-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:IssuedCapitalMember", "unit": "iso4217:EUR" } }, "fact-223": { "value": "0.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:DividendsPaid", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00/2026-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "terveyst:ReserveForInvestedUnrestrictedEquityMember", "unit": "iso4217:EUR" } }, "fact-224": { "value": "0.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:DividendsPaid", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00/2026-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:TreasurySharesMember", "unit": "iso4217:EUR" } }, "fact-225": { "value": "60800000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:DividendsPaid", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00/2026-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:RetainedEarningsMember", "unit": "iso4217:EUR" } }, "fact-226": { "value": "0.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:DividendsPaid", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00/2026-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember", "unit": "iso4217:EUR" } }, "fact-227": { "value": "60800000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:DividendsPaid", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00/2026-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-228": { "value": "0.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00/2026-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:IssuedCapitalMember", "unit": "iso4217:EUR" } }, "fact-229": { "value": "0.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00/2026-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "terveyst:ReserveForInvestedUnrestrictedEquityMember", "unit": "iso4217:EUR" } }, "fact-230": { "value": "500000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00/2026-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:TreasurySharesMember", "unit": "iso4217:EUR" } }, "fact-231": { "value": "700000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00/2026-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:RetainedEarningsMember", "unit": "iso4217:EUR" } }, "fact-232": { "value": "0.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00/2026-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember", "unit": "iso4217:EUR" } }, "fact-233": { "value": "1100000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00/2026-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-234": { "value": "100000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:Equity", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2026-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:IssuedCapitalMember", "unit": "iso4217:EUR" } }, "fact-235": { "value": "492800000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:Equity", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2026-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "terveyst:ReserveForInvestedUnrestrictedEquityMember", "unit": "iso4217:EUR" } }, "fact-236": { "value": "-14800000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:Equity", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2026-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:TreasurySharesMember", "unit": "iso4217:EUR" } }, "fact-237": { "value": "110400000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:Equity", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2026-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:RetainedEarningsMember", "unit": "iso4217:EUR" } }, "fact-238": { "value": "-4300000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:Equity", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2026-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember", "unit": "iso4217:EUR" } }, "fact-239": { "value": "584200000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:Equity", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2026-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-240": { "value": "100000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:Equity", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2024-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:IssuedCapitalMember", "unit": "iso4217:EUR" } }, "fact-241": { "value": "492800000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:Equity", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2024-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "terveyst:ReserveForInvestedUnrestrictedEquityMember", "unit": "iso4217:EUR" } }, "fact-242": { "value": "-15700000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:Equity", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2024-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:TreasurySharesMember", "unit": "iso4217:EUR" } }, "fact-243": { "value": "43500000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:Equity", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2024-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:RetainedEarningsMember", "unit": "iso4217:EUR" } }, "fact-244": { "value": "-5200000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:Equity", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2024-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember", "unit": "iso4217:EUR" } }, "fact-245": { "value": "515400000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:Equity", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2024-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-246": { "value": "0.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:ProfitLoss", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2024-01-01T00:00:00/2025-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:IssuedCapitalMember", "unit": "iso4217:EUR" } }, "fact-247": { "value": "0.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:ProfitLoss", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2024-01-01T00:00:00/2025-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "terveyst:ReserveForInvestedUnrestrictedEquityMember", "unit": "iso4217:EUR" } }, "fact-248": { "value": "0.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:ProfitLoss", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2024-01-01T00:00:00/2025-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:TreasurySharesMember", "unit": "iso4217:EUR" } }, "fact-249": { "value": "71700000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:ProfitLoss", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2024-01-01T00:00:00/2025-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:RetainedEarningsMember", "unit": "iso4217:EUR" } }, "fact-250": { "value": "0.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:ProfitLoss", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2024-01-01T00:00:00/2025-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember", "unit": "iso4217:EUR" } }, "fact-251": { "value": "71700000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:ProfitLoss", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2024-01-01T00:00:00/2025-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-252": { "value": "0.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:OtherComprehensiveIncome", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2024-01-01T00:00:00/2025-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:IssuedCapitalMember", "unit": "iso4217:EUR" } }, "fact-253": { "value": "0.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:OtherComprehensiveIncome", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2024-01-01T00:00:00/2025-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "terveyst:ReserveForInvestedUnrestrictedEquityMember", "unit": "iso4217:EUR" } }, "fact-254": { "value": "0.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:OtherComprehensiveIncome", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2024-01-01T00:00:00/2025-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:TreasurySharesMember", "unit": "iso4217:EUR" } }, "fact-255": { "value": "-100000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:OtherComprehensiveIncome", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2024-01-01T00:00:00/2025-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:RetainedEarningsMember", "unit": "iso4217:EUR" } }, "fact-256": { "value": "-2000000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:OtherComprehensiveIncome", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2024-01-01T00:00:00/2025-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember", "unit": "iso4217:EUR" } }, "fact-257": { "value": "-2100000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:OtherComprehensiveIncome", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2024-01-01T00:00:00/2025-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-258": { "value": "-0.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:DividendsPaid", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2024-01-01T00:00:00/2025-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:IssuedCapitalMember", "unit": "iso4217:EUR" } }, "fact-259": { "value": "-0.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:DividendsPaid", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2024-01-01T00:00:00/2025-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "terveyst:ReserveForInvestedUnrestrictedEquityMember", "unit": "iso4217:EUR" } }, "fact-260": { "value": "0.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:DividendsPaid", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2024-01-01T00:00:00/2025-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:TreasurySharesMember", "unit": "iso4217:EUR" } }, "fact-261": { "value": "38000000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:DividendsPaid", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2024-01-01T00:00:00/2025-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:RetainedEarningsMember", "unit": "iso4217:EUR" } }, "fact-262": { "value": "0.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:DividendsPaid", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2024-01-01T00:00:00/2025-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember", "unit": "iso4217:EUR" } }, "fact-263": { "value": "38000000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:DividendsPaid", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2024-01-01T00:00:00/2025-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-264": { "value": "0.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2024-01-01T00:00:00/2025-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:IssuedCapitalMember", "unit": "iso4217:EUR" } }, "fact-265": { "value": "0.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2024-01-01T00:00:00/2025-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "terveyst:ReserveForInvestedUnrestrictedEquityMember", "unit": "iso4217:EUR" } }, "fact-266": { "value": "400000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2024-01-01T00:00:00/2025-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:TreasurySharesMember", "unit": "iso4217:EUR" } }, "fact-267": { "value": "800000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2024-01-01T00:00:00/2025-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:RetainedEarningsMember", "unit": "iso4217:EUR" } }, "fact-268": { "value": "0.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2024-01-01T00:00:00/2025-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember", "unit": "iso4217:EUR" } }, "fact-269": { "value": "1200000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2024-01-01T00:00:00/2025-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-270": { "value": "100000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:Equity", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:IssuedCapitalMember", "unit": "iso4217:EUR" } }, "fact-271": { "value": "492800000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:Equity", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "terveyst:ReserveForInvestedUnrestrictedEquityMember", "unit": "iso4217:EUR" } }, "fact-272": { "value": "-15200000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:Equity", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:TreasurySharesMember", "unit": "iso4217:EUR" } }, "fact-273": { "value": "77900000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:Equity", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:RetainedEarningsMember", "unit": "iso4217:EUR" } }, "fact-274": { "value": "-7300000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:Equity", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember", "unit": "iso4217:EUR" } }, "fact-275": { "value": "548200000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:Equity", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-2": { "value": "Terveystalo Oyj", "dimensions": { "concept": "ifrs-full:NameOfReportingEntityOrOtherMeansOfIdentification", "language": "en", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00/2026-01-01T00:00:00" } }, "fact-3": { "value": "Finland", "dimensions": { "concept": "ifrs-full:CountryOfIncorporation", "language": "en", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00/2026-01-01T00:00:00" } }, "fact-4": { "value": "Plc", "dimensions": { "concept": "ifrs-full:LegalFormOfEntity", "language": "en", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00/2026-01-01T00:00:00" } }, "fact-5": { "value": "Finland", "dimensions": { "concept": "ifrs-full:DomicileOfEntity", "language": "en", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00/2026-01-01T00:00:00" } }, "fact-1": { "value": "Jaakonkatu 3 A 00100 Helsink", "dimensions": { "concept": "ifrs-full:AddressOfRegisteredOfficeOfEntity", "language": "en", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00/2026-01-01T00:00:00" } }, "fact-6": { "value": "Terveystalo offers comprehensive wellbeing services, primary healthcare and specialized medical care services for corporate and private customers as well as the public sector.", "dimensions": { "concept": "ifrs-full:DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities", "language": "en", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00/2026-01-01T00:00:00" } }, "fact-7": { "value": "Terveystalo Oyj", "dimensions": { "concept": "ifrs-full:NameOfParentEntity", "language": "en", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00/2026-01-01T00:00:00" } }, "fact-276": { "value": "1. Corporate information Terveystalo Plc is a Finnish public limited liability company organised under the laws of Finland and domiciled in Helsinki, Finland. The parent company, Terveystalo Plc, is listed on the Nasdaq Helsinki. Terveystalo Group (\u201cthe Group\u201d, \u201cTerveystalo\u201d) consists of the parent company and 25 subsidiaries. More information on subsidiaries is presented in note 31. A copy of the consolidated financial statements is available at the Group\u2019s website www.terveystalo.com, from Terveystalo Oyj / Corporate Communications, Jaakonkatu 3, 00100 Helsinki, Finland, or via e-mail at investors@terveystalo.com. Terveystalo is a leading private healthcare service provider in Finland and leading occupational health provider in the Nordic region. The company offers general practice and specialist medical care, diagnostic services, outpatient surgery, dental services and other adjacent services to corporate, private and public sector customers. In its meeting on 26 February 2026, the Board of Directors of Terveystalo Plc approved the publishing of these consolidated financial statements. According to the Finnish Limited Liability Companies Act, shareholders have the right to approve or reject the financial statements in the Annual General Meeting held after the publication of the financial statements. The Annual General Meeting also has the right to make a decision to amend the financial statements.", "dimensions": { "concept": "ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory", "language": "en", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00/2026-01-01T00:00:00" } }, "fact-277": { "value": "
In its meeting on 26 February 2026, the Board of Directors of Terveystalo Plc approved the publishing of
these consolidated financial statements.
", "dimensions": { "concept": "ifrs-full:DisclosureOfAuthorisationOfFinancialStatementsExplanatory", "language": "en", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00/2026-01-01T00:00:00" } }, "fact-278": { "value": "2. Accounting policies for the consolidated financial statements 2.1 Basis of preparation The consolidated financial statements of Terveystalo have been prepared in accordance with International Financial Reporting Standards (IFRS) as adopted by the European Union. The consolidated financial statements have been prepared in compliance with the IAS and IFRS standards as well as the SIC and IFRIC interpretations in force on 31 December 2025. The consolidated financial statements also comply with the regulations of Finnish accounting and company legislation complementing the IFRSs. The consolidated financial statements are presented in millions of euro and have been prepared under the historical cost basis, unless otherwise stated in the accounting principles. All figures presented have been rounded, and consequently the sum of individual figures may deviate from the presented aggregate figure. 2.4 Principles of consolidation Subsidiaries The consolidated financial statements include the parent company Terveystalo Plc and all its subsidiaries where over 50 percent of the voting rights are controlled by the parent company, or the parent company otherwise controls the company. The Group controls an entity when it is exposed to, or has rights to variable returns from its involvement with the entity, and has the ability to affect those returns through its power over the entity. The subsidiaries are included in the consolidated financial statements starting from the date on which control commences until the date on which control ceases. All subsidiaries are consolidated by using the acquisition method. The consideration transferred for the acquisition of a subsidiary comprise assets transferred, liabilities incurred, and the equity interests issued by the Group measured at fair value. Identifiable assets acquired and liabilities and contingent liabilities assumed in a business combination are measured initially at fair value at the acquisition date. On an acquisition by acquisition basis, non-controlling interest in the acquiree is measured either at fair value or at value which equals the proportional share of the non-controlling interest in the identifiable net assets acquired. All acquisition costs, except costs related to issue of debt or equity securities, are recognised as an expense as incurred. Transactions treated separately from the acquisition are recognised through the income statement and are not included in the consideration transferred. Any contingent consideration is measured at fair value, and it is classified either as a liability or equity. Contingent consideration classified as a liability is measured at fair value at the end of reporting period and the resulting profit or loss is recognised in the statement of income. Contingent consideration classified as equity is not remeasured. If the Group gains control in stages in the acquiree, the existing interest will be measured at fair value through profit or loss. Goodwill arising from an acquisition is recognised as the excess of the aggregate of the consideration transferred, the amount of non controlling interests in the acquiree and previously held equity interest in the acquiree over the fair value of the Group\u2019s share of the identifiable net assets acquired. If the consideration transferred is less than the fair value of the net assets of the subsidiary acquired, the resulting gain is recognised in profit or loss. Intra group transactions, receivables, liabilities and unrealised gains, as well as the distribution of profits within the Group are eliminated in the preparation of the consolidated financial statements. Accounting policies of subsidiaries have been aligned where necessary to correspond to the Group\u2019s principles. Transactions with non-controlling interests that do not result in the loss of control are treated as equity transactions \u2013 in other words, as transactions with owners when they are acting as owners. The difference between the fair value of the consideration paid or received and the book value of the portion of the net assets acquired or disposed is recognised in equity. When the Group ceases to have control or significant influence, any retained interest in the entity is measured at fair value through profit or loss. Associates and joint ventures Associates are entities over which the Group has significant influence. Significant influence generally arises when the Group holds over 20 percent of the voting rights, or otherwise has significant influence, but no control over the entity. Joint ventures are classified as companies in which the Group has joint control with one or more parties. Joint control exists when decisions regarding relevant activities require the approval of all parties. In making the classification, management assesses the actual nature of the arrangement as well as the contractual rights and obligations. Associates and joint ventures are consolidated using the equity method. They are initially recognised at cost, which includes transaction cost. If the Group\u2019s share of losses in associates and joint ventures exceeds the carrying amount of the investment, the investment is recognised at zero value in the consolidated statement of financial position. Recognition of further losses exceeding the carrying amount is discontinued, unless the Group has incurred legal or constructive obligations on behalf of the associate or joint venture. Unrealised gains resulting from the transactions between the Group and associates and joint ventures are eliminated according to the Group\u2019s share of ownership. Goodwill relating to an associate or joint venture is included in the carrying amount of the investment. The Group\u2019s share of the associates\u2019 and joint ventures\u2019 profit or loss for the period is separately disclosed below net finance expenses. Adjustments have been made when necessary to the associate\u2019s or joint venture\u2019s accounting policies to align to those of the Group. At each reporting date, the Group reviews the carrying amounts of the investments in associates and joint ventures to determine whether there is any objective indication of impairment. If any such evidence of impairment exists, then the impairment loss is determined. An impairment loss is the amount by which the carrying amount of an investment in associate or joint ventures exceeds its recoverable amount. An impairment loss is recognised in the statement of income. If the Group\u2019s ownership interest in an associate or joint venture is reduced, but significant influence is retained, only the relative portion of previously recognised amounts in other comprehensive income and the value of the investment in the consolidated financial statements are recognised in the statement of income as part of the gain or loss. ", "dimensions": { "concept": "ifrs-full:DisclosureOfBasisOfConsolidationExplanatory", "language": "en", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00/2026-01-01T00:00:00" } }, "fact-279": { "value": "The consolidated financial statements of Terveystalo have been prepared in accordance with International Financial Reporting Standards (IFRS) as adopted by the European Union. The consolidated financial statements have been prepared in compliance with the IAS and IFRS standards as well as the SIC and IFRIC interpretations in force on 31 December 2025.", "dimensions": { "concept": "ifrs-full:StatementOfIFRSCompliance", "language": "en", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00/2026-01-01T00:00:00" } }, "fact-280": { "value": "2.2 Application of new and amended IFRSs and new IFRIC agenda decisions New and amended standards applied in the financial year 2025 The Group has applied as from 1 January 2025 the following new and amended standards that have come into effect: \u2022 Amendments to IAS 21 \u2013 Lack of Exchangeability: The amendments require to apply a consistent approach in assessing whether a currency can be exchanged into another currency and, when it cannot, in determining the exchange rate to use and the disclosures to provide. The above-mentioned amendment has no impact on Terveystalo\u2019s consolidated financial statements. Adoption of new and amended standards and interpretations applicable in future financial years At the publication day of this Group consolidated financial statements, Terveystalo has not applied the following new and amended standards and interpretations that are effective in future periods: \u2022 IFRS 18 Presentation and Disclosure in Financial Statements* (effective for financial years beginning on or after 1 January 2027, early application is permitted). IFRS 18 will replace IAS 1 Presentation of Financial Statements. The key new requirements are as follows: \u2022 Income and expenses in the income statement to be classified into three new defined categories\u2014operating, investing and financing\u2013and two new subtotals\u2013 \u201cOperating profit or loss\u201d and \u201cProfit or loss before financing and income tax\u201d. \u2022 Disclosures about management-defined performance measures (MPMs) in the financial statements. MPMs are subtotals of income and expenses used in public communications to communicate management\u2019s view of the company\u2019s financial performance. \u2022 Disclosure of information based on enhanced general requirements on aggregation and disaggregation. In addition, specific requirements to disaggregate certain expenses in the notes will be required for companies that present operating expenses by function in the income statement. Terveystalo has started a preliminary assessment of the impacts on its consolidated financial statements. The most significant impact identified is that Terveystalo will classify income and expenses into new categories in income statement. In addition, management-defined performance measures will be disclosed in the notes New and amended standards and interpretations applicable in future financial years that are not expected to have significant impact on Terveystalo\u2019s consolidated financial statements: \u2022 Amendments to IFRS 9 and IFRS 7 \u2013 Classification and Measurement of Financial Instruments (effective for financial years beginning on or after 1 January 2026, early application is permitted) \u2022 Annual Improvements to IFRS Accounting Standards\u2014Volume 11 (effective for financial years beginning on or after 1 January 2026, early application is permitted) \u2022 Amendments to IFRS 9 and IFRS 7 \u2013 Contracts Referencing Nature-dependent Electricity (effective for financial years beginning on or after 1 January 2026, early application is permitted) \u2022 Amendments to IFRS 10 and IAS 28 \u2013 Sale or Contribution of Assets between an Investor and its Associate or Joint Venture* (available for optional adoption, effective date deferred indefinitely) New and amended standards and interpretations applicable in future financial years that are not expected to have impact on Terveystalo\u2019s consolidated financial statements: \u2022 IFRS 19 Subsidiaries without Public Accountability: Disclosures* (effective for financial years beginning on or after 1 January 2027, early application is permitted) \u2022 Amendments to IAS 21 \u2013 Translation to a Hyperinflationary Presentation Currency* (effective for financial years beginning on or after 1 January 2027) * Not yet endorsed for use by the European Union as of 31 December 2025. ", "dimensions": { "concept": "ifrs-full:DisclosureOfChangesInAccountingPoliciesExplanatory", "language": "en", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00/2026-01-01T00:00:00" } }, "fact-281": { "value": "2.3 Critical accounting estimates and judgements The preparation of the financial statements requires management to make certain estimates and assumptions that are based on management's best view of the circumstances prevailing on the reporting date, prior experience and assumptions about future events related, among other things, to the expected development of the Group's economic environment in terms of sales and cost level. However, it is possible that the realised outcomes differ from the estimates and assumptions used in the financial statements. In addition, the application of the accounting policies requires judgement, especially when the current IFRS standards have alternative accounting, valuation and presentation methods. The Group monitors the realisation of the estimates and assumptions and changes in the underlying factors on a regular basis together with the operating units by using several internal and external information sources. Changes in estimates or assumptions are recognised in the period when the estimate or assumption is revised, and in the future periods if the change affects the subsequent periods. The most important issues requiring management\u2019s judgement are presented below: Lease contracts Terveystalo\u2019s lease contracts include both termination and extension options. The Group uses the options in managing lease contracts to ensure the flexible use of premises in the Group\u2019s businesses. Management uses judgement to determine the use of termination and extension options and assesses the lease termination dates and lease terms. Based on management\u2019s judgement, the termination options which relate to perpetual lease contracts for premises that are significant will not be used and such lease contracts are recognised as long-term lease contracts. The critical accounting estimates are presented below: Provisions The most significant provisions in the statement of financial position relate mainly to loss-making contracts. Management makes estimates mainly concerning the total loss of the loss-making contracts. Intangible assets in connection with business combinations IFRS 3 requires the acquirer to recognise intangible assets separately from goodwill, if certain criteria are met. Recognising intangible assets separately at fair value requires management to estimate the expected future cash flows. Management has used available market information, when possible, in determining the fair values. If no market information of the asset has been available, the measurement of the intangible asset is based on the historical yield of the asset and the planned use in operations. The valuations are based on discounted cash flows and estimated disposal or replacement prices, and the valuation requires management to make estimates of the future use of the asset and impact on the company\u2019s financial position. Management believes that the used estimates and assumptions are reasonable for measurement of fair values. In addition, the Group\u2019s property, plant and equipment and intangible assets are assessed to determine whether there is any indication of impairment at least at each reporting date. The valuation of contingent considerations Management makes discretionary decisions and estimates when determining the valuation of deferred contingent considerations in business combinations. Judgement is applied especially when estimating the expected amount of payments and is based on potential scenarios for future returns, amounts paid under different scenarios and the probability of each scenario. Impairment testing Impairment testing for cash-generating units to which goodwill has been allocated is carried out at least annually. The recoverable amounts of cash generating units are estimated based on the calculations of their value in use. Preparation of these calculations requires use of estimates. Even though management believes that the used estimates and assumptions are appropriate, the estimated recoverable amounts may differ from the actual results.", "dimensions": { "concept": "ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory", "language": "en", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00/2026-01-01T00:00:00" } }, "fact-282": { "value": "
Subsidiaries
The consolidated financial statements include the parent company Terveystalo Plc and all its subsidiaries where
over 50 percent of the voting rights are controlled by the parent company, or the parent company otherwise
controls the company. The Group controls an entity when it is exposed to, or has rights to variable returns from
its involvement with the entity, and has the ability to affect those returns through its power over the entity.
The subsidiaries are included in the consolidated financial statements starting from the date on which control
commences until the date on which control ceases.
All subsidiaries are consolidated by using the acquisition method. The consideration transferred for the
acquisition of a subsidiary comprise assets transferred, liabilities incurred, and the equity interests issued by the
Group measured at fair value. Identifiable assets acquired and liabilities and contingent liabilities assumed in a
business combination are measured initially at fair value at the acquisition date. On an acquisition by acquisition
basis, non-controlling interest in the acquiree is measured either at fair value or at value which equals the
proportional share of the non-controlling interest in the identifiable net assets acquired.
All acquisition costs, except costs related to issue of debt or equity securities, are recognised as an expense
as incurred. Transactions treated separately from the acquisition are recognised through the income statement
and are not included in the consideration transferred. Any contingent consideration is measured at fair value,
and it is classified either as a liability or equity. Contingent consideration classified as a liability is measured at
fair value at the end of reporting period and the resulting profit or loss is recognised in the statement of income.
Contingent consideration classified as equity is not remeasured.
If the Group gains control in stages in the acquiree, the existing interest will be measured at fair value through
profit or loss.
Goodwill arising from an acquisition is recognised as the excess of the aggregate of the consideration
transferred, the amount of non controlling interests in the acquiree and previously held equity interest in the
acquiree over the fair value of the Group\u2019s share of the identifiable net assets acquired. If the consideration
transferred is less than the fair value of the net assets of the subsidiary acquired, the resulting gain is recognised
in profit or loss.
Intra group transactions, receivables, liabilities and unrealised gains, as well as the distribution of profits within the
Group are eliminated in the preparation of the consolidated financial statements. Accounting policies of subsidiaries
have been aligned where necessary to correspond to the Group\u2019s principles.
Transactions with non-controlling interests that do not result in the loss of control are treated as equity transactions
\u2013 in other words, as transactions with owners when they are acting as owners. The difference between the fair value
of the consideration paid or received and the book value of the portion of the net assets acquired or disposed is
recognised in equity.
When the Group ceases to have control or significant influence, any retained interest in the entity is measured at fair
value through profit or loss.
", "dimensions": { "concept": "ifrs-full:DescriptionOfAccountingPolicyForSubsidiariesExplanatory", "language": "en", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00/2026-01-01T00:00:00" } }, "fact-283": { "value": "
Associates and joint ventures
Associates are entities over which the Group has significant influence. Significant influence generally arises when the
Group holds over 20 percent of the voting rights, or otherwise has significant influence, but no control over the entity.
Joint ventures are classified as companies in which the Group has joint control with one or more parties. Joint control
exists when decisions regarding relevant activities require the approval of all parties. In making the classification,
management assesses the actual nature of the arrangement as well as the contractual rights and obligations.
Associates and joint ventures are consolidated using the equity method. They are initially recognised at cost, which
includes transaction cost. If the Group\u2019s share of losses in associates and joint ventures exceeds the carrying amount
of the investment, the investment is recognised at zero value in the consolidated statement of financial position.
Recognition of further losses exceeding the carrying amount is discontinued, unless the Group has incurred legal or
constructive obligations on behalf of the associate or joint venture.
Unrealised gains resulting from the transactions between the Group and associates and joint ventures are eliminated
according to the Group\u2019s share of ownership. Goodwill relating to an associate or joint venture is included in the
carrying amount of the investment. The Group\u2019s share of the associates\u2019 and joint ventures\u2019 profit or loss for the period
is separately disclosed below net finance expenses. Adjustments have been made when necessary to the associate\u2019s or
joint venture\u2019s accounting policies to align to those of the Group.
At each reporting date, the Group reviews the carrying amounts of the investments in associates and joint ventures
to determine whether there is any objective indication of impairment. If any such evidence of impairment exists, then
the impairment loss is determined. An impairment loss is the amount by which the carrying amount of an investment
in associate or joint ventures exceeds its recoverable amount. An impairment loss is recognised in the statement
of income.
If the Group\u2019s ownership interest in an associate or joint venture is reduced, but significant influence is retained, only
the relative portion of previously recognised amounts in other comprehensive income and the value of the investment
in the consolidated financial statements are recognised in the statement of income as part of the gain or loss.
", "dimensions": { "concept": "ifrs-full:DescriptionOfAccountingPolicyForInvestmentInAssociatesAndJointVenturesExplanatory", "language": "en", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00/2026-01-01T00:00:00" } }, "fact-284": { "value": "2.5 Foreign currency transactions The consolidated financial statements are presented in euro which is the functional and presentation currency of the parent company. Transactions in foreign currencies are translated into respective functional currency at the exchange rate prevailing on the transaction date. Gains and losses arising from transactions denominated in foreign currency and from translation of monetary items are recognised in profit or loss as financial income or expenses. The functional currency of the Feelgood subgroup is Swedish krona which differs from Group\u2019s presentation currency, and thus its statement of income, statement of cash flows and statement of financial position have been translated into presentation currency as follows: \u2022 Statement of income and statement of cashflows are translated at average exchange rates. \u2022 Statement of financial position is translated at the closing exchange rate at the reporting date. \u2022 All resulting exchange differences are recognised in other comprehensive income.", "dimensions": { "concept": "ifrs-full:DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory", "language": "en", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00/2026-01-01T00:00:00" } }, "fact-285": { "value": "2.6 Property, plant and equipment Items of property, plant and equipment are measured at cost less accumulated depreciation and impairment losses. Depreciation is recognised on a straight-line basis over the estimated useful lives of items of property, plant and equipment. Land is not depreciated. The estimated useful lives are as follows: Magnetic resonance imaging equipment 10 years Buildings 10\u201340 years Machinery and equipment 3\u20137 years Improvements to office premises 3\u201310 years Premises used in operations are depreciated on a straight line basis over a 40 year depreciation period. Property, plant and equipment also includes artwork which is not depreciated. Gains and losses on the sale and disposal of property, plant and equipment are presented in other operating income or other operating expenses. Maintenance expenditure is not included in the carrying amounts of property, plant and equipment. When parts of the magnetic resonance imaging equipment are replaced, the Group capitalises the replacement costs as a separate item. The residual values and useful lives of property, plant and equipment are reviewed at each reporting date Intangible assets are measured at cost and amortised on a straight line basis over the known or estimated useful lives. Amortisation periods used for intangible assets are as follows Immaterial rights 3\u20137 years Software 3\u20135 years Customer agreements and related customer relationships 3\u201312 years Trademarks 20 years or shorter useful life Other intangible assets 3\u20135 years ", "dimensions": { "concept": "ifrs-full:DescriptionOfAccountingPolicyForDepreciationExpenseExplanatory", "language": "en", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00/2026-01-01T00:00:00" } }, "fact-286": { "value": "2.6 Property, plant and equipment Items of property, plant and equipment are measured at cost less accumulated depreciation and impairment losses. Depreciation is recognised on a straight-line basis over the estimated useful lives of items of property, plant and equipment. Land is not depreciated. The estimated useful lives are as follows: Magnetic resonance imaging equipment 10 years Buildings 10\u201340 years Machinery and equipment 3\u20137 years Improvements to office premises 3\u201310 years Premises used in operations are depreciated on a straight line basis over a 40 year depreciation period. Property, plant and equipment also includes artwork which is not depreciated. Gains and losses on the sale and disposal of property, plant and equipment are presented in other operating income or other operating expenses. Maintenance expenditure is not included in the carrying amounts of property, plant and equipment. When parts of the magnetic resonance imaging equipment are replaced, the Group capitalises the replacement costs as a separate item. The residual values and useful lives of property, plant and equipment are reviewed at each reporting date .", "dimensions": { "concept": "ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory", "language": "en", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00/2026-01-01T00:00:00" } }, "fact-287": { "value": "2.7 Investment properties Investment property refers to properties held by the Group in order to earn rental income or for capital appreciation or both. Apartments, which are not used in business operations, are mainly accounted for as investment properties. Investment properties are measured at acquisition cost and depreciated on a straight-line basis over a 40-year depreciation period.", "dimensions": { "concept": "ifrs-full:DescriptionOfAccountingPolicyForInvestmentPropertyExplanatory", "language": "en", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00/2026-01-01T00:00:00" } }, "fact-288": { "value": "2.8 Goodwill and intangible assets Goodwill Goodwill arising in a business combination is recognised as the excess of the aggregate of the consideration transferred, the amount of non controlling interests in the acquiree and previously held equity interest in acquiree over the fair value of the Group\u2019s share of the identifiable net assets acquired. Goodwill is not amortised but tested for impairment annually. For impairment testing, goodwill is allocated to cash generating units or groups of cash generating units. Goodwill is measured at cost less accumulated impairment losses. An impairment loss in respect of goodwill is not reversed. Gain or loss on a disposed unit includes also the carrying amount of goodwill.", "dimensions": { "concept": "ifrs-full:DescriptionOfAccountingPolicyForGoodwillExplanatory", "language": "en", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00/2026-01-01T00:00:00" } }, "fact-289": { "value": "
Intangible assets
Intangible assets include software and licenses, as well as acquired companies\u2019 customer relationships, trademarks
and other intangible assets. Intangible assets are recognised initially at cost if the cost of the asset can be measured
reliably and if it is probable that the future economic benefits attributable to the asset will flow to the Group.
Cloud computing arrangements which meet the definition of an intangible asset are recognised as intangible
assets. Configuration and customisation costs which do not meet the definition of an intangible asset, and which
are distinct from the cloud computing arrangement, are recognised as an expense as the service is received.
Configuration and customisation costs which are not distinct from the cloud computing arrangement, are
recognised as prepaid expenses in the statement of financial position and expensed over the expected duration of
the cloud computing arrangement.
Intangible assets acquired in a business combination are recognised at fair value at the acquisition date
separately from goodwill if the assets meet the definition of an asset, are identifiable or rise from contractual or
legal rights.
Intangible assets are measured at cost and amortised on a straight line basis over the known or estimated
useful lives.
Amortisation periods used for intangible assets are as follows
Immaterial rights 3\u20137 years
Software 3\u20135 years
Customer agreements and related customer relationships 3\u201312 years
Trademarks 20 years or shorter useful life
Other intangible assets 3\u20135 years
Research and development
Research expenditure is recognised as an expense as incurred in the statement of income. Development
expenditure is capitalised as intangible assets when certain capitalisation criteria are met. Development expenditure
that does not qualify for the capitalisation is recognised as an expense. The estimated useful lives of capitalised
development expenditure are 3\u20135 years.
", "dimensions": { "concept": "ifrs-full:DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory", "language": "en", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00/2026-01-01T00:00:00" } }, "fact-290": { "value": "Research and development Research expenditure is recognised as an expense as incurred in the statement of income. Development expenditure is capitalised as intangible assets when certain capitalisation criteria are met. Development expenditure that does not qualify for the capitalisation is recognised as an expense. The estimated useful lives of capitalised development expenditure are 3\u20135 years.", "dimensions": { "concept": "ifrs-full:DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory", "language": "en", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00/2026-01-01T00:00:00" } }, "fact-291": { "value": "
2.9 Impairment
Tangible and intangible assets
At the end of each reporting period, the Group assesses whether there are any indications of impairment. If any
indications of an impairment exist, the recoverable amount of the asset is determined. For goodwill and intangible
assets not yet available for use, the recoverable amount is determined annually, irrespective of whether there is any
evidence of impairment. Evidence of impairment is assessed at the level of the Group\u2019s cash-generating units, i.e.
at the lowest unit level, which is largely independent of the other units and whose cash flows can be distinguished
from the cash flows of equivalent units.
The recoverable amount of an asset is the higher of its fair value less costs to sell or value-in-use. The value-in-use
is the amount of estimated future cash flows of an asset or cash generating unit discounted to present value. The
discount rate used is the pre-tax discount rate, which reflects the market view on the time value of money and
specific risks related to the asset.
An impairment loss is recognised when the carrying amount of an asset exceeds its recoverable amount. The
impairment loss is recognised in the statement of income. If impairment loss is related to a cash generating
unit, the impairment loss is allocated first to reduce the carrying amount of any goodwill allocated to the cash
generating unit, and then to reduce the carrying amounts of the other assets on a pro rata basis. The useful life of
an asset, which is subject to depreciation or amortisation, is reassessed when an impairment loss is recognised. The
impairment loss recognised for other assets than goodwill is reversed if there has been a change in estimates used
to determine the recoverable amount. The reversal of the impairment loss cannot exceed the carrying amount of
the asset if impairment loss had not been recognised. Impairment loss recognised for goodwill is not reversed.
", "dimensions": { "concept": "ifrs-full:DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory", "language": "en", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00/2026-01-01T00:00:00" } }, "fact-292": { "value": "2.9 Impairment Tangible and intangible assets At the end of each reporting period, the Group assesses whether there are any indications of impairment. If any indications of an impairment exist, the recoverable amount of the asset is determined. For goodwill and intangible assets not yet available for use, the recoverable amount is determined annually, irrespective of whether there is any evidence of impairment. Evidence of impairment is assessed at the level of the Group\u2019s cash-generating units, i.e. at the lowest unit level, which is largely independent of the other units and whose cash flows can be distinguished from the cash flows of equivalent units. The recoverable amount of an asset is the higher of its fair value less costs to sell or value-in-use. The value-in-use is the amount of estimated future cash flows of an asset or cash generating unit discounted to present value. The discount rate used is the pre-tax discount rate, which reflects the market view on the time value of money and specific risks related to the asset. An impairment loss is recognised when the carrying amount of an asset exceeds its recoverable amount. The impairment loss is recognised in the statement of income. If impairment loss is related to a cash generating unit, the impairment loss is allocated first to reduce the carrying amount of any goodwill allocated to the cash generating unit, and then to reduce the carrying amounts of the other assets on a pro rata basis. The useful life of an asset, which is subject to depreciation or amortisation, is reassessed when an impairment loss is recognised. The impairment loss recognised for other assets than goodwill is reversed if there has been a change in estimates used to determine the recoverable amount. The reversal of the impairment loss cannot exceed the carrying amount of the asset if impairment loss had not been recognised. Impairment loss recognised for goodwill is not reversed.", "dimensions": { "concept": "ifrs-full:DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory", "language": "en", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00/2026-01-01T00:00:00" } }, "fact-293": { "value": "Financial assets At the end of each reporting period, the Group evaluates indicators of potential impairment of a single financial asset or a group of financial assets. The Group recognises an expected credit loss for trade receivables and contract assets based on a simplified approach. Expected credit loss rates have been calculated using historical information of actual impairment losses, and the current conditions and the Group\u2019s view of the economic conditions over the expected lives of the receivables have been taken into account.", "dimensions": { "concept": "ifrs-full:DescriptionOfAccountingPolicyForImpairmentOfFinancialAssetsExplanatory", "language": "en", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00/2026-01-01T00:00:00" } }, "fact-294": { "value": "2.10 Leases Group as a lessee The Group assesses whether a contract is or contains a lease at the inception of a contract. A contract is or contains a lease if the contract conveys the right to control the use of an identified asset for a period in exchange for consideration. A lessee recognises a right-of-use asset and a lease liability on a statement of financial position at the lease commencement date. A lease term is determined as the non-cancellable period of a lease. The lease term includes periods covered by an option to extend or terminate the lease, if the Group is reasonably certain to exercise the extension option or not to exercise the termination option. Perpetual lease contracts related to significant premises are accounted for as long-term lease contracts, as, according to management judgment, the termination options for such contracts will not be used. The lease term for such contracts is determined based on the Group\u2019s strategy and network plan. The Group does not recognise short-term leases (a lease that has a lease term of 12 months or less) and leases for which the underlying asset is of low value. The lease payments associated with such leases are expensed on a straight-line basis. Initially a right-of-use asset is measured at cost, which comprises the amount of the initial measurement of the lease liability, any lease payments made at or before the commencement date, less any lease incentives, any initial direct costs incurred by the Group, and an estimate of restoration costs to be incurred by the Group. If a lease contains several lease components, they are accounted for separately. Subsequently right-of-use assets are measured at cost less any accumulated depreciation and any accumulated impairment losses and adjusted for any remeasurements of the lease liability. A right-of-use asset is depreciated from the commencement date to the earlier of the end of the useful life of the right-of-use asset or the end of the lease term. If the Group is reasonably certain to exercise the purchase option, the right-of-use asset is depreciated over its useful life. The estimated useful lives of right-of-use assets are 1-12 years. The book value and useful life of a right-of-use asset are reviewed where necessary but at least annually and an impairment loss is recognised if there is a change in expectations of the future economic benefits. A lease liability is initially measured at the present value of the lease payments that are not paid at the commencement date. The Group uses an incremental borrowing rate as the discount rate. A lease liability includes fixed payments, including in-substance fixed payments; variable lease payments that depend on an index or a rate, initially measured using the index or rate as at the commencement date; amounts expected to be payable under a residual value guarantee, and the exercise price under a purchase option that Terveystalo is reasonably certain to exercise. Subsequently, a lease liability is measured at amortised cost using the effective interest method. It is remeasured when there is a change in future lease payments arising from a change in an index or rate, if there is a change in the Terveystalo\u2019s estimate of the amount expected to be payable under a residual value guarantee or if the Group changes its assessment of whether it will exercise a purchase, extension or termination option. When a lease liability is remeasured in this way, a corresponding adjustment is made to the carrying amount of the right-to-use asset or is recorded in the statement of income if the carrying amount of the right-of-use asset has been reduced to zero.", "dimensions": { "concept": "ifrs-full:DescriptionOfAccountingPolicyForLeasesExplanatory", "language": "en", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00/2026-01-01T00:00:00" } }, "fact-295": { "value": "2.11 Financial assets and liabilities Financial assets The Group\u2019s financial assets are classified at fair value through the statement of income or, at amortised cost. Classification is based on the purpose of the acquisition of the item and is made upon initial recognition. Financial assets at fair value through the statement of income comprise of derivate assets, non-quoted equity instruments and loan receivables. Realised or unrealised gains and losses arising from changes in fair values are recognised in the statement of income in the period in which they are incurred. Financial assets at amortised cost consist of trade receivables and other receivables. They are measured at amortised cost, and they are included in non-current assets unless the Group has an intention to hold the instrument for less than 12 months from the reporting date, in which case they are included in current assets. The Group has not had financial assets at fair value through other comprehensive income during the periods 2024 or 2025. The financial asset is derecognised when the contractual rights to the cash flows expire, or the financial asset is transferred to another party, and the Group substantially transfers all the risks and rewards of ownership to another party. ", "dimensions": { "concept": "ifrs-full:DescriptionOfAccountingPolicyForFinancialAssetsExplanatory", "language": "en", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00/2026-01-01T00:00:00" } }, "fact-296": { "value": "
Financial assets at fair value through the statement of income comprise of derivate assets, non-quoted equity
instruments and loan receivables. Realised or unrealised gains and losses arising from changes in fair values are
recognised in the statement of income in the period in which they are incurred.
Financial liabilities at fair value through the statement of income comprise derivative liabilities and contingent
considerations. Realised or unrealised gains and losses arising from changes in fair values are recognised the
statement of income in the period in which they are incurred.
", "dimensions": { "concept": "ifrs-full:DescriptionOfAccountingPolicyForFinancialInstrumentsAtFairValueThroughProfitOrLossExplanatory", "language": "en", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00/2026-01-01T00:00:00" } }, "fact-297": { "value": "
The financial asset is derecognised when the contractual rights to the cash flows expire, or the financial asset
is transferred to another party, and the Group substantially transfers all the risks and rewards of ownership to
another party.
Financial liability is derecognised when the Group either settles the liability or has been legally discharged from the obligation related to the liability either through a legal process or by the borrowe ", "dimensions": { "concept": "ifrs-full:DescriptionOfAccountingPolicyForDerecognitionOfFinancialInstrumentsExplanatory", "language": "en", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00/2026-01-01T00:00:00" } }, "fact-298": { "value": "Cash and cash equivalents Cash and cash equivalents include cash in hand, bank deposits available on demand, and other short-term highly liquid investments. Items included in cash and cash equivalents have original maturities of three months or less from the acquisition date", "dimensions": { "concept": "ifrs-full:DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents", "language": "en", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00/2026-01-01T00:00:00" } }, "fact-299": { "value": "Financial liabilities The Group\u2019s financial liabilities are measured at fair value through the statement of income or at amortised cost. Financial liabilities at fair value through the statement of income comprise derivative liabilities and contingent considerations. Realised or unrealised gains and losses arising from changes in fair values are recognised the statement of income in the period in which they are incurred. Financial liabilities at amortised cost include loans from financial institutions, bonds, lease liabilities, hire purchase liabilities and trade and other payables. They are initially recognised at fair value which is based on the consideration received. Transaction costs are included in the initial amount recognised and subsequently the financial liability is measured at amortised cost using the effective interest method. Financial liabilities are included in non-current and current liabilities and they can be either interest-bearing or non-interest-bearing. Financial liabilities are classified as current liabilities, unless the Group has an unconditional right to postpone the payment of the liability to at least 12 months from the reporting date. The Group has not had financial liabilities at fair value through other comprehensive income during the periods 2024 or 2025. Financial liability is derecognised when the Group either settles the liability or has been legally discharged from the obligation related to the liability either through a legal process or by the borrowe r.", "dimensions": { "concept": "ifrs-full:DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory", "language": "en", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00/2026-01-01T00:00:00" } }, "fact-300": { "value": "2.12 Inventories Inventories are measured at the lower of cost and net realisable value. The cost of inventories is determined by using FIFO (first in, first out) method. Net realisable value is the cost of inventory less obsolescence allowance.", "dimensions": { "concept": "ifrs-full:DescriptionOfAccountingPolicyForMeasuringInventories", "language": "en", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00/2026-01-01T00:00:00" } }, "fact-301": { "value": "2.13 Employee benefits Pension benefits Pension plans are classified as either defined contribution plans or defined benefit plans. In defined contribution plans, the Group makes fixed contributions into the plan. The Group has no legal or constructive obligation to make additional payments if the pension insurance company is unable to pay pension benefits earned by employees in the reporting period or in previous periods. Contributions made into defined contribution plans are recognised through profit or loss in the reporting period to which they relate. A defined benefit plan is a pension plan under which the Group itself has the obligation to pay retirement benefits and bears the risk of change in the value of plan liability and assets. The liability recognised on the statement of financial position in respect of defined benefit pension plans is the present value of the defined benefit obligation at the end of the reporting period less fair value of plan assets. The pension liability is presented in other non-current liabilities in the statement of financial position. The defined benefit obligation is calculated annually by an independent actuary using the projected unit credit method. The present value of the defined benefit obligation is determined by discounting the estimated future cash outflows using interest rates of high- quality corporate or government bonds with approximating terms to maturity and that are denominated in the currency in which the benefits are expected to be paid. Actuarial gains and losses related to remeasurements of a defined benefit plan are recognised directly in the other comprehensive income. Interest and other expenses related to defined benefit plans are recognised directly in the statement of income. If a plan is amended or curtailed, the portion of the changed benefit related to past service by the employees, or the gain or loss on curtailment, is recognised directly in the statement of income when the plan amendment or curtailment occurs. Share-based payment transactions The benefits granted in accordance with the incentive plan are measured at fair value at the grant date and are expensed on a straight-line basis over the vesting period. The share-based payments settled with equity instruments are not revalued subsequently, and cost from these arrangements is recognised as an increase in equity. The cash-settled share-based incentives are valued at fair value at each reporting date until the settlement date and recognised as a liability. The expensed amount of the benefits is based on the Group\u2019s estimate of the amount of benefits to be paid in accordance with the fulfilment of service and performance-based vesting conditions at the end of the vesting period. Market conditions are considered in determining the fair value of the benefit. Instead, the non-market criteria, like profitability, are not considered in measuring the fair value of the benefit but are taken into account when estimating the final amount of benefits. The estimate is updated at each reporting date and changes in estimates are recorded through the statement of income.", "dimensions": { "concept": "ifrs-full:DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory", "language": "en", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00/2026-01-01T00:00:00" } }, "fact-302": { "value": "
Share-based payment transactions
The benefits granted in accordance with the incentive plan are measured at fair value at the grant date and
are expensed on a straight-line basis over the vesting period. The share-based payments settled with equity
instruments are not revalued subsequently, and cost from these arrangements is recognised as an increase in
equity. The cash-settled share-based incentives are valued at fair value at each reporting date until the settlement
date and recognised as a liability.
The expensed amount of the benefits is based on the Group\u2019s estimate of the amount of benefits to be paid
in accordance with the fulfilment of service and performance-based vesting conditions at the end of the vesting
period. Market conditions are considered in determining the fair value of the benefit. Instead, the non-market
criteria, like profitability, are not considered in measuring the fair value of the benefit but are taken into account
when estimating the final amount of benefits. The estimate is updated at each reporting date and changes in
estimates are recorded through the statement of income.
", "dimensions": { "concept": "ifrs-full:DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory", "language": "en", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00/2026-01-01T00:00:00" } }, "fact-303": { "value": "2.14 Provisions and contingent liabilities A provision is recognised when the Group has a present legal or constructive obligation as a result of a past event, and it is probable that an outflow of economic benefits will be required to settle the obligation, and a reliable estimate can be made of the amount of the obligation. Provisions are recognised at the present value of the expenditure required to fulfil the obligation. If the obligation can be partially compensated by a third party, the compensation is treated as a separate asset, but only when it is virtually certain that the compensation will be received. A provision is recognised for contracts when the unavoidable costs of meeting the obligations under the contract exceed the economic benefits expected to be received under it.", "dimensions": { "concept": "ifrs-full:DescriptionOfAccountingPolicyForProvisionsExplanatory", "language": "en", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00/2026-01-01T00:00:00" } }, "fact-304": { "value": "A contingent liability is a possible obligation arising as a result of past events, and whose existence will be confirmed only when an uncertain future event takes place, not wholly within control of the entity. Also, a present obligation which probably does not require a cash settlement or on which the value cannot be reliably estimated is considered as a contingent liability. Contingent liabilities are disclosed in the notes.", "dimensions": { "concept": "ifrs-full:DescriptionOfAccountingPolicyForContingentLiabilitiesAndContingentAssetsExplanatory", "language": "en", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00/2026-01-01T00:00:00" } }, "fact-305": { "value": "2.15 Revenue recognition The Group\u2019s revenue consists mainly of occupational healthcare services, general practice and clinic hospital operations, dental services as well as diagnostic services. The Group also provides diverse primary healthcare, special healthcare, child welfare and digital healthcare services for public sector as well as amongst other things, massage and rehabilitation services. Terveystalo offers services to three customer groups: corporate customers, private customers, and public customers. The Group does not have customers whose revenue exceeds 10 percent of the Group's total revenue. The Group\u2019s customer contracts include primarily one performance obligation, which is typically a single appointment, and the transaction prices are mainly fixed. The Group also has customer contracts that include multiple performance obligations. In some cases, the transaction price includes a variable consideration such as a discount or penalty. Possible variable considerations are assessed at each reporting date and are allocated to one or more performance obligations. The terms of payment and payment periods in customer contracts vary, but payment time is nonetheless clearly below one year. Consequently, customer contracts do not include a significant financing component. Revenue is recognised to the extent that the Group expects to be entitled to in exchange for the goods and services taking into account the terms and conditions of the customer contracts and business practices. Revenue from individual appointments is recognised at a point in time as the service has been completed. For long-term contracts for predetermined services or a bundle of services, revenue is recognised as Terveystalo fulfils the performance obligation by performing the promised service. The Group\u2019s long-term contracts are assessed to include a single performance obligation where the services provided by the Group are integrated into a single bundle of services. The Group also has long-term customer contracts where the delivery of a series of distinct services to the customer has the same pattern of transfer. In long-term customer contracts, the customer simultaneously receives and consumes the benefits from the service and, consequently, the criteria for recognising revenue over time is met. For long-term contracts, Terveystalo measures the progress towards complete satisfaction of the performance obligation by applying the input method, in which the revenue is recognised based on time elapsed. The Group views that the used method best describes the transfer of control for the services provided. Estimated costs and revenues will be re-assessed regularly during performing the services. Revisions in profit estimates as well as projected potential losses on contracts are charged through the statement of income in the period in which they become known. The Group has not incurred any substantial costs for obtaining customer contracts. Regarding private practitioners, Terveystalo acts as the principal and recognises revenue on a gross basis. Fees related to purchasing these services are recognised in materials and services expenses.", "dimensions": { "concept": "ifrs-full:DescriptionOfAccountingPolicyForRecognitionOfRevenue", "language": "en", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00/2026-01-01T00:00:00" } }, "fact-306": { "value": "2.16 Segment information The reporting structure reflects Terveystalo's operating model and is aligned with the way the company\u2019s chief operating decision-maker follows the operational performance of Terveystalo's businesses. The reporting structure was changed in the financial year 2023 due to the change in Terveystalo's operating model. Terveystalo Group comprises of three operating segments that are reportable segments: Healthcare Services, Portfolio Businesses, and Sweden. Monitoring of profitability is primarily based on operating segments. In addition, Terveystalo provides disclosure on revenue for Healthcare Services on customer and service level, and for Portfolio Businesses on service level. Terveystalo\u2019s chief operating decision-maker is the CEO who is monitoring the operating results of operating segments for the purpose of assessing performance and making decisions about resource allocation. Key financial performance measures of the segments comprise primarily revenue and segment adjusted earnings before interest, taxes, amortisation and impairment (EBITA). The evaluation of segment performance and allocation of resources is primarily based on segment adjusted EBITA, which the management estimates the most relevant measure for this purpose. Healthcare Services offers customers in Finland integrated care paths from preventive occupational health services to primary care services and to different fields of specialised care, diagnostic, and day surgery. In Healthcare Services, Terveystalo aims for industry-leading profitability and the best care outcomes. The Portfolio Businesses segment consists of business areas that aim for independent value creation utilising Terveystalo\u2019s capabilities according to their needs. The Portfolio Businesses segment includes publicly funded services, such as outsourcing and staffing services, as well as services aimed at consumers, including dental care and massage. The Sweden segment consists of Feelgood subsidiaries\u2019 operations in Sweden, which are focused on occupational health and consultation for organisational management and harmful use. In Sweden, Terveystalo aims for profitable growth in the medium and long term. In addition to operating segments, Terveystalo provides information for Other section. Other reported figures mainly consist of parent company expenses as well as unallocated Group-level adjustments and provisions.", "dimensions": { "concept": "ifrs-full:DescriptionOfAccountingPolicyForSegmentReportingExplanatory", "language": "en", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00/2026-01-01T00:00:00" } }, "fact-307": { "value": "2.17 Government grants Government grants are presented in other operating income as far as they do not relate to acquired assets. Grants are recognised when there is reasonable assurance that grants will be received, and the Group will comply with the conditions associated with the grants.", "dimensions": { "concept": "ifrs-full:DescriptionOfAccountingPolicyForGovernmentGrants", "language": "en", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00/2026-01-01T00:00:00" } }, "fact-308": { "value": "2.18 Operating profit IAS 1 standard does not define operating profit. The Group has defined it as follows: Operating profit is calculated by adding other operating income to revenue, deducting costs related to materials and services, deducting costs related to employee benefits, depreciation, amortisation and impairments as well as other operating expenses.", "dimensions": { "concept": "ifrs-full:DisclosureOfProfitLossFromOperatingActivitiesExplanatory", "language": "en", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00/2026-01-01T00:00:00" } }, "fact-309": { "value": "2.19 Earnings per share Basic earnings per share is calculated by dividing profit or loss attributable to the shareholders of the parent company by the weighted average number of shares outstanding during the financial period. The Group\u2019s share- based incentive plan has a dilution effect related to the earnings per share.", "dimensions": { "concept": "ifrs-full:DescriptionOfAccountingPolicyForEarningsPerShareExplanatory", "language": "en", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00/2026-01-01T00:00:00" } }, "fact-310": { "value": "
2.20 Income taxes
Income taxes primarily include current and deferred taxes. Tax related to items recognised directly in equity or in
other comprehensive income is also recognised in equity or in other comprehensive income. Current tax assets
and liabilities are measured at the amount expected to be received from or paid to taxation authorities, using the
rates and laws that have been enacted by the date of the statement of financial position. Income taxes include any
adjustment to tax in respect of previous years.
Deferred tax is recognised in respect of all temporary differences between the carrying amounts of assets and
liabilities for financial reporting purposes and the amounts in taxation. Deferred tax is not recognised in the
initial recognition of assets or liabilities in a transaction that is not a business combination and that affects neither
accounting nor taxable profit nor loss at the date of the transaction. Deferred tax is not recognised for non-tax- deductible goodwill or for subsidiaries\u2019 retained earnings to the extent that it is probable that the temporary difference will not reverse in the foreseeable future. Deferred taxes relate primarily to the difference between the book value and tax base of capitalised customer relationships and trademarks, and to provisions related primarily to loss-making contracts
A deferred tax asset is recognised to the extent that it is probable that future taxable profits will be available
against which they can be used and using the losses is considered probable.
Deferred taxes are calculated using tax rates enacted by the reporting date.
", "dimensions": { "concept": "ifrs-full:DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory", "language": "en", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00/2026-01-01T00:00:00" } }, "fact-311": { "value": "2.20 Income taxes Income taxes primarily include current and deferred taxes. Tax related to items recognised directly in equity or in other comprehensive income is also recognised in equity or in other comprehensive income. Current tax assets and liabilities are measured at the amount expected to be received from or paid to taxation authorities, using the rates and laws that have been enacted by the date of the statement of financial position. Income taxes include any adjustment to tax in respect of previous years. Deferred tax is recognised in respect of all temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts in taxation. Deferred tax is not recognised in the initial recognition of assets or liabilities in a transaction that is not a business combination and that affects neither accounting nor taxable profit nor loss at the date of the transaction. Deferred tax is not recognised for non-tax- deductible goodwill or for subsidiaries\u2019 retained earnings to the extent that it is probable that the temporary difference will not reverse in the foreseeable future. Deferred taxes relate primarily to the difference between the book value and tax base of capitalised customer relationships and trademarks, and to provisions related primarily to loss-making contracts A deferred tax asset is recognised to the extent that it is probable that future taxable profits will be available against which they can be used and using the losses is considered probable. Deferred taxes are calculated using tax rates enacted by the reporting date.", "dimensions": { "concept": "ifrs-full:DescriptionOfAccountingPolicyForIncomeTaxExplanatory", "language": "en", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00/2026-01-01T00:00:00" } }, "fact-312": { "value": "2.21 Assets held for sale Non-current assets (or groups of disposable items) are classified as held for sale when the amount equivalent to their carrying amount is expected to be recovered primarily through their sale rather than through continued use, and the sale is highly probable. They are presented at their carrying amount or fair value less costs to sell, whichever is lower. Depreciation of intangible and tangible assets ceases at the time of classification", "dimensions": { "concept": "ifrs-full:DescriptionOfAccountingPolicyForNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleExplanatory", "language": "en", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00/2026-01-01T00:00:00" } }, "fact-313": { "value": "3. Business combinations Business combinations 2025 During the year 2025, the Group made three corporate acquisitions. On 30 April 2025, Terveystalo Healthcare Oy acquired 100 percent of the dental health services provider Veikkolan Hammasl\u00e4\u00e4k\u00e4riasema Oy. On 30 May 2025, Terveystalo Healthcare Oy acquired 100 percent of the mental health services provider Recuror Oy. On 31 December 2025, Terveystalo Healthcare Oy acquired 100 percent of the ophthalmology services providers Silm\u00e4sairaala Pilke Oy and Turun Silm\u00e4laser Oy. The following table summarises the acquisition date fair values of the consideration transferred as well as the recognised amounts of assets acquired and liabilities assumed at the acquisition date. The statement of financial position of acquired companies has been prepared in accordance with IFRS and Terveystalo\u2019s accounting principles in all material respect. The following table is preliminary, and the information has been consolidated, because the acquisitions are not material individually.
Consideration transferred
EUR mill.
2025
Purchase price, payable in cash
9.9
Contingent consideration
5.9
Total consideration transferred
15.8
Identifiable assets acquired and liabilities assumed
EUR mill.
2025
Cash and cash equivalents
0.3
Intangible assets
0.0
Property, plant and equipment
0.0
Right-of-use assets
0.1
Trade and other receivables
0.5
Lease liabilities
-0.1
Trade and other payables
-0.4
Total identifiable net assets acquired
0.5
Goodwill
15.3
As a result of these business combinations, a preliminary goodwill amounting to EUR 15.3 million was recognised. The goodwill is attributable to skills of the workforce and synergies expected to be achieved. The recognised goodwill is not tax-deductible. Cashflow impact of the acquisitions made during 2025 was EUR -9.5 million. The fair value of the acquired trade and other receivables amounted to EUR 0.5 million, for which the risk of impairment has been deemed as non-significant. The Group has incurred acquisition-related expenses of EUR 0.4 million related to transfer tax, consulting, valuation or equivalent services. The expenses have been included in other operating expenses. The contributed revenue recognised from the acquisitions during the year 2025 was EUR 2.1 million and loss was EUR 0.2 million. If the acquisition had occurred on 1 January 2025, management estimates that the Group\u2019s consolidated revenue in 2025 would have been EUR 1,280.8 million and the consolidated result for the period would have been EUR 92.9 million. Business combinations 2024 During the year 2024, the Group made three corporate acquisitions and one business acquisition. On 31 March 2024, Terveystalo Healthcare Oy acquired 100 percent of the imaging services provider SRK Group Oy and an indirect 100 percent ownership in its subsidiaries Suomen Radiologikeskus Oy, iRad Oy and Kajaanin Radiologikeskus Oy. On 1 July 2024, Feelgood F\u00f6retagsh\u00e4lsov\u00e5rd AB acquired 100 percent of the Swedish occupational health provider Clarah\u00e4lsan AB. On 6 September 2024, Suomen Terveystalo Oy acquired 100 percent of the general and specialist medical services, psychology services and physiotherapy services provider Cityl\u00e4karna Mariehamn Ab. On 30 November 2024, Rela-hierojat Oy acquired massage business operations previously operated as franchising business. The following table summarises the acquisition date fair values of the consideration transferred as well as the recognised amounts of assets acquired and liabilities assumed at the acquisition date. The statement of financial position of acquired companies has been prepared in accordance with IFRS and Terveystalo\u2019s accounting principles in all material respect. The information has been consolidated, because the acquisitions are not material individually.
Consideration transferred
EUR mill.
2024
Purchase price, payable in cash
8.1
Contingent consideration
0.8
Total consideration transferred
8.9
Identifiable assets acquired and liabilities assumed
EUR mill.
2024
Cash and cash equivalents
0.8
Intangible assets
0.2
Property, plant and equipment
0.5
Right-of-use assets
1.2
Trade and other receivables
1.5
Financial liabilities
-0.1
Lease liabilities
-1.2
Trade and other payables
-2.2
Total identifiable net assets acquired
0.6
Goodwill
8.3
As a result of these business combinations, a goodwill amounting to EUR 8.3 million was recognised. The goodwill is attributable to skills of the workforce and synergies expected to be achieved. EUR 0.0 million of the recognised goodwill is deductible in taxation. During the year 2025, effect to goodwill arising from corporate and business acquisitions made in year 2024 was EUR 0.4 million. Cashflow impact of the acquisitions made during 2024 was EUR -7.1 million. In 2025, cashflow impact arising from business combinations made in previous financial years was EUR -1.2 million due to adjustments to purchase prices and additional purchase prices paid. The fair value of the acquired trade and other receivables amounted to EUR 1.5 million, for which the risk of impairment has been deemed as non-significant. The Group has incurred acquisition-related expenses of EUR 0.3 million related to transfer tax, consulting, valuation or equivalent services. The expenses have been included in other operating expenses. The contributed revenue recognised from the acquisitions during the year 2024 was EUR 6.8 million and profit was EUR 0.1 million. If the acquisition had occurred on 1 January 2024, management estimates that the Group\u2019s consolidated revenue in 2024 would have been EUR 1,345.0 million and the consolidated result for the period would have been EUR 72.0 million.", "dimensions": { "concept": "ifrs-full:DisclosureOfBusinessCombinationsExplanatory", "language": "en", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00/2026-01-01T00:00:00" } }, "fact-314": { "value": "4. Segment information Terveystalo Group\u2019s operating segments are Healthcare Services, Portfolio Businesses, and Sweden. These are also reportable segments, and operating segments are not aggregated.
1.1.-31.12.2025 Healthcare Portfolio Segments Internal
EUR mill. services
Businesses
Sweden
total
Other
eliminations
Total
Revenue
Revenues from external
customers
1,014.9
188.5
75.5
1,278.9
-
-
1,278.9
Revenues from transactions
with other operating
segments of the same entity
16.2
4.0
0.1
20.3
-
-20.3
-
Total revenue
1,031.0
192.5
75.6
1,299.1
-
-20.3
1,278.9
Adjusted EBITA
166.7
13.7
-1.3
179.1
0.2
-
179.3
Adjustments (EBITA)
4.6
0.5
5.6
10.7
4.0
-
14.7
Adjusted EBIT
154.6
12.6
-2.6
164.6
-8.3
-
156.3
Adjustments (EBIT)
4.6
0.5
5.6
10.7
8.1
-
18.8
Depreciations
6.4
0.9
7.2
14.5
58.4
-
72.9
1.1.-31.12.2024 Healthcare Portfolio Segments Internal
EUR mill. services
Businesses
Sweden
total
Other
eliminations
Total
Revenue
Revenues from external
customers
1,026.8
231.6
81.6
1,340.0
-
-
1,340.0
Revenues from transactions
with other operating
segments of the same entity
16.0
6.9
0.2
23.1
-
-23.1
-
Total revenue
1,042.8
238.5
81.8
1,363.1
-
-23.1
1,340.0
Adjusted EBITA
162.0
10.3
-2.0
170.3
0.7
-
171.0
Adjustments (EBITA)
7.6
0.3
6.3
14.2
9.2
-
23.5
Adjusted EBIT
143.7
9.1
-3.4
149.3
-8.9
-
140.5
Adjustments (EBIT)
7.6
0.3
7.2
15.1
9.2
-
24.4
Depreciations
6.8
1.1
7.0
14.8
60.1
-
74.9
Adjustments (EBITA)*, EUR mill.
2025
2024
Acquisition-related expenses
1)
-0.1
-0.7
Restructuring-related expenses
2)
1.1
1.9
Gains and losses on sale of assets, net
3)
-0.1
0.6
Strategic projects and other items affecting to comparability
13.9
21.6
Adjustments
14.7
23.5
Adjustments (EBIT)*, EUR mill.
2025
2024
Acquisition-related expenses
1)
-0.1
-0.7
Restructuring-related expenses
2)
1.1
1.9
Gains and losses on sale of assets, net
3)
-0.1
0.6
Impairment losses
4.1
0.9
Strategic projects and other items affecting to comparability
13.9
21.6
Adjustments
18.8
24.4
* Adjustments are material items outside the ordinary course of business and these relate to acquisition-related expenses, restructuring- related expenses, gains and losses on sale of assets (net), strategic projects, impairment losses and other items affecting comparability. The adjustments in the Healthcare Services -segment in the financial year 2025 are mainly related to a development program (EUR 3.2 million). The adjustments in the Other section in the financial year 2025 are mainly related to profit improvement programs (EUR 2.9 million), an impairment of goodwill in the child welfare services business (EUR 4.1 million), and a partial tax audit related to value-added taxation that was still ongoing at the reporting date (EUR 1.8 million). The adjustments in the Other section also include the recognition of contingent additional purchase prices (EUR -0.9 million). In the financial year 2025, the adjustments in the Sweden -segment are related to a profit improvement program. Healthcare services segment adjustments in the financial year 2024 includes a one-off item of EUR 5.6 million related to renovation and maintenance liabilities in a single location over a period of more than ten years. 1) Including transaction costs and expenses from integration of acquired businesses. 2) Including restructuring of network and business operations. 3) Including sales of business operations Reconciliation of the total of the reportable segment's adjusted EBIT and adjusted EBITA to the Group's profit before taxes
EUR mill.
31 Dec 2025
31 Dec 2024
Profit before taxes
116.6
89.6
Share of profits of joint ventures
0.2
-
Net finance expenses
20.7
26.5
Adjustments
18.8
24.4
Other
8.3
8.9
Segment's adjusted EBIT
164.6
149.3
Amortisation and impairment losses
27.1
31.5
Adjustments
-4.1
-0.9
Other
-8.5
-9.6
Adjusted EBITA
179.1
170.3
Non-current assets by geographical areas Non-current assets include property, plant and equipment, right-of-use assets, goodwill, other intangible assets, investment properties and investments in associates and joint ventures.
EUR mill.
31 Dec 2025
31 Dec 2024
Finland
1,137.0
1,112.6
Sweden
75.1
69.5
Total
1,212.1
1,182.1
", "dimensions": { "concept": "ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory", "language": "en", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00/2026-01-01T00:00:00" } }, "fact-315": { "value": "
5. Revenue
The Group's distribution of revenue is based on three segments: Healthcare Services, Portfolio Businesses, and
Sweden. For more information on segments, refer to note 4, Segment information. The revenue of Healthcare
Services is divided by services and customer groups. The revenue of Portfolio Businesses is divided by services.
Terveystalo offers its primary and outpatient secondary health care services to three distinct customer groups:
corporate customers, private customers, and public customers. The Group does not have customers whose revenue
exceeds 10 percent of the Group's total revenue.
Corporate customers constitute Terveystalo\u2019s largest customer group. Terveystalo\u2019s corporate customers consist
of the company\u2019s occupational health care customers, excluding municipal occupational health care customers. The
company provides statutory occupational health services and other occupational health and well-being services for
corporate customers of all sizes.
Private customers include private individuals and families. The company\u2019s strong brand, easy access to services
without long waiting times, leading service portfolio for private customers, families, and senior citizens, and
personalised digital services give Terveystalo a competitive edge over public health care services and encourage
customers to invest in their own health. Services for private customers are paid for either by the customers
themselves or by their insurance companies.
Terveystalo\u2019s public customer group is made up of Finnish public sector organisations, such as municipalities,
municipal federations, and hospital districts, as well as municipal occupational health care customers. The services
offered to public sector customers include full and partial outsourcings, health care staffing services, specialised
care services, other health care services, as well as occupational health care services for municipalities, municipal
federations, and hospital districts.
Disaggregation of revenue
EUR mill.
1.1.\u201331.12.2025
1.1.\u201331.12.2024
Healthcare Services
1,031.0
1,042.8
Portfolio Businesses
192.5
238.5
Sweden
75.6
81.8
Segments total
1,299.1
1,363.1
Other
-20.3
-23.1
Total
1,278.9
1,340.0
Healthcare Services, revenue
EUR mill.
1.1.\u201331.12.2025
1.1.\u201331.12.2024
By customer
Occupational health customers
588.5
602.2
Consumer customers
223.7
223.8
Insurance customers
187.6
179.5
Service sales
31.3
37.4
Total
1,031.0
1,042.8
By service
Appointments
680.8
686.1
Diagnostics
250.7
254.2
Other
99.5
102.5
Total
1,031.0
1,042.8
Portfolio Businesses, revenue
EUR mill.
1.1.\u201331.12.2025
1.1.\u201331.12.2024
Outsourcing services
54.8
82.8
Staffing services
53.1
73.1
Dental care
52.4
50.3
Other
32.2
32.4
Total
192.5
238.5
Timing of satisfying performance obligations
EUR mill.
1.1.\u201331.12.2025
1.1.\u201331.12.2024
At a point in time
1,222.4
1,255.3
Over time
56.4
84.7
Total
1,278.9
1,340.0
Balances in the statement of financial position
EUR mill.
31 Dec 2025
31 Dec 2024
Contract assets
6.1
7.9
Contract liabilities
6.6
7.0
The Group will satisfy performance obligations related to the contract liabilities within one year.
", "dimensions": { "concept": "ifrs-full:DisclosureOfRevenueFromContractsWithCustomersExplanatory", "language": "en", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00/2026-01-01T00:00:00" } }, "fact-316": { "value": "5. Revenue The Group's distribution of revenue is based on three segments: Healthcare Services, Portfolio Businesses, and Sweden. For more information on segments, refer to note 4, Segment information. The revenue of Healthcare Services is divided by services and customer groups. The revenue of Portfolio Businesses is divided by services. Terveystalo offers its primary and outpatient secondary health care services to three distinct customer groups: corporate customers, private customers, and public customers. The Group does not have customers whose revenue exceeds 10 percent of the Group's total revenue. Corporate customers constitute Terveystalo\u2019s largest customer group. Terveystalo\u2019s corporate customers consist of the company\u2019s occupational health care customers, excluding municipal occupational health care customers. The company provides statutory occupational health services and other occupational health and well-being services for corporate customers of all sizes. Private customers include private individuals and families. The company\u2019s strong brand, easy access to services without long waiting times, leading service portfolio for private customers, families, and senior citizens, and personalised digital services give Terveystalo a competitive edge over public health care services and encourage customers to invest in their own health. Services for private customers are paid for either by the customers themselves or by their insurance companies. Terveystalo\u2019s public customer group is made up of Finnish public sector organisations, such as municipalities, municipal federations, and hospital districts, as well as municipal occupational health care customers. The services offered to public sector customers include full and partial outsourcings, health care staffing services, specialised care services, other health care services, as well as occupational health care services for municipalities, municipal federations, and hospital districts.
Disaggregation of revenue
EUR mill.
1.1.\u201331.12.2025
1.1.\u201331.12.2024
Healthcare Services
1,031.0
1,042.8
Portfolio Businesses
192.5
238.5
Sweden
75.6
81.8
Segments total
1,299.1
1,363.1
Other
-20.3
-23.1
Total
1,278.9
1,340.0
Healthcare Services, revenue
EUR mill.
1.1.\u201331.12.2025
1.1.\u201331.12.2024
By customer
Occupational health customers
588.5
602.2
Consumer customers
223.7
223.8
Insurance customers
187.6
179.5
Service sales
31.3
37.4
Total
1,031.0
1,042.8
By service
Appointments
680.8
686.1
Diagnostics
250.7
254.2
Other
99.5
102.5
Total
1,031.0
1,042.8
Portfolio Businesses, revenue
EUR mill.
1.1.\u201331.12.2025
1.1.\u201331.12.2024
Outsourcing services
54.8
82.8
Staffing services
53.1
73.1
Dental care
52.4
50.3
Other
32.2
32.4
Total
192.5
238.5
Timing of satisfying performance obligations
EUR mill.
1.1.\u201331.12.2025
1.1.\u201331.12.2024
At a point in time
1,222.4
1,255.3
Over time
56.4
84.7
Total
1,278.9
1,340.0
Balances in the statement of financial position
EUR mill.
31 Dec 2025
31 Dec 2024
Contract assets
6.1
7.9
Contract liabilities
6.6
7.0
The Group will satisfy performance obligations related to the contract liabilities within one year.", "dimensions": { "concept": "ifrs-full:DisclosureOfRevenueExplanatory", "language": "en", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00/2026-01-01T00:00:00" } }, "fact-317": { "value": "
6. Other operating income
EUR mill.
1.1.\u201331.12.2025
1.1.\u201331.12.2024
Rental income
0.7
0.9
Gains on sale of property, plant and equipment
0.2
0.3
Other items
3.1
2.5
Total
4.0
3.7
10. Other operating expenses
Specification of other operating expenses
EUR mill.
1.1.\u201331.12.2025
1.1.\u201331.12.2024
External services
-14.2
-18.6
Operating and maintenance expenses for premises and equipment
-24.1
-26.9
ICT expenses
-45.0
-43.8
Non-statutory personnel expenses
-8.1
-8.4
Leases and charges
-4.4
-6.0
Travel expenses
-6.3
-7.1
Marketing and communication
-13.9
-11.1
Acquisition-related expenses
-0.3
-0.3
Other costs
-15.8
-21.6
Total
-132.1
-143.7
Auditor's fees
In thousands of euro
1.1.\u201331.12.2025
1.1.\u201331.12.2024
Audit and auditor's statements based on laws and regulations
Audit, KPMG
-425.1
-436.5
Auditor's statements based on laws and regulations, KPMG*
-73.5
-123.6
Total
-498.6
-560.1
Non audit services
Tax services, KPMG
-4.4
-9.8
Other services, KPMG
-27.8
-30.1
Total
-32.2
-39.9
Auditor's fees total
-530.8
-600.0
Auditor's fees have been presented excluding value-added tax. Non-audit services paid for the parent company\u2019s auditor, KPMG Oy Ab, were 32 (40) thousand euros in total. * Including limited assurance of Sustainability statement .", "dimensions": { "concept": "ifrs-full:DisclosureOfOtherOperatingIncomeExpenseExplanatory", "language": "en", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00/2026-01-01T00:00:00" } }, "fact-318": { "value": "
6. Other operating income
EUR mill.
1.1.\u201331.12.2025
1.1.\u201331.12.2024
Rental income
0.7
0.9
Gains on sale of property, plant and equipment
0.2
0.3
Other items
3.1
2.5
Total
4.0
3.7
", "dimensions": { "concept": "ifrs-full:DisclosureOfOtherOperatingIncomeExplanatory", "language": "en", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00/2026-01-01T00:00:00" } }, "fact-319": { "value": "
7. Materials and services
EUR mill.
1.1.\u201331.12.2025
1.1.\u201331.12.2024
Purchases of materials
-38.2
-41.4
Change in inventories
0.4
0.1
External services
-472.0
-508.5
Total
-509.8
-549.8
", "dimensions": { "concept": "ifrs-full:DisclosureOfCostOfSalesExplanatory", "language": "en", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00/2026-01-01T00:00:00" } }, "fact-320": { "value": "
7. Materials and services
EUR mill.
1.1.\u201331.12.2025
1.1.\u201331.12.2024
Purchases of materials
-38.2
-41.4
Change in inventories
0.4
0.1
External services
-472.0
-508.5
Total
-509.8
-549.8
", "dimensions": { "concept": "ifrs-full:DisclosureOfExpensesExplanatory", "language": "en", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00/2026-01-01T00:00:00" } }, "fact-321": { "value": "
8. Employee benefit expenses
EUR mill.
1.1.\u201331.12.2025
1.1.\u201331.12.2024
Wages and salaries
-328.4
-349.5
Share-based payments
-1.7
-1.6
Pension expenses \u2014 defined contribution plans
-53.8
-56.9
Other social security costs
-19.5
-19.8
Total
-403.5
-427.8
Number of personnel at the end of the reporting period*
8,356
9,153
* Financial year 2025 does not include Turun Silm\u00e4laser Oy and Silm\u00e4sairaala Pilke Oy which were acquired 31 December 2025. Financial
year 2024 does not include the companies acquired during 2024 in Finland (SRK Group Oy, Suomen Radiologikeskus Oy, iRad Oy and
Kajaanin Radiologikeskus Oy and Cityl\u00e4karna Mariehamn Ab).
", "dimensions": { "concept": "ifrs-full:DisclosureOfInformationAboutEmployeesExplanatory", "language": "en", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00/2026-01-01T00:00:00" } }, "fact-322": { "value": "
8. Employee benefit expenses
EUR mill.
1.1.\u201331.12.2025
1.1.\u201331.12.2024
Wages and salaries
-328.4
-349.5
Share-based payments
-1.7
-1.6
Pension expenses \u2014 defined contribution plans
-53.8
-56.9
Other social security costs
-19.5
-19.8
Total
-403.5
-427.8
Number of personnel at the end of the reporting period*
8,356
9,153
* Financial year 2025 does not include Turun Silm\u00e4laser Oy and Silm\u00e4sairaala Pilke Oy which were acquired 31 December 2025. Financial year 2024 does not include the companies acquired during 2024 in Finland (SRK Group Oy, Suomen Radiologikeskus Oy, iRad Oy and Kajaanin Radiologikeskus Oy and Cityl\u00e4karna Mariehamn Ab28. Defined benefit plans The Group has defined benefit plans in Sweden in the Feelgood subgroup. These consists of PSA and PA-KL plans which are closed and for which all the participants have either retired or left the Group. There are no assets related to the Group\u2019s defined benefit plans. The defined benefit plans determine the amount of pension to be paid and the benefits to be paid for disability and at termination of employment. The benefits in these plans are usually based on the length of employment and the level of final salary. The weighted average duration of the defined benefit obligations was seven years at the reporting date. Summary of the impact of the defined benefit plans in the financial statements
EUR mill.
2025
2024
Present value of the defined benefit obligations
1.2
1.3
Expenses related to defined benefit plans
-0.0
0.0
Remeasurements of defined benefit obligations
-0.0
0.1
Reconciliation of the defined benefit obligation
EUR mill.
2025
2024
1 Jan
1.3
1.3
Interest expense (+) / income (-)
0.0
0.1
Benefits paid
-0.1
-0.1
Remeasurement of the obligation
Actuarial gain (-) / loss (+) from change in financial assumptions
-0.0
0.1
Translation differences
0.1
-0.0
31 Dec
1.2
1.3
Applied actuarial assumptions
%
2025
2024
Discount rate
3.40
2.70
Inflation
1.70
1.80
The discount rate is determined based on the yield of Swedish housing market bonds which have a length that approximates the Group\u2019s pension obligations. Sensitivity analysis of the relevant actuarial assumptions\u2019 impact on defined benefit obligation
EUR mill.
2025
2024
0.5%-point increase in the principal assumption
Discount rate
-0.1
-0.0
Inflation
0.1
0.0
0.5%-point decrease in the principal assumption
Discount rate
0.2
0.0
Inflation
-0.2
-0.0
An external actuary has performed the sensitivity analysis for one variable at a time while holding all other variables constant and regardless of the actual volatility of the given variable. Consequently, the purpose of the analysis is not to quantify the expected change in the defined benefit obligation but to illustrate the sensitivity of the value of the obligation to these variables. Compensation for the key management Remuneration to the CEO, in thousands of euro 2025 2024 Fixed pay 472.0 438.2 Other benefits 12.0 13.8 Short-term incentives 413.3 577.7 Share-based payments 327.5 336.2 Pensions (statutory) 147.4 169.1 Total 1,372.2 1,535.0 Renumeration to the CEO is presented on an accrual basis.
Remuneration to the members of the Executive team
(excluding CEO), in thousands of euro
2025
2024
Fixed pay
1,582.7
1,568.1
Other benefits
53.2
40.6
Short-term incentives
435.0
700.5
Share-based payments
363.5
308.3
Termination benefits
44.0
36.0
Pensions (statutory)
344.8
384.4
Total
2,823.2
3,037.9
Renumeration to the members of the Executive team is presented on an accrual basis.
2025
2024
Remuneration to the Annual fee Annual fee Other Annual fee Annual fee Other
Board of Directors, in settled in settled in Meeting financial settled in settled in Meeting financial
thousands of euro cash shares fees benefits* cash shares fees benefits*
Kauniskangas Kari
(Chairman of the
board)
55.1
36.7
18.9
0.6
54.0
36.0
15.8
0.5
Pullola Kristian
32.4
21.6
13.0
0.3
31.8
21.2
10.7
0.3
Rosenberg Matts
32.4
21.6
13.0
0.3
31.8
21.2
10.7
0.3
Lemne Carola
25.9
17.2
15.3
0.3
25.4
16.9
14.5
0.3
Lehtoranta Ari
25.9
17.2
13.0
0.3
25.4
16.9
10.1
0.3
Hasselberg Sofia
25.9
17.2
20.3
0.3
25.4
16.9
17.2
0.3
Saraj\u00e4rvi Teija
25.9
17.2
13.0
0.3
25.4
16.9
8.1
0.3
Member of the Board of Directors until 26 March 2024
Viippola Katri
-
-
-
-
-
-
2.0
-
Total
223.3
148.9
106.4
2.2
219.2
146.0
89.0
2.2
* Other financial benefits include transfer tax fees for the annual fees paid in shares Bonus scheme The Company operates a bonus scheme, which is determined by the Board of Directors of the Company upon the recommendation of the Remuneration Committee. The CEO and the members of the Executive Team are eligible to participate in the bonus scheme in accordance with the Company\u2019s bonus policy. Annual bonuses are payable based on the attainment of key performance targets of the Company. The key performance targets of the CEO and the Executive Team are based on the Company\u2019s adjusted EBITA as well as the individual business and performance targets. The individual business and performance targets are set by the manager of the participant in the bonus scheme. The Board of Directors of Terveystalo Plc has resolved on share-based incentive plans directed to the Group\u2019s key employees. More information on the share-based incentive plans is presented in note 19. Share-based payments. ", "dimensions": { "concept": "ifrs-full:DisclosureOfEmployeeBenefitsExplanatory", "language": "en", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00/2026-01-01T00:00:00" } }, "fact-323": { "value": "
9. Depreciation, amortisation and impairment
EUR mill.
1.1.\u201331.12.2025
1.1.\u201331.12.2024
Depreciation and amortisation by asset type
Intangible assets
Trademarks
-4.7
-4.7
Customer relationships
-1.7
-2.2
Other intangible assets
-16.5
-20.4
Total
-23.0
-27.2
Property, plant and equipment
Buildings
-0.0
-0.1
Machinery and equipment
-14.6
-16.4
Improvement to premises
-6.8
-7.3
Total
-21.5
-23.7
Right-of-use assets
-51.4
-51.2
Investment property
-0.0
-0.0
Depreciation and amortisation total
-95.8
-102.1
Impairment losses by asset groups
Goodwill
-4.1
-
Other intangible assets
-
-2.5
Land and water
-
-0.0
Buildings and structures
-
-0.2
Other property, plant and equipment
-
-0.1
Machinery and equipment
-0.0
-0.0
Improvement to premises
-0.0
-0.3
Right-of-use assets
-
-1.1
Stocks and shares
-
-0.1
Impairment total
-4.1
-4.2
Total depreciation, amortisation and impairment losses
-100.0
-106.4
", "dimensions": { "concept": "ifrs-full:DisclosureOfDepreciationAndAmortisationExpenseExplanatory", "language": "en", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00/2026-01-01T00:00:00" } }, "fact-324": { "value": "
9. Depreciation, amortisation and impairment
EUR mill.
1.1.\u201331.12.2025
1.1.\u201331.12.2024
Depreciation and amortisation by asset type
Intangible assets
Trademarks
-4.7
-4.7
Customer relationships
-1.7
-2.2
Other intangible assets
-16.5
-20.4
Total
-23.0
-27.2
Property, plant and equipment
Buildings
-0.0
-0.1
Machinery and equipment
-14.6
-16.4
Improvement to premises
-6.8
-7.3
Total
-21.5
-23.7
Right-of-use assets
-51.4
-51.2
Investment property
-0.0
-0.0
Depreciation and amortisation total
-95.8
-102.1
Impairment losses by asset groups
Goodwill
-4.1
-
Other intangible assets
-
-2.5
Land and water
-
-0.0
Buildings and structures
-
-0.2
Other property, plant and equipment
-
-0.1
Machinery and equipment
-0.0
-0.0
Improvement to premises
-0.0
-0.3
Right-of-use assets
-
-1.1
Stocks and shares
-
-0.1
Impairment total
-4.1
-4.2
Total depreciation, amortisation and impairment losses
-100.0
-106.4
16. Impairment testing of cash-generating units including goodwill
Goodwill is not amortised but it is tested for impairment at least annually. The regular impairment testing of
Terveystalo Group is conducted annually based on the situation at the end of October.
Terveystalo Group consists of three operating segments: Healthcare Services, Portfolio Businesses, and Sweden.
Healthcare Services and Sweden are also cash-generating units. The Portfolio Businesses segment includes Public and
Private payor cash-generating units.
Healthcare Services and Sweden consist of units with their own budgets and performance measurement and
are centrally managed. Portfolio Businesses are managed as a whole, they partly share resources and are centrally
managed, but cash flows generated, marketing functions and identifiable assets are different for Public and
Private payors.
In 2024 and 2025, based on impairment testing calculations performed, there was no impairment needs to goodwill
for cash-generating units. For all cash-generating units, recoverable amounts exceeded their carrying amounts.
At the balance sheet date of 31 December 2025, the assets and liabilities of child welfare services business were
classified as held for sale, forming a separate cash-generating unit. In conjunction with this classification, the net
assets of the child welfare services business were valued to reflect the fair value less costs to sell. As a result of
the revaluation, an impairment of EUR 4.1 million was recorded on the goodwill allocated to child welfare services
business. The impairment is reported under the Other section. The assets held for sale and associated liabilities of the
child welfare services business were previously included in the Portfolio Businesses, public payor cash-generating unit
before being classified as held for sale. Additional information on assets held for sale can be found in Note 32.
Goodwill arising from business combinations has been allocated to cash-generating units as shown in the
table below.
31 Dec 2025
31 Dec 2024
EUR mill.
Goodwill
%
Impairment
Goodwill
%
Healthcare Services
621.3
74.1%
-
607.2
73.2%
Portfolio Businesses, Public payor
140.5
16.7%
-
149.4
18.0%
Portfolio Businesses, Private payor
30.8
3.7%
-
29.1
3.5%
Sweden
46.3
5.5%
-
43.7
5.3%
Total
838.8
100.0%
-
829.4
100.0%
Transfer to assets held for sale
4.9
-
4.1
-
-
In financial years 2024 and 2025, there were four cash generating units in total. The recoverable amounts of the
cash-generating units are based on value-in-use calculations which have been calculated using discounted cash
flow projections. The key assumptions used in the calculations are terminal period revenue growth rate, profitability
(EBIT %) and the discount rate. The projections are based on the budgets and estimates for the years 2026\u20132029,
including the long-term growth, which have been approved by the management.
Portfolio Portfolio
The assumptions used in impairment Healthcare Businesses, Public Businesses,
calculations in 2025 Services payor
Private payor
Sweden
The length of impairment testing period
4 years
4 years
4 years
4 years
Terminal period revenue growth rate
2.0%
2.0%
2.0%
2.0%
Profitability (EBIT %) during the terminal period
11.9%
6.0%
4.9%
5.1%
Discount rate (Pre-tax WACC)
8.7%
9.7%
8.6%
9.2%
Discount rate (Post-tax WACC)
7.3%
8.2%
7.3%
7.8%
Portfolio Portfolio
The assumptions used in impairment Healthcare Businesses, Public Businesses,
calculations in 2024 Services payor
Private payor
Sweden
The length of impairment testing period
4 years
4 years
4 years
4 years
Terminal period revenue growth rate
2.0%
2.0%
2.0%
2.0%
Profitability (EBIT %) during the terminal period
13.8%
7.8%
9.4%
5.7%
Discount rate (Pre-tax WACC)
8.5%
9.9%
8.5%
8.6%
Discount rate (Post-tax WACC)
7.2%
8.3%
7.2%
7.4%
Revenue growth during the terminal period is based on a flat growth factor which corresponds to long-term
target inflation of the European Central Bank. Profitability during the terminal period is based on the assumed
organic growth under normal market situation, general development in healthcare services market and long-term
estimates by the Group\u2019s management.
The discount rate used in impairment testing has been Pre-tax WACC of which the components are risk-free
interest rate, risk premiums, industry-specific beta, industry-specific cost of debt, and industry specific equity/debt
ratios.
Sensitivity analysis
The Group has assessed the sensitivity of the impairment testing to the effect of the most critical assumptions used
in the calculation. The table below shows the required change in a single assumption that the recoverable amount
would fall below the carrying amount.
Variable
2025
2024
Terminal period revenue growth rate
Healthcare Services
Decrease over 12.5 percentage points
Decrease over 24.5 percentage points
Portfolio Businesses, Public payor
Decrease over 0.4 percentage points
Decrease over 2.1 percentage points
Portfolio Businesses, Private payor
Decrease over 5.7 percentage points
Decrease over 21.3 percentage points
Sweden
Decrease over 2.4 percentage points
Decrease over 1.8 percentage points
Profitability (EBIT %) during the terminal period
Healthcare Services
Decrease over 9.0 percentage points
Decrease over 12.3 percentage points
Portfolio Businesses, Public payor
Decrease over 0.4 percentage points
Decrease over 2.1 percentage points
Portfolio Businesses, Private payor
Decrease over 2.7 percentage points
Decrease over 8.0 percentage points
Sweden
Decrease over 1.6 percentage points
Decrease over 1.5 percentage points
Discount rate (Pre-tax WACC)
Healthcare Services
Increase over 9.1 percentage points
Increase over 18.8 percentage points
Portfolio Businesses, Public payor
Increase over 0.4 percentage points
Increase over 2.2 percentage points
Portfolio Businesses, Private payor
Increase over 4.5 percentage points
Increase over 15.8 percentage points
Sweden
Increase over 2.0 percentage points
Increase over 1.8 percentage points
When assessing the recoverable amounts of cash generating units, management believes that no reasonably
possible change in any of the key variables used would lead to a situation where the recoverable amount of the
units would fall below their carrying amount in Healthcare Services or Portfolio Businesses, Private payor cash-
generating units.
According to the impairment testing, for Portfolio Businesses, Public payor and Sweden cash-generating units,
changes in critical assumptions presented in table above would lead to carrying amount of assets to be equivalent
to recoverable amount. Portfolio Businesses, Public payor cash-generating unit\u2019s carrying amount of tested assets
at the time of impairment testing was EUR 147.4 million. Sweden cash-generating unit\u2019s carrying amount of tested
assets at the time of impairment testing was EUR 49.9 million.
", "dimensions": { "concept": "ifrs-full:DisclosureOfImpairmentOfAssetsExplanatory", "language": "en", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00/2026-01-01T00:00:00" } }, "fact-325": { "value": "
10. Other operating expenses
Specification of other operating expenses
EUR mill.
1.1.\u201331.12.2025
1.1.\u201331.12.2024
External services
-14.2
-18.6
Operating and maintenance expenses for premises and equipment
-24.1
-26.9
ICT expenses
-45.0
-43.8
Non-statutory personnel expenses
-8.1
-8.4
Leases and charges
-4.4
-6.0
Travel expenses
-6.3
-7.1
Marketing and communication
-13.9
-11.1
Acquisition-related expenses
-0.3
-0.3
Other costs
-15.8
-21.6
Total
-132.1
-143.7
", "dimensions": { "concept": "ifrs-full:DisclosureOfGeneralAndAdministrativeExpenseExplanatory", "language": "en", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00/2026-01-01T00:00:00" } }, "fact-326": { "value": "10. Other operating expenses
Specification of other operating expenses
EUR mill.
1.1.\u201331.12.2025
1.1.\u201331.12.2024
External services
-14.2
-18.6
Operating and maintenance expenses for premises and equipment
-24.1
-26.9
ICT expenses
-45.0
-43.8
Non-statutory personnel expenses
-8.1
-8.4
Leases and charges
-4.4
-6.0
Travel expenses
-6.3
-7.1
Marketing and communication
-13.9
-11.1
Acquisition-related expenses
-0.3
-0.3
Other costs
-15.8
-21.6
Total
-132.1
-143.7
Auditor's fees
In thousands of euro
1.1.\u201331.12.2025
1.1.\u201331.12.2024
Audit and auditor's statements based on laws and regulations
Audit, KPMG
-425.1
-436.5
Auditor's statements based on laws and regulations, KPMG*
-73.5
-123.6
Total
-498.6
-560.1
Non audit services
Tax services, KPMG
-4.4
-9.8
Other services, KPMG
-27.8
-30.1
Total
-32.2
-39.9
Auditor's fees total
-530.8
-600.0
Auditor's fees have been presented excluding value-added tax. Non-audit services paid for the parent company\u2019s auditor, KPMG Oy Ab, were 32 (40) thousand euros in total. * Including limited assurance of Sustainability statement ", "dimensions": { "concept": "ifrs-full:DisclosureOfOtherOperatingExpenseExplanatory", "language": "en", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00/2026-01-01T00:00:00" } }, "fact-327": { "value": "
Auditor's fees
In thousands of euro
1.1.\u201331.12.2025
1.1.\u201331.12.2024
Audit and auditor's statements based on laws and regulations
Audit, KPMG
-425.1
-436.5
Auditor's statements based on laws and regulations, KPMG*
-73.5
-123.6
Total
-498.6
-560.1
Non audit services
Tax services, KPMG
-4.4
-9.8
Other services, KPMG
-27.8
-30.1
Total
-32.2
-39.9
Auditor's fees total
-530.8
-600.0
Auditor's fees have been presented excluding value-added tax. Non-audit services paid for the parent company\u2019s auditor, KPMG Oy Ab, were 32 (40) thousand euros in total. * Including limited assurance of Sustainability statement ", "dimensions": { "concept": "ifrs-full:DisclosureOfAuditorsRemunerationExplanatory", "language": "en", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00/2026-01-01T00:00:00" } }, "fact-328": { "value": "
11. Financial income and expenses
EUR mill.
1.1.\u201331.12.2025
1.1.\u201331.12.2024
Interest income on loans and other receivables
1.8
2.1
Dividend income
0.0
0.0
Total financial income
1.8
2.1
Interest expense on loans from financial institutions
-8.7
-13.9
Interest expense on bonds
-5.4
-5.3
Interest expenses on lease liabilities
-6.5
-6.5
Change in fair value of interest rate derivatives
-1.0
-1.6
Other financial expenses
-1.3
-1.3
Total financial expenses
-23.0
-28.6
Net financial expenses
-21.2
-26.5
", "dimensions": { "concept": "ifrs-full:DisclosureOfInterestIncomeExpenseExplanatory", "language": "en", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00/2026-01-01T00:00:00" } }, "fact-329": { "value": "
11. Financial income and expenses
EUR mill.
1.1.\u201331.12.2025
1.1.\u201331.12.2024
Interest income on loans and other receivables
1.8
2.1
Dividend income
0.0
0.0
Total financial income
1.8
2.1
Interest expense on loans from financial institutions
-8.7
-13.9
Interest expense on bonds
-5.4
-5.3
Interest expenses on lease liabilities
-6.5
-6.5
Change in fair value of interest rate derivatives
-1.0
-1.6
Other financial expenses
-1.3
-1.3
Total financial expenses
-23.0
-28.6
Net financial expenses
-21.2
-26.5
", "dimensions": { "concept": "ifrs-full:DisclosureOfInterestIncomeExplanatory", "language": "en", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00/2026-01-01T00:00:00" } }, "fact-330": { "value": "
11. Financial income and expenses
EUR mill.
1.1.\u201331.12.2025
1.1.\u201331.12.2024
Interest income on loans and other receivables
1.8
2.1
Dividend income
0.0
0.0
Total financial income
1.8
2.1
Interest expense on loans from financial institutions
-8.7
-13.9
Interest expense on bonds
-5.4
-5.3
Interest expenses on lease liabilities
-6.5
-6.5
Change in fair value of interest rate derivatives
-1.0
-1.6
Other financial expenses
-1.3
-1.3
Total financial expenses
-23.0
-28.6
Net financial expenses
-21.2
-26.5
", "dimensions": { "concept": "ifrs-full:DisclosureOfInterestExpenseExplanatory", "language": "en", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00/2026-01-01T00:00:00" } }, "fact-331": { "value": "
11. Financial income and expenses
EUR mill.
1.1.\u201331.12.2025
1.1.\u201331.12.2024
Interest income on loans and other receivables
1.8
2.1
Dividend income
0.0
0.0
Total financial income
1.8
2.1
Interest expense on loans from financial institutions
-8.7
-13.9
Interest expense on bonds
-5.4
-5.3
Interest expenses on lease liabilities
-6.5
-6.5
Change in fair value of interest rate derivatives
-1.0
-1.6
Other financial expenses
-1.3
-1.3
Total financial expenses
-23.0
-28.6
Net financial expenses
-21.2
-26.5
", "dimensions": { "concept": "ifrs-full:DisclosureOfFinanceIncomeExplanatory", "language": "en", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00/2026-01-01T00:00:00" } }, "fact-332": { "value": "
11. Financial income and expenses
EUR mill.
1.1.\u201331.12.2025
1.1.\u201331.12.2024
Interest income on loans and other receivables
1.8
2.1
Dividend income
0.0
0.0
Total financial income
1.8
2.1
Interest expense on loans from financial institutions
-8.7
-13.9
Interest expense on bonds
-5.4
-5.3
Interest expenses on lease liabilities
-6.5
-6.5
Change in fair value of interest rate derivatives
-1.0
-1.6
Other financial expenses
-1.3
-1.3
Total financial expenses
-23.0
-28.6
Net financial expenses
-21.2
-26.5
", "dimensions": { "concept": "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory", "language": "en", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00/2026-01-01T00:00:00" } }, "fact-333": { "value": "
11. Financial income and expenses
EUR mill.
1.1.\u201331.12.2025
1.1.\u201331.12.2024
Interest income on loans and other receivables
1.8
2.1
Dividend income
0.0
0.0
Total financial income
1.8
2.1
Interest expense on loans from financial institutions
-8.7
-13.9
Interest expense on bonds
-5.4
-5.3
Interest expenses on lease liabilities
-6.5
-6.5
Change in fair value of interest rate derivatives
-1.0
-1.6
Other financial expenses
-1.3
-1.3
Total financial expenses
-23.0
-28.6
Net financial expenses
-21.2
-26.5
", "dimensions": { "concept": "ifrs-full:DisclosureOfFinanceCostExplanatory", "language": "en", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00/2026-01-01T00:00:00" } }, "fact-334": { "value": "12. Taxes 12.1 Income taxes
Income taxes in the statement of income
EUR mill.
1.1.\u201331.12.2025
1.1.\u201331.12.2024
Current tax for the reporting year
-27.3
-20.7
Income taxes for previous periods
0.2
-0.1
Change in deferred taxes
3.6
2.8
Total income taxes
-23.5
-18.0
Reconciliation of the Group's tax rate to the Finnish tax rate
EUR mill.
1.1.\u201331.12.2025
1.1.\u201331.12.2024
Profit or loss before taxes
116.2
89.6
Tax using the parent company's tax rate
-23.2
-17.9
Tax rates in foreign jurisdictions
0.1
0.1
Tax exempt income
0.3
0.5
Non-deductible expenses
-1.1
-0.5
Share of profit in joint ventures
0.0
-
Recognition of previously unrecognised tax losses
0.1
0.0
Tax losses for which no deferred taxes are recognised
-0.3
-0.0
Taxes from previous periods
0.2
-0.1
Other
0.3
0.1
Total income taxes in the statement of income
-23.5
-18.0
Global minimum top-up tax (Pillar 2) The Terveystalo Group has conducted OECD\u2019s global minimum tax calculations (Pillar Two) for the taxation of its group companies. The Group operates in Finland, Sweden and, to a limited extent, Estonia. Based on the calculation, the Group\u2019s effective tax rate is 16 percent at minimum in all reportable jurisdictions. Consequently, no top-up taxes are expected to arise or become payable within the Terveystalo Group under the applicable tax regulation.", "dimensions": { "concept": "ifrs-full:DisclosureOfIncomeTaxExplanatory", "language": "en", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00/2026-01-01T00:00:00" } }, "fact-335": { "value": "
Global minimum top-up tax (Pillar 2)
The Terveystalo Group has conducted OECD\u2019s global minimum tax calculations (Pillar Two) for the taxation of
its group companies. The Group operates in Finland, Sweden and, to a limited extent, Estonia. Based on the
calculation, the Group\u2019s effective tax rate is 16 percent at minimum in all reportable jurisdictions. Consequently,
no top-up taxes are expected to arise or become payable within the Terveystalo Group under the applicable tax
regulation.
", "dimensions": { "concept": "ifrs-full:DisclosureOfKnownOrReasonablyEstimableInformationAboutExposureToPillarTwoIncomeTaxesExplanatory", "language": "en", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00/2026-01-01T00:00:00" } }, "fact-336": { "value": "
12.2 Deferred tax assets and liabilities
Deferred tax assets 2025
Recognised in
Business the statement of Translation
EUR mill.
1 Jan 2025
combinations income
differences
31 Dec 2025
Provisions
1.0
-
-0.2
-
0.8
Tax losses carried forward
2.6
-
1.6
0.2
4.3
Leases
1.9
0.0
0.4
0.0
2.3
Interest rate derivatives
0.1
-
-0.1
-
-
Other temporary differences
1.6
-
0.4
-
2.0
Total
7.1
0.0
2.2
0.2
9.3
Deferred tax liabilities 2025
Recognised in
Investments in the statement Translation
EUR mill.
1 Jan 2025
joint ventures of income
differences
Reclassification
31 Dec 2025
Reversal of goodwill
amortisation
3.4
-
0.2
-
-
3.6
Business combinations
10.2
0.4
-1.7
0.0
-
8.8
Depreciation difference
3.7
-
0.4
-
-
4.1
Loan withdrawal expense
0.2
-
-0.1
-
-
0.2
Interest rate derivatives
0.7
-
-0.3
-
-
0.4
Other temporary differences
0.7
-
0.0
0.0
-
0.7
Transfer to assets held for sale
-
-
-
-
-0.0
-0.0
Total
18.7
0.4
-1.4
0.0
-0.0
17.6
The Group has no material deductible temporary differences, unused tax losses or unused tax credits for which no
deferred tax asset has been recognised.
Deferred taxes from lease agreements 2025
Recognised
in the
Business statement of Translation
EUR mill.
1 Jan 2025
combinations
Additions
Disposals
income
differences
31 Dec 2025
Deferred tax asset
38.5
0.0
13.8
-2.3
-9.8
0.2
40.4
Deferred tax liability
-36.6
-0.0
-13.8
2.3
10.3
-0.2
-38.1
Total
1.9
0.0
0.0
0.0
0.5
0.0
2.3
Deferred tax assets 2024
Recognised in
Business the statement of
EUR mill.
1 Jan 2024
combinations
income
31 Dec 2024
Provisions
1.2
-
-0.2
1.0
Tax losses carried forward
1.5
-
1.1
2.6
Leases
1.5
0.0
0.4
1.9
Interest rate derivatives
0.0
-
0.0
0.1
Other temporary differences
1.8
-
-0.2
1.6
Total
6.0
0.0
1.2
7.1
Deferred tax liabilities 2024
Recognised in
Business the statement of Translation
EUR mill.
1 Jan 2024
combinations income
difference
31 Dec 2024
Reversal of goodwill
amortisation
3.2
-
0.2
-
3.4
Business combinations
11.9
-
-1.6
-0.1
10.2
Depreciation difference
3.3
-
0.4
-
3.7
Loan withdrawal expense
0.2
-
-0.1
-
0.2
Interest rate derivatives
0.9
-
-0.3
-
0.7
Other temporary differences
0.8
-
-0.1
-
0.7
Total
20.2
-
-1.5
-0.1
18.7
The Group has no material deductible temporary differences, unused tax losses or unused tax credits for which no
deferred tax asset has been recognised.
Deferred taxes from lease agreements 2024
Recognised
in the
Business statement of Translation
EUR mill.
1 Jan 2024
combinations
Additions
Disposals
income
difference
31 Dec 2024
Deferred tax asset
44.8
0.2
10.5
-1.2
-15.8
-0.0
38.5
Deferred tax liability
-43.3
-0.2
-10.5
1.2
16.2
0.0
-36.6
Total
1.5
0.0
0.0
0.0
0.4
0.0
1.9
", "dimensions": { "concept": "ifrs-full:DisclosureOfTaxReceivablesAndPayablesExplanatory", "language": "en", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00/2026-01-01T00:00:00" } }, "fact-337": { "value": "12.2 Deferred tax assets and liabilities
Deferred tax assets 2025
Recognised in
Business the statement of Translation
EUR mill.
1 Jan 2025
combinations income
differences
31 Dec 2025
Provisions
1.0
-
-0.2
-
0.8
Tax losses carried forward
2.6
-
1.6
0.2
4.3
Leases
1.9
0.0
0.4
0.0
2.3
Interest rate derivatives
0.1
-
-0.1
-
-
Other temporary differences
1.6
-
0.4
-
2.0
Total
7.1
0.0
2.2
0.2
9.3
Deferred tax liabilities 2025
Recognised in
Investments in the statement Translation
EUR mill.
1 Jan 2025
joint ventures of income
differences
Reclassification
31 Dec 2025
Reversal of goodwill
amortisation
3.4
-
0.2
-
-
3.6
Business combinations
10.2
0.4
-1.7
0.0
-
8.8
Depreciation difference
3.7
-
0.4
-
-
4.1
Loan withdrawal expense
0.2
-
-0.1
-
-
0.2
Interest rate derivatives
0.7
-
-0.3
-
-
0.4
Other temporary differences
0.7
-
0.0
0.0
-
0.7
Transfer to assets held for sale
-
-
-
-
-0.0
-0.0
Total
18.7
0.4
-1.4
0.0
-0.0
17.6
The Group has no material deductible temporary differences, unused tax losses or unused tax credits for which no deferred tax asset has been recognised.
Deferred taxes from lease agreements 2025
Recognised
in the
Business statement of Translation
EUR mill.
1 Jan 2025
combinations
Additions
Disposals
income
differences
31 Dec 2025
Deferred tax asset
38.5
0.0
13.8
-2.3
-9.8
0.2
40.4
Deferred tax liability
-36.6
-0.0
-13.8
2.3
10.3
-0.2
-38.1
Total
1.9
0.0
0.0
0.0
0.5
0.0
2.3
Deferred tax assets 2024
Recognised in
Business the statement of
EUR mill.
1 Jan 2024
combinations
income
31 Dec 2024
Provisions
1.2
-
-0.2
1.0
Tax losses carried forward
1.5
-
1.1
2.6
Leases
1.5
0.0
0.4
1.9
Interest rate derivatives
0.0
-
0.0
0.1
Other temporary differences
1.8
-
-0.2
1.6
Total
6.0
0.0
1.2
7.1
Deferred tax liabilities 2024
Recognised in
Business the statement of Translation
EUR mill.
1 Jan 2024
combinations income
difference
31 Dec 2024
Reversal of goodwill
amortisation
3.2
-
0.2
-
3.4
Business combinations
11.9
-
-1.6
-0.1
10.2
Depreciation difference
3.3
-
0.4
-
3.7
Loan withdrawal expense
0.2
-
-0.1
-
0.2
Interest rate derivatives
0.9
-
-0.3
-
0.7
Other temporary differences
0.8
-
-0.1
-
0.7
Total
20.2
-
-1.5
-0.1
18.7
The Group has no material deductible temporary differences, unused tax losses or unused tax credits for which no deferred tax asset has been recognised.
Deferred taxes from lease agreements 2024
Recognised
in the
Business statement of Translation
EUR mill.
1 Jan 2024
combinations
Additions
Disposals
income
difference
31 Dec 2024
Deferred tax asset
44.8
0.2
10.5
-1.2
-15.8
-0.0
38.5
Deferred tax liability
-43.3
-0.2
-10.5
1.2
16.2
0.0
-36.6
Total
1.5
0.0
0.0
0.0
0.4
0.0
1.9
", "dimensions": { "concept": "ifrs-full:DisclosureOfDeferredTaxesExplanatory", "language": "en", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00/2026-01-01T00:00:00" } }, "fact-338": { "value": "
13. Earnings per share
EUR mill.
1.1.\u201331.12.2025
1.1.\u201331.12.2024
Result attributable to the equity holders of the company, EUR mill.
92.6
71.7
Weighted average number of outstanding shares, in thousands
126,647
126,597
Diluted average number of outstanding shares, in thousands
126,781
126,727
Basic earnings per share for result attributable to the equity holders of the company, EUR
0.73
0.57
Diluted earnings per share for result attributable to the equity holders of the company, EUR
0.73
0.57
", "dimensions": { "concept": "ifrs-full:DisclosureOfEarningsPerShareExplanatory", "language": "en", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00/2026-01-01T00:00:00" } }, "fact-339": { "value": "14. Tangible assets 14.1 Property, plant and equipment
Land and water, Other tangible
2025 buildings and Machinery and Improvement to assets and
MEUR constructions equipment premises
advances paid
Total
Acquisition cost 1 Jan 2025
2.3
196.6
80.8
7.7
287.4
Business combination
-
0.0
0.0
-
0.0
Additions
-
12.0
0.9
17.9
30.8
Disposals
-
-0.4
-
-
-0.4
Translation differences
0.0
0.2
0.0
0.0
0.3
Transfers between items
-
2.9
12.3
-15.2
-
Transfer to assets held for
sale*
-
-0.6
-0.5
-
-1.1
Acquisition cost 31 Dec 2025
2.3
210.7
93.5
10.3
316.9
Accumulated depreciation
and impairment losses
1 Jan 2025
-1.5
-148.4
-49.7
-0.1
-199.7
Depreciation
-0.0
-14.6
-6.8
-
-21.5
Impairment losses
-
-0.0
-0.0
-
-0.0
Translation differences
-0.0
-0.2
-0.0
-
-0.2
Transfer to assets held for
sale*
-
0.3
0.2
-
0.5
Accumulated depreciation
and impairment losses
31 Dec 2025
-1.5
-162.8
-56.4
-0.1
-220.9
Carrying amount 1 Jan 2025
0.8
48.2
31.1
7.5
87.7
Carrying amount 31 Dec 2025
0.8
47.8
37.2
10.2
96.0
* Additional information regarding assets held for sale in note 32.
Land and water, Other tangible
2024 buildings and Machinery and Improvement to assets and
MEUR constructions equipment premises
advances paid
Total
Acquisition cost 1 Jan 2024
2.3
179.7
76.6
1.1
259.7
Business combination
-
0.5
0.0
-
0.5
Additions
-
16.6
1.0
10.1
27.6
Disposals
-
-0.3
-
-
-0.3
Translation differences
-0.0
-0.1
-0.0
-0.0
-0.1
Transfers between items
-
0.4
3.1
-3.5
-
Acquisition cost 31 Dec 2024
2.3
196.6
80.8
7.7
287.4
Accumulated depreciation
and impairment losses
1 Jan 2024
-1.2
-132.1
-42.2
-
-175.5
Depreciation
-0.1
-16.4
-7.3
-
-23.7
Impairment losses
-0.2
-0.0
-0.3
-0.1
-0.5
Translation differences
0.0
0.1
0.0
-
0.1
Accumulated depreciation
and impairment losses
31 Dec 2024
-1.5
-148.4
-49.7
-0.1
-199.7
Carrying amount 1 Jan 2024
1.2
47.5
34.5
1.1
84.2
Carrying amount 31 Dec 2024
0.8
48.2
31.1
7.5
87.7
", "dimensions": { "concept": "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory", "language": "en", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00/2026-01-01T00:00:00" } }, "fact-340": { "value": "
14.2 Right of-use-assets
2025 Other right-of-
MEUR
Premises
use assets
Total
Acquisition cost 1 Jan 2025
446.3
41.1
487.4
Business combination
0.1
-
0.1
Additions
68.3
0.7
69.0
Disposals
-9.0
-
-9.0
Translation differences
2.1
0.1
2.1
Transfers between items
-0.2
0.2
-
Transfer to assets held for sale*
-5.3
-
-5.3
Acquisition cost 31 Dec 2025
502.3
42.0
544.4
Accumulated depreciation and impairment losses 1 Jan 2025
-266.9
-37.7
-304.7
Depreciation for the reporting period
-49.4
-2.1
-51.4
Translation differences
-1.2
-0.0
-1.2
Transfer to assets held for sale*
2.4
-
2.4
Accumulated depreciation and impairment losses 31 Dec 2025
-315.0
-39.9
-354.9
Carrying amount 1 Jan 2025
179.4
3.3
182.7
Carrying amount 31 Dec 2025
187.3
2.2
189.5
* Additional information regarding assets held for sale in note 32.
2024 Other right-of-
MEUR
Premises
use assets
Total
Acquisition cost 1 Jan 2024
424.0
40.9
464.9
Business combination
1.2
-
1.2
Additions
28.4
0.2
28.7
Disposals
-6.5
-0.1
-6.5
Translation differences
-0.9
-0.0
-0.9
Acquisition cost 31 Dec 2024
446.3
41.1
487.4
Accumulated depreciation and impairment losses 1 Jan 2024
-217.9
-34.9
-252.8
Depreciation for the reporting period
-48.8
-2.4
-51.2
Impairment losses
-0.6
-0.4
-1.1
Translation differences
0.4
0.0
0.4
Accumulated depreciation and impairment losses 31 Dec 2024
-266.9
-37.7
-304.7
Carrying amount 1 Jan 2024
206.1
6.0
212.1
Carrying amount 31 Dec 2024
179.4
3.3
182.7
14.3 Lease liabilities
31 Dec 2025
MEUR
Premises
Other
Total
Non-current lease liabilities
154.4
2.1
156.5
Current lease liabilities
43.9
2.2
46.1
Transfers to liabilities directly associated with the assets held for sale
-2.9
-
-2.9
Total lease liabilities
195.4
4.2
199.7
* Additional information regarding assets held for sale in note 32.
31 Dec 2024
MEUR
Premises
Other
Total
Non-current lease liabilities
141.0
3.6
144.5
Current lease liabilities
45.1
2.2
47.3
Total lease liabilities
186.1
5.8
191.8
", "dimensions": { "concept": "ifrs-full:DisclosureOfLeasesExplanatory", "language": "en", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00/2026-01-01T00:00:00" } }, "fact-341": { "value": "
15. Goodwill and intangible assets
Other intangible
2025 Customer assets and
MEUR
Goodwill
relationships
Trademarks
advances paid
Total
Acquisition cost 1 Jan 2025
954.7
167.5
88.6
168.6
1,379.5
Business combination
15.8
-
-
-
15.8
Additions
-
-
-
20.8
20.8
Translation differences
2.6
0.3
0.2
0.8
3.9
Transfer to assets held for
sale*
-8.9
-1.4
-
-0.0
-10.3
Acquisition cost 31 Dec 2025
964.1
166.4
88.8
190.1
1,409.5
Accumulated amortisations
and impairment losses
1 Jan 2025
-125.3
-158.4
-47.8
-136.6
-468.1
Amortisation
-
-1.7
-4.7
-16.4
-22.8
Impairment losses*
-4.1
-
-
-
-4.1
Translation differences
-
-0.1
-0.1
-0.4
-0.7
Transfer to assets held for
sale*
4.1
1.2
-
0.0
5.2
Accumulated amortisations
and impairment losses
31 Dec 2025
-125.3
-159.1
-52.6
-153.5
-490.4
Carrying amount 1 Jan 2025
829.4
9.2
40.8
32.1
911.4
Carrying amount 31 Dec 2025
838.8
7.4
36.3
36.7
919.2
* Additional information regarding assets held for sale and related impairments in note 32 .
Other intangible
2024 Customer assets and
MEUR
Goodwill
relationships
Trademarks
advances paid
Total
Acquisition cost 1 Jan 2024
948.8
167.8
88.7
156.6
1,361.9
Business combination
8.5
-
-
0.1
8.6
Additions
-
-
-
12.2
12.2
Disposals*
-1.1
-0.1
-
-
-1.2
Translation differences
-1.4
-0.2
-0.1
-0.4
-2.1
Acquisition cost 31 Dec 2024
954.7
167.5
88.6
168.6
1,379.5
Accumulated amortisations
and impairment losses
1 Jan 2024
-125.3
-156.2
-43.2
-113.9
-438.6
Amortisation
-
-2.2
-4.7
-20.4
-27.2
Impairment losses
-
-
-
-2.5
-2.5
Translation differences
-
0.1
0.0
0.2
0.2
Accumulated amortisations
and impairment losses
31 Dec 2024
-125.3
-158.4
-47.8
-136.6
-468.1
Carrying amount 1 Jan 2024
823.5
11.6
45.6
42.8
923.4
Carrying amount 31 Dec 2024
829.4
9.2
40.8
32.1
911.4
* Disposals to goodwill and customer relationships relate to the sale of entire share capital of Sivupersoona Oy, a company providing sign language interpreting services
Development expenditure
Other intangible assets include development expenditure as follows:
2025
EUR mill.
Acquisition cost 1 Jan 2025
70.0
Additions
2.0
Transfers from advance payments
9.4
Translation differences
0.4
Transfer to assets held for sale*
-0.0
Acquisition cost 31 Dec 2025
81.8
Accumulated amortisations and impairment losses 1 Jan 2025
-43.4
Amortisation and impairment losses
-13.9
Transfer to assets held for sale*
0.0
Accumulated amortisations and impairment losses 31 Dec 2025
-57.4
Carrying amount 1 Jan 2025
26.5
Carrying amount 31 Dec 2025
24.4
* Additional information regarding assets held for sale in note 32.
2024
EUR mill.
Acquisition cost 1 Jan 2024
57.8
Business combination
0.1
Additions
3.9
Transfers from advance payments
8.3
Translation differences
-0.1
Acquisition cost 31 Dec 2024
70.0
Accumulated amortisations and impairment losses 1 Jan 2024
-25.2
Amortisation and impairment losses
-18.3
Accumulated amortisations and impairment losses 31 Dec 2024
-43.4
Carrying amount 1 Jan 2024
32.6
Carrying amount 31 Dec 2024
26.5
", "dimensions": { "concept": "ifrs-full:DisclosureOfIntangibleAssetsAndGoodwillExplanatory", "language": "en", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00/2026-01-01T00:00:00" } }, "fact-342": { "value": "
15. Goodwill and intangible assets
Other intangible
2025 Customer assets and
MEUR
Goodwill
relationships
Trademarks
advances paid
Total
Acquisition cost 1 Jan 2025
954.7
167.5
88.6
168.6
1,379.5
Business combination
15.8
-
-
-
15.8
Additions
-
-
-
20.8
20.8
Translation differences
2.6
0.3
0.2
0.8
3.9
Transfer to assets held for
sale*
-8.9
-1.4
-
-0.0
-10.3
Acquisition cost 31 Dec 2025
964.1
166.4
88.8
190.1
1,409.5
Accumulated amortisations
and impairment losses
1 Jan 2025
-125.3
-158.4
-47.8
-136.6
-468.1
Amortisation
-
-1.7
-4.7
-16.4
-22.8
Impairment losses*
-4.1
-
-
-
-4.1
Translation differences
-
-0.1
-0.1
-0.4
-0.7
Transfer to assets held for
sale*
4.1
1.2
-
0.0
5.2
Accumulated amortisations
and impairment losses
31 Dec 2025
-125.3
-159.1
-52.6
-153.5
-490.4
Carrying amount 1 Jan 2025
829.4
9.2
40.8
32.1
911.4
Carrying amount 31 Dec 2025
838.8
7.4
36.3
36.7
919.2
* Additional information regarding assets held for sale and related impairments in note 32
Other intangible
2024 Customer assets and
MEUR
Goodwill
relationships
Trademarks
advances paid
Total
Acquisition cost 1 Jan 2024
948.8
167.8
88.7
156.6
1,361.9
Business combination
8.5
-
-
0.1
8.6
Additions
-
-
-
12.2
12.2
Disposals*
-1.1
-0.1
-
-
-1.2
Translation differences
-1.4
-0.2
-0.1
-0.4
-2.1
Acquisition cost 31 Dec 2024
954.7
167.5
88.6
168.6
1,379.5
Accumulated amortisations
and impairment losses
1 Jan 2024
-125.3
-156.2
-43.2
-113.9
-438.6
Amortisation
-
-2.2
-4.7
-20.4
-27.2
Impairment losses
-
-
-
-2.5
-2.5
Translation differences
-
0.1
0.0
0.2
0.2
Accumulated amortisations
and impairment losses
31 Dec 2024
-125.3
-158.4
-47.8
-136.6
-468.1
Carrying amount 1 Jan 2024
823.5
11.6
45.6
42.8
923.4
Carrying amount 31 Dec 2024
829.4
9.2
40.8
32.1
911.4
* Disposals to goodwill and customer relationships relate to the sale of entire share capital of Sivupersoona Oy, a company providing sign language interpreting services Development expenditure Other intangible assets include development expenditure as follows:
2025
EUR mill.
Acquisition cost 1 Jan 2025
70.0
Additions
2.0
Transfers from advance payments
9.4
Translation differences
0.4
Transfer to assets held for sale*
-0.0
Acquisition cost 31 Dec 2025
81.8
Accumulated amortisations and impairment losses 1 Jan 2025
-43.4
Amortisation and impairment losses
-13.9
Transfer to assets held for sale*
0.0
Accumulated amortisations and impairment losses 31 Dec 2025
-57.4
Carrying amount 1 Jan 2025
26.5
Carrying amount 31 Dec 2025
24.4
* Additional information regarding assets held for sale in note 32.
2024
EUR mill.
Acquisition cost 1 Jan 2024
57.8
Business combination
0.1
Additions
3.9
Transfers from advance payments
8.3
Translation differences
-0.1
Acquisition cost 31 Dec 2024
70.0
Accumulated amortisations and impairment losses 1 Jan 2024
-25.2
Amortisation and impairment losses
-18.3
Accumulated amortisations and impairment losses 31 Dec 2024
-43.4
Carrying amount 1 Jan 2024
32.6
Carrying amount 31 Dec 2024
26.5
", "dimensions": { "concept": "ifrs-full:DisclosureOfIntangibleAssetsExplanatory", "language": "en", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00/2026-01-01T00:00:00" } }, "fact-343": { "value": "Development expenditure Other intangible assets include development expenditure as follows:
2025
EUR mill.
Acquisition cost 1 Jan 2025
70.0
Additions
2.0
Transfers from advance payments
9.4
Translation differences
0.4
Transfer to assets held for sale*
-0.0
Acquisition cost 31 Dec 2025
81.8
Accumulated amortisations and impairment losses 1 Jan 2025
-43.4
Amortisation and impairment losses
-13.9
Transfer to assets held for sale*
0.0
Accumulated amortisations and impairment losses 31 Dec 2025
-57.4
Carrying amount 1 Jan 2025
26.5
Carrying amount 31 Dec 2025
24.4
* Additional information regarding assets held for sale in note 32.
2024
EUR mill.
Acquisition cost 1 Jan 2024
57.8
Business combination
0.1
Additions
3.9
Transfers from advance payments
8.3
Translation differences
-0.1
Acquisition cost 31 Dec 2024
70.0
Accumulated amortisations and impairment losses 1 Jan 2024
-25.2
Amortisation and impairment losses
-18.3
Accumulated amortisations and impairment losses 31 Dec 2024
-43.4
Carrying amount 1 Jan 2024
32.6
Carrying amount 31 Dec 2024
26.5
", "dimensions": { "concept": "ifrs-full:DisclosureOfResearchAndDevelopmentExpenseExplanatory", "language": "en", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00/2026-01-01T00:00:00" } }, "fact-345": { "value": "16. Impairment testing of cash-generating units including goodwill Goodwill is not amortised but it is tested for impairment at least annually. The regular impairment testing of Terveystalo Group is conducted annually based on the situation at the end of October. Terveystalo Group consists of three operating segments: Healthcare Services, Portfolio Businesses, and Sweden. Healthcare Services and Sweden are also cash-generating units. The Portfolio Businesses segment includes Public and Private payor cash-generating units. Healthcare Services and Sweden consist of units with their own budgets and performance measurement and are centrally managed. Portfolio Businesses are managed as a whole, they partly share resources and are centrally managed, but cash flows generated, marketing functions and identifiable assets are different for Public and Private payors. In 2024 and 2025, based on impairment testing calculations performed, there was no impairment needs to goodwill for cash-generating units. For all cash-generating units, recoverable amounts exceeded their carrying amounts. At the balance sheet date of 31 December 2025, the assets and liabilities of child welfare services business were classified as held for sale, forming a separate cash-generating unit. In conjunction with this classification, the net assets of the child welfare services business were valued to reflect the fair value less costs to sell. As a result of the revaluation, an impairment of EUR 4.1 million was recorded on the goodwill allocated to child welfare services business. The impairment is reported under the Other section. The assets held for sale and associated liabilities of the child welfare services business were previously included in the Portfolio Businesses, public payor cash-generating unit before being classified as held for sale. Additional information on assets held for sale can be found in Note 32. Goodwill arising from business combinations has been allocated to cash-generating units as shown in the table below.
31 Dec 2025
31 Dec 2024
EUR mill.
Goodwill
%
Impairment
Goodwill
%
Healthcare Services
621.3
74.1%
-
607.2
73.2%
Portfolio Businesses, Public payor
140.5
16.7%
-
149.4
18.0%
Portfolio Businesses, Private payor
30.8
3.7%
-
29.1
3.5%
Sweden
46.3
5.5%
-
43.7
5.3%
Total
838.8
100.0%
-
829.4
100.0%
Transfer to assets held for sale
4.9
-
4.1
-
-
In financial years 2024 and 2025, there were four cash generating units in total. The recoverable amounts of the cash-generating units are based on value-in-use calculations which have been calculated using discounted cash flow projections. The key assumptions used in the calculations are terminal period revenue growth rate, profitability (EBIT %) and the discount rate. The projections are based on the budgets and estimates for the years 2026\u20132029, including the long-term growth, which have been approved by the management.
Portfolio Portfolio
The assumptions used in impairment Healthcare Businesses, Public Businesses,
calculations in 2025 Services payor
Private payor
Sweden
The length of impairment testing period
4 years
4 years
4 years
4 years
Terminal period revenue growth rate
2.0%
2.0%
2.0%
2.0%
Profitability (EBIT %) during the terminal period
11.9%
6.0%
4.9%
5.1%
Discount rate (Pre-tax WACC)
8.7%
9.7%
8.6%
9.2%
Discount rate (Post-tax WACC)
7.3%
8.2%
7.3%
7.8%
Portfolio Portfolio
The assumptions used in impairment Healthcare Businesses, Public Businesses,
calculations in 2024 Services payor
Private payor
Sweden
The length of impairment testing period
4 years
4 years
4 years
4 years
Terminal period revenue growth rate
2.0%
2.0%
2.0%
2.0%
Profitability (EBIT %) during the terminal period
13.8%
7.8%
9.4%
5.7%
Discount rate (Pre-tax WACC)
8.5%
9.9%
8.5%
8.6%
Discount rate (Post-tax WACC)
7.2%
8.3%
7.2%
7.4%
Revenue growth during the terminal period is based on a flat growth factor which corresponds to long-term target inflation of the European Central Bank. Profitability during the terminal period is based on the assumed organic growth under normal market situation, general development in healthcare services market and long-term estimates by the Group\u2019s management. The discount rate used in impairment testing has been Pre-tax WACC of which the components are risk-free interest rate, risk premiums, industry-specific beta, industry-specific cost of debt, and industry specific equity/debt ratios. Sensitivity analysis The Group has assessed the sensitivity of the impairment testing to the effect of the most critical assumptions used in the calculation. The table below shows the required change in a single assumption that the recoverable amount would fall below the carrying amount.
Variable
2025
2024
Terminal period revenue growth rate
Healthcare Services
Decrease over 12.5 percentage points
Decrease over 24.5 percentage points
Portfolio Businesses, Public payor
Decrease over 0.4 percentage points
Decrease over 2.1 percentage points
Portfolio Businesses, Private payor
Decrease over 5.7 percentage points
Decrease over 21.3 percentage points
Sweden
Decrease over 2.4 percentage points
Decrease over 1.8 percentage points
Profitability (EBIT %) during the terminal period
Healthcare Services
Decrease over 9.0 percentage points
Decrease over 12.3 percentage points
Portfolio Businesses, Public payor
Decrease over 0.4 percentage points
Decrease over 2.1 percentage points
Portfolio Businesses, Private payor
Decrease over 2.7 percentage points
Decrease over 8.0 percentage points
Sweden
Decrease over 1.6 percentage points
Decrease over 1.5 percentage points
Discount rate (Pre-tax WACC)
Healthcare Services
Increase over 9.1 percentage points
Increase over 18.8 percentage points
Portfolio Businesses, Public payor
Increase over 0.4 percentage points
Increase over 2.2 percentage points
Portfolio Businesses, Private payor
Increase over 4.5 percentage points
Increase over 15.8 percentage points
Sweden
Increase over 2.0 percentage points
Increase over 1.8 percentage points
When assessing the recoverable amounts of cash generating units, management believes that no reasonably possible change in any of the key variables used would lead to a situation where the recoverable amount of the units would fall below their carrying amount in Healthcare Services or Portfolio Businesses, Private payor cash- generating units. According to the impairment testing, for Portfolio Businesses, Public payor and Sweden cash-generating units, changes in critical assumptions presented in table above would lead to carrying amount of assets to be equivalent to recoverable amount. Portfolio Businesses, Public payor cash-generating unit\u2019s carrying amount of tested assets at the time of impairment testing was EUR 147.4 million. Sweden cash-generating unit\u2019s carrying amount of tested assets at the time of impairment testing was EUR 49.9 million.", "dimensions": { "concept": "ifrs-full:DisclosureOfGoodwillExplanatory", "language": "en", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00/2026-01-01T00:00:00" } }, "fact-346": { "value": "17. Investment properties Carrying amount of investment properties
EUR mill.
1.1.\u201331.12.2025
1.1.\u201331.12.2024
Carrying amount at the beginning of the period
0.3
0.3
Depreciation
-0.0
-0.0
Carrying amount at the end of the period
0.2
0.3
Income and expenses related to investment properties
EUR mill.
1.1.\u201331.12.2025
1.1.\u201331.12.2024
Rental income from investment properties
0.0
0.1
Operating expenses for investment properties
-0.0
-0.0
Total
0.0
0.0
Income and expenses relating to investment properties are presented based on the Group\u2019s ownership in the investment properties. There are no other contractual obligations related to investment properties. Fair values of investment properties
Value per m
2
(In
Total value
thousands of (In thousands
Investment
m
2
euro) of euro)
Koy Jyv\u00e4skyl\u00e4n V\u00e4in\u00f6nkatu 30
1,348
0.2
269
The value of Kiinteist\u00f6 Oy Jyv\u00e4skyl\u00e4n V\u00e4in\u00f6nkatu has been determined based on the Group\u2019s share of ownership (16.81%)", "dimensions": { "concept": "ifrs-full:DisclosureOfInvestmentPropertyExplanatory", "language": "en", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00/2026-01-01T00:00:00" } }, "fact-347": { "value": "
18. Associated companies and joint ventures
Associated companies
Terveystalo has the following associated companies which are all consolidated using the equity method. The Group
has no individually material associates.
Associated companies 31 Dec 2025
Domicile
Ownership
Voting rights
Terveyden Tuottajat Oy
Finland
0.0%
48.7%
Summarised financial information on associated companies
EUR mill.
2025
2024
Carrying amount
0.0
0.0
Joint ventures
Terveystalo has the following joint ventures which are all consolidated using the equity method.
Joint ventures 31 Dec 2025
Domicile
Ownership
Voting rights
Roxellen BidCo AB
Sweden
25.4%
25.4%
Summarised financial information on joint ventures
EUR mill.
2025
2024
Carrying amount
7.2
-
Group's share of total comprehensive income
-0.2
-
", "dimensions": { "concept": "ifrs-full:DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory", "language": "en", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00/2026-01-01T00:00:00" } }, "fact-348": { "value": "18. Associated companies and joint ventures Associated companies Terveystalo has the following associated companies which are all consolidated using the equity method. The Group has no individually material associates.
Associated companies 31 Dec 2025
Domicile
Ownership
Voting rights
Terveyden Tuottajat Oy
Finland
0.0%
48.7%
Summarised financial information on associated companies
EUR mill.
2025
2024
Carrying amount
0.0
0.0
", "dimensions": { "concept": "ifrs-full:DisclosureOfSignificantInvestmentsInAssociatesExplanatory", "language": "en", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00/2026-01-01T00:00:00" } }, "fact-349": { "value": "Joint ventures Terveystalo has the following joint ventures which are all consolidated using the equity method.
Joint ventures 31 Dec 2025
Domicile
Ownership
Voting rights
Roxellen BidCo AB
Sweden
25.4%
25.4%
Summarised financial information on joint ventures
EUR mill.
2025
2024
Carrying amount
7.2
-
Group's share of total comprehensive income
-0.2
-
", "dimensions": { "concept": "ifrs-full:DisclosureOfJointVenturesExplanatory", "language": "en", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00/2026-01-01T00:00:00" } }, "fact-350": { "value": "19. Share-based payments Performance Share Plan 2021 Performance Share Plan 2021 is targeted at Terveystalo\u2019s key employees. The long-term share-based payment plan is based on a rolling three- year performance period structure, with a new performance period starting each year, if so decided by the Board. The Board decides on the participants, performance measures and targets as well as earning opportunities on an annual basis. Rewards are conditional on the fulfilment of a three-year service condition and performance conditions tied to financial targets that are set separately. The reward is granted as a gross number of Terveystalo shares, including a cash portion for taxes and tax-related expenses arising from the reward to the employee. The reward is settled as net shares. The plan is fully accounted for as an equity settled share-based payment. Under the plan, four performance periods, 2022\u20132024, 2023\u20132025, 2024\u20132026 and 2025\u20132027, have been launched. During 2025, Performance Period 2022\u20132024 ended, and, in consequence, the shares earned were granted according to realization of the plan\u2019s conditional performance measures. In total, 46,869 net shares were granted. The impact of the Performance Period 2022\u20132024 to the result for the period has been EUR 0.1 million, and the total cost of the plan was EUR 1.6 million. 41 persons were included in the arrangement. The impact of the Performance Period 2023\u20132025 to the result for the period has been EUR 0.4 million, and the expected total cost of the plan is EUR 1.5 million. 42 persons are included in the arrangement. The impact of the Performance Period 2024\u20132026 to the result for the period has been EUR 0.6 million, and the expected total cost of the plan is EUR 1.7 million. 57 persons are included in the arrangement. The impact of the Performance Period 2025\u20132027 to the result for the period has been EUR 0.6 million, and the expected total cost of the plan is EUR 2.5 million. 69 persons are included in the arrangement.
Performance Share Plan 2021
2025\u20132027
2024\u20132026
2023\u20132025
2022\u20132024
Grant date
2 Apr 2025
2 Apr 2024
3 Apr 2023
1 Apr 2022
Maximum number of share awards
700,000
640,000
640,000
683,085
Outstanding at 1 Jan 2025
-
581,000
488,666
384,308
Granted share awards during the period
657,000
17,334
8,666
-
Forfeited share awards during the period
57,000
106,000
68,666
289,155
Exercised share awards during the period
-
-
-
95,153
Outstanding at 31 Dec 2025
600,000
492,334
428,666
-
Fair value of the share award at grant date
8.9
6.2
6.6
9.2
End of the performance period
28 Feb 2028
28 Feb 2027
28 Feb 2026
28 Feb 2025
End of the vesting period, expected
31 Mar 2028
31 Mar 2027
31 Mar 2026
17 Mar 2025
Vesting conditions
Service condition,
Service condition, Service condition, Service condition,
total Shareholder total Shareholder total Shareholder total Shareholder
Return (TSR), EBITA Return (TSR), EBITA Return (TSR) Return (TSR)
Exercised
In shares and cash
In shares and cash
In shares and cash
In shares and cash
Restricted Share Plan Restricted Share Plan offers individually selected employees an opportunity to earn a fixed number of shares after a vesting period. Rewards are conditional on the fulfilment of a service condition during the vesting period. The reward is granted as a gross number of Terveystalo shares, including a cash portion for taxes and tax-related expenses arising from the reward to the employee. The reward is settled as net shares. The plan is fully accounted for as an equity settled share-based payment. Four vesting periods have been launched in the plan. During 2025, vesting period 2022\u20132024 ended, and, in consequence, the shares earned were granted according to realization of the plan\u2019s conditional performance measures. In total, 3,448 net shares were granted. At the end of the reporting period, a total of 10 persons were included in the arrangement. The impact to the result of the vesting periods 2022\u20132024, 2023\u20132025, 2024\u20132026 and 2025\u20132027 has been EUR 0.1 million, and the expected total cost of the plan is EUR 0.4 million.
Restricted Share Plan
2025\u20132027
2024\u20132026
2023\u20132025
2022\u20132024
Grant date
25 Jun 2025
15 May 2024
3 Apr 2023
22 Jun 2022
Maximum number of share awards
70,000
64,000
64,000
68,309
Outstanding at 1 Jan 2025
-
23,000
21,000
9,000
Granted share awards during the period
4,000
-
-
-
Forfeited share awards during the period
-
-
3,000
2,000
Exercised share awards during the period
-
-
-
7,000
Outstanding at 31 Dec 2025
4,000
23,000
18,000
-
Fair value of the share award at grant date
9.9
7.9
6.6
9.5
End of the performance period
28 Feb 2028
28 Feb 2027
28 Feb 2026
28 Feb 2025
End of the vesting period, expected
31 Mar 2028
31 Mar 2027
31 Mar 2026
17 Mar 2025
Vesting conditions
Service condition
Service condition
Service condition
Service condition
Exercised
In shares and cash
In shares and cash
In shares and cash
In shares and cash
", "dimensions": { "concept": "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory", "language": "en", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00/2026-01-01T00:00:00" } }, "fact-351": { "value": "
20. Financial assets and liabilities \u2013 carrying amount, fair values and
fair value hierarchy
Financial assets Financial assets
and liabilities at and liabilities at Carrying Fair value
EUR mill. 31 Dec 2025 fair value amortised cost
amount
Fair value
hierarchy
Financial assets
Non-current
Loan receivables
0.0
-
0.0
0.0
Level 2
Unquoted equity investments
1.7
-
1.7
1.7
Level 3
Current
Trade receivables
-
103.0
103.0
103.0
Cash and cash equivalents
-
75.2
75.2
75.2
Interest rate derivatives
3.8
-
3.8
3.8
Level 2
Total
5.4
178.2
183.7
183.7
Financial liabilities
Non-current
Loans from financial institutions
-
232.8
232.8
232.8
Level 2
Bonds
-
99.5
99.5
103.4
Level 1
Contingent considerations
4.8
-
4.8
4.8
Level 3
Current
Loans from financial institutions
-
48.8
48.8
48.8
Level 2
Trade payables
-
47.1
47.1
47.1
Contingent considerations
2.8
-
2.8
2.8
Level 3
Interest rate derivatives
0.4
-
0.4
0.4
Level 2
Total
8.0
428.2
436.2
440.1
Financial assets and liabilities classified at fair value hierarchy level 3 consist of unquoted equity investments and contingent considerations from business combinations. The measurement of unquoted equity investments is based on the managements estimate of future cash flows arising from the investments and the measurement of contingent considerations is based on the amounts specified in purchase agreements and the management estimate on whether the consideration will be realised. The effect on earnings arising from the changes of fair values of financial assets and liabilities classified at fair value hierarchy level 3 has been EUR 1.2 (1.2) million. Financial assets Financial assets and liabilities at and liabilities at Carrying Fair value EUR mill. 31 Dec 2024 fair value amortised cost amount Fair value hierarchy Financial assets Non-current Loan receivables 0.0 - 0.0 0.0 Level 2 Unquoted equity investments 0.7 - 0.7 0.7 Level 3 Current Trade receivables - 117.5 117.5 117.5 Cash and cash equivalents - 65.2 65.2 65.2 Interest rate derivatives 3.4 - 3.4 3.4 Level 2 Total 4.2 182.6 186.7 186.7 Financial liabilities Non-current Loans from financial institutions - 249.2 249.2 249.2 Level 2 Bonds - 99.3 99.3 104.3 Level 1 Hire purchase liabilities - 0.0 0.0 0.0 Level 2 Contingent considerations 2.1 - 2.1 2.1 Level 3 Current Loans from financial institutions - 29.7 29.7 29.7 Level 2 Hire purchase liabilities - 0.0 0.0 0.0 Level 2 Trade payables - 55.6 55.6 55.6 Contingent considerations 2.1 - 2.1 2.1 Level 3 Interest rate derivatives 0.3 - 0.3 0.3 Level 2 Total 4.6 433.8 438.3 443.4", "dimensions": { "concept": "ifrs-full:DisclosureOfFinancialInstrumentsAtFairValueThroughProfitOrLossExplanatory", "language": "en", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00/2026-01-01T00:00:00" } }, "fact-352": { "value": "20. Financial assets and liabilities \u2013 carrying amount, fair values and fair value hierarchy
Financial assets Financial assets
and liabilities at and liabilities at Carrying Fair value
EUR mill. 31 Dec 2025 fair value amortised cost
amount
Fair value
hierarchy
Financial assets
Non-current
Loan receivables
0.0
-
0.0
0.0
Level 2
Unquoted equity investments
1.7
-
1.7
1.7
Level 3
Current
Trade receivables
-
103.0
103.0
103.0
Cash and cash equivalents
-
75.2
75.2
75.2
Interest rate derivatives
3.8
-
3.8
3.8
Level 2
Total
5.4
178.2
183.7
183.7
Financial liabilities
Non-current
Loans from financial institutions
-
232.8
232.8
232.8
Level 2
Bonds
-
99.5
99.5
103.4
Level 1
Contingent considerations
4.8
-
4.8
4.8
Level 3
Current
Loans from financial institutions
-
48.8
48.8
48.8
Level 2
Trade payables
-
47.1
47.1
47.1
Contingent considerations
2.8
-
2.8
2.8
Level 3
Interest rate derivatives
0.4
-
0.4
0.4
Level 2
Total
8.0
428.2
436.2
440.1
Financial assets and liabilities classified at fair value hierarchy level 3 consist of unquoted equity investments and contingent considerations from business combinations. The measurement of unquoted equity investments is based on the managements estimate of future cash flows arising from the investments and the measurement of contingent considerations is based on the amounts specified in purchase agreements and the management estimate on whether the consideration will be realised. The effect on earnings arising from the changes of fair values of financial assets and liabilities classified at fair value hierarchy level 3 has been EUR 1.2 (1.2) million. Financial assets Financial assets and liabilities at and liabilities at Carrying Fair value EUR mill. 31 Dec 2024 fair value amortised cost amount Fair value hierarchy Financial assets Non-current Loan receivables 0.0 - 0.0 0.0 Level 2 Unquoted equity investments 0.7 - 0.7 0.7 Level 3 Current Trade receivables - 117.5 117.5 117.5 Cash and cash equivalents - 65.2 65.2 65.2 Interest rate derivatives 3.4 - 3.4 3.4 Level 2 Total 4.2 182.6 186.7 186.7 Financial liabilities Non-current Loans from financial institutions - 249.2 249.2 249.2 Level 2 Bonds - 99.3 99.3 104.3 Level 1 Hire purchase liabilities - 0.0 0.0 0.0 Level 2 Contingent considerations 2.1 - 2.1 2.1 Level 3 Current Loans from financial institutions - 29.7 29.7 29.7 Level 2 Hire purchase liabilities - 0.0 0.0 0.0 Level 2 Trade payables - 55.6 55.6 55.6 Contingent considerations 2.1 - 2.1 2.1 Level 3 Interest rate derivatives 0.3 - 0.3 0.3 Level 2 Total 4.6 433.8 438.3 443.4", "dimensions": { "concept": "ifrs-full:DisclosureOfFinancialInstrumentsDesignatedAtFairValueThroughProfitOrLossExplanatory", "language": "en", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00/2026-01-01T00:00:00" } }, "fact-353": { "value": "20. Financial assets and liabilities \u2013 carrying amount, fair values and fair value hierarchy
Financial assets Financial assets
and liabilities at and liabilities at Carrying Fair value
EUR mill. 31 Dec 2025 fair value amortised cost
amount
Fair value
hierarchy
Financial assets
Non-current
Loan receivables
0.0
-
0.0
0.0
Level 2
Unquoted equity investments
1.7
-
1.7
1.7
Level 3
Current
Trade receivables
-
103.0
103.0
103.0
Cash and cash equivalents
-
75.2
75.2
75.2
Interest rate derivatives
3.8
-
3.8
3.8
Level 2
Total
5.4
178.2
183.7
183.7
Financial liabilities
Non-current
Loans from financial institutions
-
232.8
232.8
232.8
Level 2
Bonds
-
99.5
99.5
103.4
Level 1
Contingent considerations
4.8
-
4.8
4.8
Level 3
Current
Loans from financial institutions
-
48.8
48.8
48.8
Level 2
Trade payables
-
47.1
47.1
47.1
Contingent considerations
2.8
-
2.8
2.8
Level 3
Interest rate derivatives
0.4
-
0.4
0.4
Level 2
Total
8.0
428.2
436.2
440.1
Financial assets and liabilities classified at fair value hierarchy level 3 consist of unquoted equity investments and contingent considerations from business combinations. The measurement of unquoted equity investments is based on the managements estimate of future cash flows arising from the investments and the measurement of contingent considerations is based on the amounts specified in purchase agreements and the management estimate on whether the consideration will be realised. The effect on earnings arising from the changes of fair values of financial assets and liabilities classified at fair value hierarchy level 3 has been EUR 1.2 (1.2) million. Financial assets Financial assets and liabilities at and liabilities at Carrying Fair value EUR mill. 31 Dec 2024 fair value amortised cost amount Fair value hierarchy Financial assets Non-current Loan receivables 0.0 - 0.0 0.0 Level 2 Unquoted equity investments 0.7 - 0.7 0.7 Level 3 Current Trade receivables - 117.5 117.5 117.5 Cash and cash equivalents - 65.2 65.2 65.2 Interest rate derivatives 3.4 - 3.4 3.4 Level 2 Total 4.2 182.6 186.7 186.7 Financial liabilities Non-current Loans from financial institutions - 249.2 249.2 249.2 Level 2 Bonds - 99.3 99.3 104.3 Level 1 Hire purchase liabilities - 0.0 0.0 0.0 Level 2 Contingent considerations 2.1 - 2.1 2.1 Level 3 Current Loans from financial institutions - 29.7 29.7 29.7 Level 2 Hire purchase liabilities - 0.0 0.0 0.0 Level 2 Trade payables - 55.6 55.6 55.6 Contingent considerations 2.1 - 2.1 2.1 Level 3 Interest rate derivatives 0.3 - 0.3 0.3 Level 2 Total 4.6 433.8 438.3 443.4", "dimensions": { "concept": "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory", "language": "en", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00/2026-01-01T00:00:00" } }, "fact-354": { "value": "20. Financial assets and liabilities \u2013 carrying amount, fair values and fair value hierarchy
Financial assets Financial assets
and liabilities at and liabilities at Carrying Fair value
EUR mill. 31 Dec 2025 fair value amortised cost
amount
Fair value
hierarchy
Financial assets
Non-current
Loan receivables
0.0
-
0.0
0.0
Level 2
Unquoted equity investments
1.7
-
1.7
1.7
Level 3
Current
Trade receivables
-
103.0
103.0
103.0
Cash and cash equivalents
-
75.2
75.2
75.2
Interest rate derivatives
3.8
-
3.8
3.8
Level 2
Total
5.4
178.2
183.7
183.7
Financial liabilities
Non-current
Loans from financial institutions
-
232.8
232.8
232.8
Level 2
Bonds
-
99.5
99.5
103.4
Level 1
Contingent considerations
4.8
-
4.8
4.8
Level 3
Current
Loans from financial institutions
-
48.8
48.8
48.8
Level 2
Trade payables
-
47.1
47.1
47.1
Contingent considerations
2.8
-
2.8
2.8
Level 3
Interest rate derivatives
0.4
-
0.4
0.4
Level 2
Total
8.0
428.2
436.2
440.1
Financial assets and liabilities classified at fair value hierarchy level 3 consist of unquoted equity investments and contingent considerations from business combinations. The measurement of unquoted equity investments is based on the managements estimate of future cash flows arising from the investments and the measurement of contingent considerations is based on the amounts specified in purchase agreements and the management estimate on whether the consideration will be realised. The effect on earnings arising from the changes of fair values of financial assets and liabilities classified at fair value hierarchy level 3 has been EUR 1.2 (1.2) million. Financial assets Financial assets and liabilities at and liabilities at Carrying Fair value EUR mill. 31 Dec 2024 fair value amortised cost amount Fair value hierarchy Financial assets Non-current Loan receivables 0.0 - 0.0 0.0 Level 2 Unquoted equity investments 0.7 - 0.7 0.7 Level 3 Current Trade receivables - 117.5 117.5 117.5 Cash and cash equivalents - 65.2 65.2 65.2 Interest rate derivatives 3.4 - 3.4 3.4 Level 2 Total 4.2 182.6 186.7 186.7 Financial liabilities Non-current Loans from financial institutions - 249.2 249.2 249.2 Level 2 Bonds - 99.3 99.3 104.3 Level 1 Hire purchase liabilities - 0.0 0.0 0.0 Level 2 Contingent considerations 2.1 - 2.1 2.1 Level 3 Current Loans from financial institutions - 29.7 29.7 29.7 Level 2 Hire purchase liabilities - 0.0 0.0 0.0 Level 2 Trade payables - 55.6 55.6 55.6 Contingent considerations 2.1 - 2.1 2.1 Level 3 Interest rate derivatives 0.3 - 0.3 0.3 Level 2 Total 4.6 433.8 438.3 443.4", "dimensions": { "concept": "ifrs-full:DisclosureOfFairValueOfFinancialInstrumentsExplanatory", "language": "en", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00/2026-01-01T00:00:00" } }, "fact-355": { "value": "20. Financial assets and liabilities \u2013 carrying amount, fair values and fair value hierarchy
Financial assets Financial assets
and liabilities at and liabilities at Carrying Fair value
EUR mill. 31 Dec 2025 fair value amortised cost
amount
Fair value
hierarchy
Financial assets
Non-current
Loan receivables
0.0
-
0.0
0.0
Level 2
Unquoted equity investments
1.7
-
1.7
1.7
Level 3
Current
Trade receivables
-
103.0
103.0
103.0
Cash and cash equivalents
-
75.2
75.2
75.2
Interest rate derivatives
3.8
-
3.8
3.8
Level 2
Total
5.4
178.2
183.7
183.7
Financial liabilities
Non-current
Loans from financial institutions
-
232.8
232.8
232.8
Level 2
Bonds
-
99.5
99.5
103.4
Level 1
Contingent considerations
4.8
-
4.8
4.8
Level 3
Current
Loans from financial institutions
-
48.8
48.8
48.8
Level 2
Trade payables
-
47.1
47.1
47.1
Contingent considerations
2.8
-
2.8
2.8
Level 3
Interest rate derivatives
0.4
-
0.4
0.4
Level 2
Total
8.0
428.2
436.2
440.1
Financial assets and liabilities classified at fair value hierarchy level 3 consist of unquoted equity investments and contingent considerations from business combinations. The measurement of unquoted equity investments is based on the managements estimate of future cash flows arising from the investments and the measurement of contingent considerations is based on the amounts specified in purchase agreements and the management estimate on whether the consideration will be realised. The effect on earnings arising from the changes of fair values of financial assets and liabilities classified at fair value hierarchy level 3 has been EUR 1.2 (1.2) million. Financial assets Financial assets and liabilities at and liabilities at Carrying Fair value EUR mill. 31 Dec 2024 fair value amortised cost amount Fair value hierarchy Financial assets Non-current Loan receivables 0.0 - 0.0 0.0 Level 2 Unquoted equity investments 0.7 - 0.7 0.7 Level 3 Current Trade receivables - 117.5 117.5 117.5 Cash and cash equivalents - 65.2 65.2 65.2 Interest rate derivatives 3.4 - 3.4 3.4 Level 2 Total 4.2 182.6 186.7 186.7 Financial liabilities Non-current Loans from financial institutions - 249.2 249.2 249.2 Level 2 Bonds - 99.3 99.3 104.3 Level 1 Hire purchase liabilities - 0.0 0.0 0.0 Level 2 Contingent considerations 2.1 - 2.1 2.1 Level 3 Current Loans from financial institutions - 29.7 29.7 29.7 Level 2 Hire purchase liabilities - 0.0 0.0 0.0 Level 2 Trade payables - 55.6 55.6 55.6 Contingent considerations 2.1 - 2.1 2.1 Level 3 Interest rate derivatives 0.3 - 0.3 0.3 Level 2 Total 4.6 433.8 438.3 443.4", "dimensions": { "concept": "ifrs-full:DisclosureOfBorrowingsExplanatory", "language": "en", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00/2026-01-01T00:00:00" } }, "fact-356": { "value": "21. Financial risks 21.1 Financial risk management The Group is exposed to various financial risks in its normal business activities. The objective of the Group\u2019s risk management is to minimise the negative effects of changes in the financial markets on the Group\u2019s result and valuation. The Group\u2019s main financial risks are interest rate risk, credit risk and liquidity risk. The Group\u2019s risk management principles are approved by the Board of Directors and the Group\u2019s financial department is responsible for the implementation of the principles. The Group\u2019s financial department identifies and assesses risks and acquires instruments needed to hedge against them. 21.2 Interest rate risk and currency risk The Group\u2019s interest rate risk arises from its loans from financial institutions issued at a floating rate. In 2025, the Group\u2019s average interest rate for loans from financial institutions has been 3.8 (4.9) percent. If the interests would have been one percentage point higher it would have caused an increase of EUR 1.5 (1.6) million in interest expenses during the year 2025. The Group does not apply hedge accounting according to IFRS 9. The Group\u2019s subsidiaries have the following open interest rate derivative contracts at the reporting date: \u2022 Interest rate swap agreements based on which the Group pays fixed 0.48, 2.29 and 2.12 percent interest rate and receives variable interest on EUR 50.0, 40.0 and 40.0 million loan capital. \u2022 Interest rate swap agreements based on which the Group pays variable interest rate and receives fixed interest on EUR 15.0 and 25.0 million loan capital. Besides Finland, the Group has operations in Sweden and to a minor extent in Estonia and is thereby exposed to currency risk arising from Swedish krona. As billing and purchasing of the Group companies is conducted in the local currency, the transaction risk exposure for Terveystalo is insignificant. During the year 2025, the Group incurred foreign exchange change of EUR -0.0 (-0.0) million. However, the group is exposed to exchange rate translation differences, which are booked in other comprehensive income that may be reclassified as profit or loss. 21.3 Credit risk The majority of the Group\u2019s incoming cash flows are payments from established institutions, public sector and companies with appropriate credit rating. However, the Group\u2019s trade receivables include credit risk. Credit risk is managed mainly by monitoring the customer\u2019s credit rating on a regular basis and by co-operating with collection agencies. In addition, the Group\u2019s customers include private people whose invoicing is primarily carried out in connection with the rendering of services The Group has no major customer specific risk concentrations and its credit risk is diversified. Credit risk is managed by monitoring the amount, maturity distribution and turnover of trade receivables. Credit risk is also monitored on a client by client basis. The Group\u2019s maximum credit risk is equal to the carrying amount of financial assets at the reporting date. The maturity distribution of the Group\u2019s trade receivables is disclosed in note 22. Trade and other receivables. 21.4 Refinancing risk and liquidity risk The Group aims to ensure sufficient liquidity through efficient cash management and adequate credit limits. Refinancing risk is managed through a balanced portfolio that includes loans with sufficiently long maturities. The Group aims to assess and monitor continuously the amount of funding required by business operations, in order to ensure sufficient liquidity to finance its operations, to repay maturing loans as well as to carry out investments and acquisitions of companies according to the growth strategy. The Group\u2019s cash and cash equivalents comprise cash in bank accounts, cash in hand and cash payments not yet recorded into the Group\u2019s bank accounts (cash in transit) at the reporting date. The Group manages liquidity risk by monitoring unused liquidity reserves and forecasting future cash flows. The Group has an overdraft facility and undrawn credit facilities, of which EUR 93.0 (93.0) million remained unused at the reporting date. The Group has EUR 381.1 million of bank loans and bonds. Uncertainty in financial markets may cause the cost of financing needed for the Group\u2019s business operations to rise or become more difficult to obtain. The Group may not necessarily obtain financing on competitive terms or at all, and it may not be able to fulfill its obligations according to the financing arrangements. The table below presents a contractual maturity analysis of financial liabilities. The cash flow figures are undiscounted and they include both interest payments and repayments of principals. Interest payments which are based on variable rates have been presented using variable rates as of the end of the reporting date. Maturity analysis of liquidity risk
31 Dec 2025
Carrying Contractual
EUR mill. amount
cash flows
1 year
1\u20132 years
2\u20135 years
Over 5 years
Loans from financial
institutions
281.6
292.3
51.5
218.0
22.7
-
Bonds
99.5
113.4
5.4
5.4
102.7
-
Lease liabilities
199.7
227.0
51.2
44.0
77.9
53.8
Trade payables
48.5
48.5
48.5
-
-
-
Total
629.3
681.1
156.6
267.4
203.3
53.8
31 Dec 2024
Carrying Contractual
EUR mill. amount
cash flows
1 year
1\u20132 years
2\u20135 years
Over 5 years
Loans from financial
institutions
278.8
274.9
15.4
18.6
240.9
-
Bonds
99.3
118.8
5.4
5.4
108.0
-
Lease liabilities
191.8
214.1
52.4
46.9
70.4
44.4
Hire purchase liabilities
0.0
0.0
0.0
0.0
-
-
Trade payables
55.6
55.6
55.6
-
-
-
Interest rate derivatives
0.3
-
-
-
-
-
Total
625.9
663.5
128.9
70.9
419.4
44.4
21.5 Capital management The objective of the Group\u2019s capital management is to support business operations and to ensure competitive operating conditions with optimal capital structure, as well as to enable the implementation of the strategy. In addition to operative cash flows, the capital structure is managed by potential share issues, acquisition of treasury shares by increasing or repayment of financial liabilities, possible conversions between equity and financial liabilities, as well as through operative decisions on investments and growth, and potential disposals of assets in order to reduce liabilities. The development of the Group\u2019s capital structure is monitored, amongst other things, with the following: change in net debt, ratio of net debt to operating margin, and the cash flow forecast. The Group\u2019s net debt to equity ratio (gearing) was 87.0 (92.1) percent at the reporting date. The ratio is calculated by dividing interest bearing net debt with equity. The net debt includes interest bearing liabilities less interest bearing receivables and cash and cash equivalents. The Group\u2019s interest bearing liabilities were EUR 583.7 (570.0) million at the reporting date. A significant part of the interest bearing liabilities consists of loans from financial institutions. The Group\u2019s loan agreements include a covenant, based on which creditors can demand an immediate repayment of the loans if a certain covenant limit is breached. The covenant relates to the ratio between EBITDA and net debt. The Group has met all covenant terms and conditions during the reporting period and at the reporting date.", "dimensions": { "concept": "ifrs-full:DisclosureOfFinancialRiskManagementExplanatory", "language": "en", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00/2026-01-01T00:00:00" } }, "fact-357": { "value": "
21.2 Interest rate risk and currency risk
The Group\u2019s interest rate risk arises from its loans from financial institutions issued at a floating rate. In 2025, the
Group\u2019s average interest rate for loans from financial institutions has been 3.8 (4.9) percent. If the interests would
have been one percentage point higher it would have caused an increase of EUR 1.5 (1.6) million in interest expenses
during the year 2025.
The Group does not apply hedge accounting according to IFRS 9. The Group\u2019s subsidiaries have the following
open interest rate derivative contracts at the reporting date:
\u2022 Interest rate swap agreements based on which the Group pays fixed 0.48, 2.29 and 2.12 percent interest rate and
receives variable interest on EUR 50.0, 40.0 and 40.0 million loan capital.
\u2022 Interest rate swap agreements based on which the Group pays variable interest rate and receives fixed interest
on EUR 15.0 and 25.0 million loan capital.
Besides Finland, the Group has operations in Sweden and to a minor extent in Estonia and is thereby exposed
to currency risk arising from Swedish krona. As billing and purchasing of the Group companies is conducted in
the local currency, the transaction risk exposure for Terveystalo is insignificant. During the year 2025, the Group
incurred foreign exchange change of EUR -0.0 (-0.0) million. However, the group is exposed to exchange rate
translation differences, which are booked in other comprehensive income that may be reclassified as profit or loss.
", "dimensions": { "concept": "ifrs-full:DisclosureOfDerivativeFinancialInstrumentsExplanatory", "language": "en", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00/2026-01-01T00:00:00" } }, "fact-358": { "value": "21.2 Interest rate risk and currency risk The Group\u2019s interest rate risk arises from its loans from financial institutions issued at a floating rate. In 2025, the Group\u2019s average interest rate for loans from financial institutions has been 3.8 (4.9) percent. If the interests would have been one percentage point higher it would have caused an increase of EUR 1.5 (1.6) million in interest expenses during the year 2025. The Group does not apply hedge accounting according to IFRS 9. The Group\u2019s subsidiaries have the following open interest rate derivative contracts at the reporting date: \u2022 Interest rate swap agreements based on which the Group pays fixed 0.48, 2.29 and 2.12 percent interest rate and receives variable interest on EUR 50.0, 40.0 and 40.0 million loan capital. \u2022 Interest rate swap agreements based on which the Group pays variable interest rate and receives fixed interest on EUR 15.0 and 25.0 million loan capital. Besides Finland, the Group has operations in Sweden and to a minor extent in Estonia and is thereby exposed to currency risk arising from Swedish krona. As billing and purchasing of the Group companies is conducted in the local currency, the transaction risk exposure for Terveystalo is insignificant. During the year 2025, the Group incurred foreign exchange change of EUR -0.0 (-0.0) million. However, the group is exposed to exchange rate translation differences, which are booked in other comprehensive income that may be reclassified as profit or loss. ", "dimensions": { "concept": "ifrs-full:DisclosureOfMarketRiskExplanatory", "language": "en", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00/2026-01-01T00:00:00" } }, "fact-359": { "value": "
21.3 Credit risk
The majority of the Group\u2019s incoming cash flows are payments from established institutions, public sector and
companies with appropriate credit rating. However, the Group\u2019s trade receivables include credit risk. Credit risk is
managed mainly by monitoring the customer\u2019s credit rating on a regular basis and by co-operating with collection
agencies. In addition, the Group\u2019s customers include private people whose invoicing is primarily carried out in
connection with the rendering of services .
The Group has no major customer specific risk concentrations and its credit risk is diversified. Credit risk is
managed by monitoring the amount, maturity distribution and turnover of trade receivables. Credit risk is also
monitored on a client by client basis.
The Group\u2019s maximum credit risk is equal to the carrying amount of financial assets at the reporting date. The
maturity distribution of the Group\u2019s trade receivables is disclosed in note 22. Trade and other receivables.
", "dimensions": { "concept": "ifrs-full:DisclosureOfCreditRiskExplanatory", "language": "en", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00/2026-01-01T00:00:00" } }, "fact-360": { "value": "
21.4 Refinancing risk and liquidity risk
The Group aims to ensure sufficient liquidity through efficient cash management and adequate credit limits.
Refinancing risk is managed through a balanced portfolio that includes loans with sufficiently long maturities. The
Group aims to assess and monitor continuously the amount of funding required by business operations, in order to
ensure sufficient liquidity to finance its operations, to repay maturing loans as well as to carry out investments and
acquisitions of companies according to the growth strategy.
The Group\u2019s cash and cash equivalents comprise cash in bank accounts, cash in hand and cash payments not yet
recorded into the Group\u2019s bank accounts (cash in transit) at the reporting date.
The Group manages liquidity risk by monitoring unused liquidity reserves and forecasting future cash flows.
The Group has an overdraft facility and undrawn credit facilities, of which EUR 93.0 (93.0) million remained
unused at the reporting date.
The Group has EUR 381.1 million of bank loans and bonds. Uncertainty in financial markets may cause the cost
of financing needed for the Group\u2019s business operations to rise or become more difficult to obtain. The Group
may not necessarily obtain financing on competitive terms or at all, and it may not be able to fulfill its obligations
according to the financing arrangements.
The table below presents a contractual maturity analysis of financial liabilities. The cash flow figures are
undiscounted and they include both interest payments and repayments of principals. Interest payments which are
based on variable rates have been presented using variable rates as of the end of the reporting date.
Maturity analysis of liquidity risk
31 Dec 2025
Carrying Contractual
EUR mill. amount
cash flows
1 year
1\u20132 years
2\u20135 years
Over 5 years
Loans from financial
institutions
281.6
292.3
51.5
218.0
22.7
-
Bonds
99.5
113.4
5.4
5.4
102.7
-
Lease liabilities
199.7
227.0
51.2
44.0
77.9
53.8
Trade payables
48.5
48.5
48.5
-
-
-
Total
629.3
681.1
156.6
267.4
203.3
53.8
31 Dec 2024
Carrying Contractual
EUR mill. amount
cash flows
1 year
1\u20132 years
2\u20135 years
Over 5 years
Loans from financial
institutions
278.8
274.9
15.4
18.6
240.9
-
Bonds
99.3
118.8
5.4
5.4
108.0
-
Lease liabilities
191.8
214.1
52.4
46.9
70.4
44.4
Hire purchase liabilities
0.0
0.0
0.0
0.0
-
-
Trade payables
55.6
55.6
55.6
-
-
-
Interest rate derivatives
0.3
-
-
-
-
-
Total
625.9
663.5
128.9
70.9
419.4
44.4
", "dimensions": { "concept": "ifrs-full:DisclosureOfLiquidityRiskExplanatory", "language": "en", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00/2026-01-01T00:00:00" } }, "fact-361": { "value": "
21.5 Capital management
The objective of the Group\u2019s capital management is to support business operations and to ensure competitive
operating conditions with optimal capital structure, as well as to enable the implementation of the strategy.
In addition to operative cash flows, the capital structure is managed by potential share issues, acquisition of
treasury shares by increasing or repayment of financial liabilities, possible conversions between equity and financial
liabilities, as well as through operative decisions on investments and growth, and potential disposals of assets in
order to reduce liabilities.
The development of the Group\u2019s capital structure is monitored, amongst other things, with the following: change
in net debt, ratio of net debt to operating margin, and the cash flow forecast.
The Group\u2019s net debt to equity ratio (gearing) was 87.0 (92.1) percent at the reporting date. The ratio is calculated
by dividing interest bearing net debt with equity. The net debt includes interest bearing liabilities less interest
bearing receivables and cash and cash equivalents. The Group\u2019s interest bearing liabilities were EUR 583.7 (570.0)
million at the reporting date. A significant part of the interest bearing liabilities consists of loans from financial
institutions.
The Group\u2019s loan agreements include a covenant, based on which creditors can demand an immediate
repayment of the loans if a certain covenant limit is breached. The covenant relates to the ratio between EBITDA
and net debt. The Group has met all covenant terms and conditions during the reporting period and at the
reporting date.
", "dimensions": { "concept": "ifrs-full:DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory", "language": "en", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00/2026-01-01T00:00:00" } }, "fact-362": { "value": "22. Trade and other receivables and contract assets
Carrying amounts of trade and other receivables and contract assets
EUR mill.
2025
2024
Non-current
Loan receivables
0.3
0.3
Total non-current receivables
0.3
0.3
Current
Trade receivables
96.9
109.6
Other receivables
2.7
1.9
Prepaid expenses
14.8
12.2
Derivative assets
3.8
3.4
Contract assets
6.1
7.9
Total
124.2
135.0
Specification of prepaid expenses
EUR mill.
2025
2024
Personnel related prepaid expenses
0.2
0.2
Prepayments
11.3
8.0
Other prepaid expenses
3.3
4.1
Total
14.8
12.2
During the reporting period, the Group has recognised final credit losses and expected credit losses on trade receivables and contract assets through the statement of income totaling EUR 1.7 (1.9) million. Impairment loss provision is based on a simplified approach. Estimated impairment loss rates have been calculated using historical information of actual impairment losses, and the current conditions and the Group\u2019s view of the economic conditions over the expected lives of the receivables have been taken into account. Based on the Group\u2019s view, the carrying amount of trade receivables corresponds to the maximum credit risk if the contractual parties are unable to meet their obligations related to trade receivables. The fair value of other receivables and prepaid expenses corresponds with their carrying amount.
Ageing of trade receivables and recognised credit losses
Trade receivables Recognised
2025 and contract Expected credit expected credit
EUR mill. assets total loss
loss
Carrying amount
Contract assets
6.1
-0.0%
-0.0
6.1
Not past due
86.6
-0.1%
-0.1
86.6
Past due
Less than 30 days
6.5
-0.5%
-0.0
6.4
31\u201390 days
2.7
-1.5%
-0.0
2.6
91\u2013180 days
0.8
-6.7%
-0.1
0.7
Over 180 days
2.0
-74.5%
-1.5
0.5
Total
104.7
-1.7
103.0
Information about credit risk related to trade receivables is stated in note 21. Financial risks
Ageing of trade receivables and recognised credit losses
Recognised
2024 Trade receivables Expected credit expected credit
EUR mill. total loss
loss
Carrying amount
Contract assets
7.9
-0.0%
-0.0
7.9
Not past due
97.4
-0.1%
-0.1
97.3
Past due
Less than 30 days
7.4
-0.5%
-0.0
7.4
31\u201390 days
1.8
-1.3%
-0.0
1.8
91\u2013180 days
2.6
-9.4%
-0.2
2.3
Over 180 days
2.3
-68.9%
-1.6
0.7
Total
119.5
-1.9
117.5
Information about credit risk related to trade receivables is stated in note 21. Financial risks", "dimensions": { "concept": "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory", "language": "en", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00/2026-01-01T00:00:00" } }, "fact-363": { "value": "During the reporting period, the Group has recognised final credit losses and expected credit losses on trade receivables and contract assets through the statement of income totaling EUR 1.7 (1.9) million. Impairment loss provision is based on a simplified approach. Estimated impairment loss rates have been calculated using historical information of actual impairment losses, and the current conditions and the Group\u2019s view of the economic conditions over the expected lives of the receivables have been taken into account. Based on the Group\u2019s view, the carrying amount of trade receivables corresponds to the maximum credit risk if the contractual parties are unable to meet their obligations related to trade receivables. The fair value of other receivables and prepaid expenses corresponds with their carrying amount.
Ageing of trade receivables and recognised credit losses
Trade receivables Recognised
2025 and contract Expected credit expected credit
EUR mill. assets total loss
loss
Carrying amount
Contract assets
6.1
-0.0%
-0.0
6.1
Not past due
86.6
-0.1%
-0.1
86.6
Past due
Less than 30 days
6.5
-0.5%
-0.0
6.4
31\u201390 days
2.7
-1.5%
-0.0
2.6
91\u2013180 days
0.8
-6.7%
-0.1
0.7
Over 180 days
2.0
-74.5%
-1.5
0.5
Total
104.7
-1.7
103.0
Information about credit risk related to trade receivables is stated in note 21. Financial risks
Ageing of trade receivables and recognised credit losses
Recognised
2024 Trade receivables Expected credit expected credit
EUR mill. total loss
loss
Carrying amount
Contract assets
7.9
-0.0%
-0.0
7.9
Not past due
97.4
-0.1%
-0.1
97.3
Past due
Less than 30 days
7.4
-0.5%
-0.0
7.4
31\u201390 days
1.8
-1.3%
-0.0
1.8
91\u2013180 days
2.6
-9.4%
-0.2
2.3
Over 180 days
2.3
-68.9%
-1.6
0.7
Total
119.5
-1.9
117.5
Information about credit risk related to trade receivables is stated in note 21. Financial risks.
", "dimensions": { "concept": "ifrs-full:DisclosureOfAllowanceForCreditLossesExplanatory", "language": "en", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00/2026-01-01T00:00:00" } }, "fact-365": { "value": "23. Cash and cash equivalents The Group\u2019s cash and cash equivalents on 31 December 2025, amounting to EUR 75.2 (65.2) million consist of cash in hand and bank as well as cash payments on the bank settlement account at the reporting date. The carrying amounts in the statement of financial position correspond to the maximum amount of credit risk if the contractual parties are unable to meet their obligations. However, no significant counterparty risks are associated with cash and cash equivalents. The fair value of cash and cash equivalents correspond to their carrying amounts.", "dimensions": { "concept": "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory", "language": "en", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00/2026-01-01T00:00:00" } }, "fact-366": { "value": "
24. Share capital and invested non-restricted equity reserve
Invested
Number of Number non-
outstanding of treasury Number of restricted
shares, shares, shares total, Share equity Treasury
EUR mill. 1,000 pcs 1,000 pcs 1,000 pcs capital reserve
shares
Total
1 Jan 2024
126,556
480
127,037
0.1
492.8
-15.7
477.2
Acquisition of treasury shares
49
-49
-
-
-
0.4
0.4
Cancellation of treasury
shares
-
-
-
-
-
-
-
31 Dec 2024
126,605
432
127,037
0.1
492.8
-15.2
477.6
1 Jan 2025
126,605
432
127,037
0.1
492.8
-15.2
477.6
Acquisition of treasury shares
50
-50
-
-
-
0.5
0.5
Cancellation of treasury
shares
-
-
-
-
-
-
-
31 Dec 2025
126,655
381
127,037
0.1
492.8
-14.8
478.1
Shares and share capital On 31 December 2025, the number of shares is 127,036,531 of which the number of outstanding shares is 126,655,143 and number of treasury shares is 381,388. The Company has a single share class. The shares have no nominal value. All shares issued have been paid in full. Each share has one vote at the Annual General Meeting and equal rights to dividends and other distribution of assets. Terveystalo Plc\u2019s share is listed on Nasdaq Helsinki Oy. The trading code is TTALO. Terveystalo Plc\u2019s shares belong to the book-entry system maintained by Euroclear Finland Oy", "dimensions": { "concept": "ifrs-full:DisclosureOfTreasurySharesExplanatory", "language": "en", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00/2026-01-01T00:00:00" } }, "fact-367": { "value": "24. Share capital and invested non-restricted equity reserve
Invested
Number of Number non-
outstanding of treasury Number of restricted
shares, shares, shares total, Share equity Treasury
EUR mill. 1,000 pcs 1,000 pcs 1,000 pcs capital reserve
shares
Total
1 Jan 2024
126,556
480
127,037
0.1
492.8
-15.7
477.2
Acquisition of treasury shares
49
-49
-
-
-
0.4
0.4
Cancellation of treasury
shares
-
-
-
-
-
-
-
31 Dec 2024
126,605
432
127,037
0.1
492.8
-15.2
477.6
1 Jan 2025
126,605
432
127,037
0.1
492.8
-15.2
477.6
Acquisition of treasury shares
50
-50
-
-
-
0.5
0.5
Cancellation of treasury
shares
-
-
-
-
-
-
-
31 Dec 2025
126,655
381
127,037
0.1
492.8
-14.8
478.1
Shares and share capital On 31 December 2025, the number of shares is 127,036,531 of which the number of outstanding shares is 126,655,143 and number of treasury shares is 381,388. The Company has a single share class. The shares have no nominal value. All shares issued have been paid in full. Each share has one vote at the Annual General Meeting and equal rights to dividends and other distribution of assets. Terveystalo Plc\u2019s share is listed on Nasdaq Helsinki Oy. The trading code is TTALO. Terveystalo Plc\u2019s shares belong to the book-entry system maintained by Euroclear Finland Oy. Invested non restricted equity reserve Invested non restricted equity reserve consists of other investments similar to equity and the subscription price of shares to the extent that it has not been recorded in share capital according to specific resolution. According to the current Finnish Companies Act, subscription price of new shares is recognised in the share capital, unless it has not been according to Issuance Resolution fully or partly recognised in invested non-restricted equity reserve Distributable funds On 31 December 2025, the distributable funds of the parent company totalled EUR 582.1 million including the profit of the financial period 2025 of EUR 83.9 million. The Board of Directors proposes to the Annual General Meeting that a dividend of EUR 0.64 (0. 48) per share totalling EUR 81. 1 (60.8) million be paid based on the statement of financial position adopted for the financial year ended on 31 December 2025. The dividend would be paid in two instalments as follows: \u2022 The first dividend installment of EUR 0.32 per share would be paid to the shareholders who are registered in the shareholders' register of the Company maintained by Euroclear Finland Ltd, on the record date of the first dividend installment on 26 March 2026. The Board of Directors proposes that the first dividend installment would be paid on 8 April 2026. \u2022 The second dividend installment of EUR 0.32 per share would be paid to shareholders who are registered in the shareholders' register of the Company maintained by Euroclear Finland Ltd, on the record date of the second dividend installment on 8 October 2026. The Board of Directors proposes that the second dividend installment would be paid on 15 October 2026. The Board of Directors also proposes that the Annual General Meeting would authorise the Board of Directors to resolve, if necessary, on a new record date and date of payment for the second dividend installment should the rules of Euroclear Finland Ltd or statutes applicable to the Finnish book-entry system change or otherwise so require. The dividend proposed by the Board of Directors to the Annual General Meeting is not deducted from distributable equity until approved by the Annual General Meeting of Shareholders. No material changes have taken place in the company\u2019s financial position since the end of the financial year. The liquidity of the company is good and the proposed allocation of funds, in the view of the Board of Directors, does not endanger the company's solvency.", "dimensions": { "concept": "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "language": "en", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00/2026-01-01T00:00:00" } }, "fact-368": { "value": "
Invested non restricted equity reserve
Invested non restricted equity reserve consists of other investments similar to equity and the subscription price of shares to the extent that it has not been recorded in share capital according to specific resolution. According to the current Finnish Companies Act, subscription price of new shares is recognised in the share capital, unless it has not been according to Issuance Resolution fully or partly recognised in invested non-restricted equity reserve ", "dimensions": { "concept": "ifrs-full:DisclosureOfReservesAndOtherEquityInterestExplanatory", "language": "en", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00/2026-01-01T00:00:00" } }, "fact-369": { "value": "Distributable funds On 31 December 2025, the distributable funds of the parent company totalled EUR 582.1 million including the profit of the financial period 2025 of EUR 83.9 million. The Board of Directors proposes to the Annual General Meeting that a dividend of EUR 0.64 (0. 48) per share totalling EUR 81. 1 (60.8) million be paid based on the statement of financial position adopted for the financial year ended on 31 December 2025. The dividend would be paid in two instalments as follows: \u2022 The first dividend installment of EUR 0.32 per share would be paid to the shareholders who are registered in the shareholders' register of the Company maintained by Euroclear Finland Ltd, on the record date of the first dividend installment on 26 March 2026. The Board of Directors proposes that the first dividend installment would be paid on 8 April 2026. \u2022 The second dividend installment of EUR 0.32 per share would be paid to shareholders who are registered in the shareholders' register of the Company maintained by Euroclear Finland Ltd, on the record date of the second dividend installment on 8 October 2026. The Board of Directors proposes that the second dividend installment would be paid on 15 October 2026. The Board of Directors also proposes that the Annual General Meeting would authorise the Board of Directors to resolve, if necessary, on a new record date and date of payment for the second dividend installment should the rules of Euroclear Finland Ltd or statutes applicable to the Finnish book-entry system change or otherwise so require. The dividend proposed by the Board of Directors to the Annual General Meeting is not deducted from distributable equity until approved by the Annual General Meeting of Shareholders. No material changes have taken place in the company\u2019s financial position since the end of the financial year. The liquidity of the company is good and the proposed allocation of funds, in the view of the Board of Directors, does not endanger the company's solvency", "dimensions": { "concept": "ifrs-full:DisclosureOfDividendsExplanatory", "language": "en", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00/2026-01-01T00:00:00" } }, "fact-370": { "value": "0.64", "decimals": 2, "dimensions": { "concept": "ifrs-full:DividendsProposedOrDeclaredBeforeFinancialStatementsAuthorisedForIssueButNotRecognisedAsDistributionToOwnersPerShare", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00/2026-01-01T00:00:00", "unit": "iso4217:EUR/xbrli:shares" } }, "fact-371": { "value": "0.48", "decimals": 2, "dimensions": { "concept": "ifrs-full:DividendsRecognisedAsDistributionsToOwnersPerShare", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00/2026-01-01T00:00:00", "unit": "iso4217:EUR/xbrli:shares" } }, "fact-372": { "value": "81100000.0", "decimals": -5, "dimensions": { "concept": "ifrs-full:DividendsProposedOrDeclaredBeforeFinancialStatementsAuthorisedForIssueButNotRecognisedAsDistributionToOwners", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00/2026-01-01T00:00:00", "unit": "iso4217:EUR" } }, "fact-373": { "value": "25. Financial liabilities
Non-cash changes
Business Translation
EUR mill.
1 Jan 2025
Cash flows
combinations
Other changes
differences
31 Dec 2025
Loans from financial
institutions
278.8
2.5
-
0.3
-
281.6
Bonds
99.3
-
-
0.2
-
99.5
Hire purchase liabilities
0.0
-0.0
-
-
-
-
Lease liabilities
191.8
-48.8
0.1
56.7
-0.3
199.7
Total
569.9
-46.3
0.1
57.2
-0.3
580.8
Non-cash changes
Business Translation
EUR mill.
1 Jan 2025
Cash flows
combinations
Other changes
differences
31 Dec 2024
Loans from financial
institutions
313.8
-35.3
0.1
0.1
-
278.8
Bonds
99.1
-
-
0.2
-
99.3
Hire purchase liabilities
3.8
-3.8
-
-
-
0.0
Lease liabilities
219.1
-53.6
1.2
25.0
0.0
191.8
Total
635.7
-92.6
1.3
25.4
0.0
569.9
The Group\u2019s loan agreements include a covenant, based on which creditors can demand an immediate repayment of the loans if a certain covenant limit is breached. The covenant relates to the ratio between EBITDA and net debt. The Group has met all covenant terms and conditions during the reporting period and at the reporting date.", "dimensions": { "concept": "ifrs-full:DisclosureOfFinancialLiabilitiesExplanatory", "language": "en", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00/2026-01-01T00:00:00" } }, "fact-374": { "value": "
26. Trade and other payables
Carrying amounts of trade and other payables
EUR mill.
2025
2024
Trade payables
47.1
55.6
Other payables
84.8
82.3
Contract liabilities
6.6
7.0
Derivative liabilities
0.4
0.3
Accrued expenses
73.6
85.1
Total
212.4
230.3
Specification of other payables
EUR mill.
2025
2024
Doctor's fee liabilities
45.6
50.1
VAT liabilities
27.0
23.0
Other
12.1
9.1
Total
84.8
82.3
Specification of accrued expenses
EUR mill.
2025
2024
Personnel-related accrued expenses
64.1
74.6
Interest liabilities
4.2
4.8
Other
5.3
5.6
Total
73.6
85.1
", "dimensions": { "concept": "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory", "language": "en", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00/2026-01-01T00:00:00" } }, "fact-375": { "value": "26. Trade and other payables
Carrying amounts of trade and other payables
EUR mill.
2025
2024
Trade payables
47.1
55.6
Other payables
84.8
82.3
Contract liabilities
6.6
7.0
Derivative liabilities
0.4
0.3
Accrued expenses
73.6
85.1
Total
212.4
230.3
Specification of other payables
EUR mill.
2025
2024
Doctor's fee liabilities
45.6
50.1
VAT liabilities
27.0
23.0
Other
12.1
9.1
Total
84.8
82.3
Specification of accrued expenses
EUR mill.
2025
2024
Personnel-related accrued expenses
64.1
74.6
Interest liabilities
4.2
4.8
Other
5.3
5.6
Total
73.6
85.1
", "dimensions": { "concept": "ifrs-full:DisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatory", "language": "en", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00/2026-01-01T00:00:00" } }, "fact-376": { "value": "27. Provisions
Carrying amounts of provisions
EUR mill.
2025
2024
Non-current provisions
1.6
3.3
Current provisions
3.1
2.9
Total
4.8
6.2
EUR mill.
2025
2024
Onerous contracts
1.6
3.1
Other provisions
3.2
3.1
Total
4.8
6.2
Changes in provisions during the financial year 2025
Onerous
EUR mill.
contracts
Other provisions
Total
1 Jan 2025
3.1
3.1
6.2
Increase in provisions
0.0
0.8
0.8
Used provisions
-1.5
-0.5
-2.0
Transfer to liabilities directly associated with assets held for sale
-
-0.2
-0.2
31 Dec 2025
1.6
3.2
4.8
Changes in provisions during the financial year 2024
Onerous
EUR mill.
contracts
Other provisions
Total
1 Jan 2024
4.1
2.0
6.1
Increase in provisions
0.0
2.7
2.7
Used provisions
-1.1
-1.6
-2.7
31 Dec 2024
3.1
3.1
6.2
", "dimensions": { "concept": "ifrs-full:DisclosureOfProvisionsExplanatory", "language": "en", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00/2026-01-01T00:00:00" } }, "fact-377": { "value": "
28. Defined benefit plans
The Group has defined benefit plans in Sweden in the Feelgood subgroup. These consists of PSA and PA-KL plans
which are closed and for which all the participants have either retired or left the Group. There are no assets related
to the Group\u2019s defined benefit plans. The defined benefit plans determine the amount of pension to be paid and the
benefits to be paid for disability and at termination of employment. The benefits in these plans are usually based
on the length of employment and the level of final salary. The weighted average duration of the defined benefit
obligations was seven years at the reporting date.
Summary of the impact of the defined benefit plans in the financial statements
EUR mill.
2025
2024
Present value of the defined benefit obligations
1.2
1.3
Expenses related to defined benefit plans
-0.0
0.0
Remeasurements of defined benefit obligations
-0.0
0.1
Reconciliation of the defined benefit obligation
EUR mill.
2025
2024
1 Jan
1.3
1.3
Interest expense (+) / income (-)
0.0
0.1
Benefits paid
-0.1
-0.1
Remeasurement of the obligation
Actuarial gain (-) / loss (+) from change in financial assumptions
-0.0
0.1
Translation differences
0.1
-0.0
31 Dec
1.2
1.3
Applied actuarial assumptions
%
2025
2024
Discount rate
3.40
2.70
Inflation
1.70
1.80
The discount rate is determined based on the yield of Swedish housing market bonds which have a length that approximates the Group\u2019s pension obligations. Sensitivity analysis of the relevant actuarial assumptions\u2019 impact on defined benefit obligation
EUR mill.
2025
2024
0.5%-point increase in the principal assumption
Discount rate
-0.1
-0.0
Inflation
0.1
0.0
0.5%-point decrease in the principal assumption
Discount rate
0.2
0.0
Inflation
-0.2
-0.0
An external actuary has performed the sensitivity analysis for one variable at a time while holding all other variables constant and regardless of the actual volatility of the given variable. Consequently, the purpose of the analysis is not to quantify the expected change in the defined benefit obligation but to illustrate the sensitivity of the value of the obligation to these variables", "dimensions": { "concept": "ifrs-full:DisclosureOfDefinedBenefitPlansExplanatory", "language": "en", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00/2026-01-01T00:00:00" } }, "fact-379": { "value": "
29. Collateral and contingent liabilities
EUR mill.
31 Dec 2025
31 Dec 2024
Business mortgages
0.7
0.7
Real estate mortgages
-
0.2
Total
0.7
0.9
Securities for own debts
Deposits
0.1
0.2
Guarantees
0.4
0.1
Total
0.5
0.3
", "dimensions": { "concept": "ifrs-full:DisclosureOfContingentLiabilitiesExplanatory", "language": "en", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00/2026-01-01T00:00:00" } }, "fact-380": { "value": "29. Collateral and contingent liabilities
EUR mill.
31 Dec 2025
31 Dec 2024
Business mortgages
0.7
0.7
Real estate mortgages
-
0.2
Total
0.7
0.9
Securities for own debts
Deposits
0.1
0.2
Guarantees
0.4
0.1
Total
0.5
0.3
", "dimensions": { "concept": "ifrs-full:DisclosureOfCollateralExplanatory", "language": "en", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00/2026-01-01T00:00:00" } }, "fact-381": { "value": "29. Collateral and contingent liabilities
EUR mill.
31 Dec 2025
31 Dec 2024
Business mortgages
0.7
0.7
Real estate mortgages
-
0.2
Total
0.7
0.9
Securities for own debts
Deposits
0.1
0.2
Guarantees
0.4
0.1
Total
0.5
0.3
As part of the regular development and maintenance of the network of clinics and hospitals, the Group continuously enters into lease agreements related to operational activities. The lease term lengths vary from one year to 20 years. The transfer of lease management may occur in the future, at which point the lease liability is recorded at the moment of the transfer of management. 23 December 2025 Terveystalo signed an agreement to acquire Hohde Group, consisting of Hammas Hohde Oy dental clinics and Loisto Laboratoriot Oy dental laboratories. The arrangement is expected to be completed in 2026. The debt-free purchase price is approximately EUR 88 million.", "dimensions": { "concept": "ifrs-full:DisclosureOfCommitmentsExplanatory", "language": "en", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00/2026-01-01T00:00:00" } }, "fact-382": { "value": "
30. Related party transactions
Group\u2019s related parties
The Group\u2019s related parties include the parent company as well as subsidiaries and associated companies. In
addition, related parties also include the members of the Board of Directors, Group management and the CEO, as
well as their close family members and entities in which they have control or joint control.
The relationships of the parent company and the subsidiaries are disclosed in note 31. Group companies.
Related party transactions
2025
Sales
Purchases
Receivables
Payables
Associated companies
0.4
4.4
0.0
0.4
Joint ventures
0.2
0.4
0.2
0.1
Total
0.6
4.8
0.2
0.5
2024 Sales Purchases Receivables Payables Associated companies 0.5 6.1 0.2 0.4 Total 0.5 6.1 0.2 0.4 Compensation for the key management Remuneration to the CEO, in thousands of euro 2025 2024 Fixed pay 472.0 438.2 Other benefits 12.0 13.8 Short-term incentives 413.3 577.7 Share-based payments 327.5 336.2 Pensions (statutory) 147.4 169.1 Total 1,372.2 1,535.0 Renumeration to the CEO is presented on an accrual basis
Remuneration to the members of the Executive team
(excluding CEO), in thousands of euro
2025
2024
Fixed pay
1,582.7
1,568.1
Other benefits
53.2
40.6
Short-term incentives
435.0
700.5
Share-based payments
363.5
308.3
Termination benefits
44.0
36.0
Pensions (statutory)
344.8
384.4
Total
2,823.2
3,037.9
Renumeration to the members of the Executive team is presented on an accrual basis.
2025
2024
Remuneration to the Annual fee Annual fee Other Annual fee Annual fee Other
Board of Directors, in settled in settled in Meeting financial settled in settled in Meeting financial
thousands of euro cash shares fees benefits* cash shares fees benefits*
Kauniskangas Kari
(Chairman of the
board)
55.1
36.7
18.9
0.6
54.0
36.0
15.8
0.5
Pullola Kristian
32.4
21.6
13.0
0.3
31.8
21.2
10.7
0.3
Rosenberg Matts
32.4
21.6
13.0
0.3
31.8
21.2
10.7
0.3
Lemne Carola
25.9
17.2
15.3
0.3
25.4
16.9
14.5
0.3
Lehtoranta Ari
25.9
17.2
13.0
0.3
25.4
16.9
10.1
0.3
Hasselberg Sofia
25.9
17.2
20.3
0.3
25.4
16.9
17.2
0.3
Saraj\u00e4rvi Teija
25.9
17.2
13.0
0.3
25.4
16.9
8.1
0.3
Member of the Board of Directors until 26 March 2024
Viippola Katri
-
-
-
-
-
-
2.0
-
Total
223.3
148.9
106.4
2.2
219.2
146.0
89.0
2.2
* Other financial benefits include transfer tax fees for the annual fees paid in shares
Bonus scheme
The Company operates a bonus scheme, which is determined by the Board of Directors of the Company upon the
recommendation of the Remuneration Committee. The CEO and the members of the Executive Team are eligible
to participate in the bonus scheme in accordance with the Company\u2019s bonus policy. Annual bonuses are payable
based on the attainment of key performance targets of the Company. The key performance targets of the CEO and
the Executive Team are based on the Company\u2019s adjusted EBITA as well as the individual business and performance
targets. The individual business and performance targets are set by the manager of the participant in the bonus
scheme.
The Board of Directors of Terveystalo Plc has resolved on share-based incentive plans directed to the Group\u2019s key
employees. More information on the share-based incentive plans is presented in note 19. Share-based payments.
Management holdings
Name
Position
31 Dec 2025
Kari Kauniskangas
Chairman of the Board of Directors
29,285
Matts Rosenberg
Member of the Board of Directors
18,902
Carola Lemne
Member of the Board of Directors
11,640
Kristian Pullola
Member of the Board of Directors
12,611
Ari Lehtoranta
Member of the Board of Directors
10,018
Sofia Hasselberg
Member of the Board of Directors
6,013
Teija Saraj\u00e4rvi
Member of the Board of Directors
3,514
Ville Iho
President and CEO
33,183
Juuso Pajunen
Chief Financial Officer
24,269
Petteri Lankinen
Chief Medical Officer
-
Laura Karotie
Senior Vice President, Corporate Health
-
Henri M\u00e4enalanen
Executive Vice President, Portfolio Businesses
4,444
Stefan Kullgren
Executive Vice President, Swedish Business Area
10,000
Ilari Richard
Senior Vice President, Digital Services
6,337
Minttu Sinisalo
Senior Vice President, Human Resources
5,627
Petra Gr\u00e4sbeck
Senior Vice President, Communications and Public Affairs
175
", "dimensions": { "concept": "ifrs-full:DisclosureOfRelatedPartyExplanatory", "language": "en", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00/2026-01-01T00:00:00" } }, "fact-383": { "value": "
Management holdings
Name
Position
31 Dec 2025
Kari Kauniskangas
Chairman of the Board of Directors
29,285
Matts Rosenberg
Member of the Board of Directors
18,902
Carola Lemne
Member of the Board of Directors
11,640
Kristian Pullola
Member of the Board of Directors
12,611
Ari Lehtoranta
Member of the Board of Directors
10,018
Sofia Hasselberg
Member of the Board of Directors
6,013
Teija Saraj\u00e4rvi
Member of the Board of Directors
3,514
Ville Iho
President and CEO
33,183
Juuso Pajunen
Chief Financial Officer
24,269
Petteri Lankinen
Chief Medical Officer
-
Laura Karotie
Senior Vice President, Corporate Health
-
Henri M\u00e4enalanen
Executive Vice President, Portfolio Businesses
4,444
Stefan Kullgren
Executive Vice President, Swedish Business Area
10,000
Ilari Richard
Senior Vice President, Digital Services
6,337
Minttu Sinisalo
Senior Vice President, Human Resources
5,627
Petra Gr\u00e4sbeck
Senior Vice President, Communications and Public Affairs
175
", "dimensions": { "concept": "ifrs-full:DisclosureOfInformationAboutKeyManagementPersonnelExplanatory", "language": "en", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00/2026-01-01T00:00:00" } }, "fact-384": { "value": "31. Group companies The Group\u2019s parent company is Terveystalo Plc domiciled in Finland.
Subsidiaries as at 31 December 2025
Company name
Domicile
Group's share
Group's voting rights
Cityl\u00e4karna Mariehamn AB
Finland
100.0%
100.0%
Clarah\u00e4lsan AB
Sweden
100.0%
100.0%
EAM TTALO Holding Oy*
Finland
0.0%
0.0%
Feelgood F\u00f6retagsh\u00e4lsa Dalarna AB
Sweden
100.0%
100.0%
Feelgood F\u00f6retagsh\u00e4lsov\u00e5rd AB
Sweden
100.0%
100.0%
Feelgood H\u00e4lsoforum AB
Sweden
100.0%
100.0%
Feelgood Sjukv\u00e5rd AB
Sweden
100.0%
100.0%
Feelgood Svenska AB
Sweden
100.0%
100.0%
Idavallen AB
Sweden
100.0%
100.0%
L\u00e4nsh\u00e4lsan Sk\u00e5ne AB
Sweden
100.0%
100.0%
Medimar Scandinavia AB
Finland
100.0%
100.0%
N\u00e4mndemansg\u00e5rden i Sverige AB
Sweden
100.0%
100.0%
Rela-hierojat Oy
Finland
100.0%
100.0%
Sauma Lastensuojelupalvelut Oy
Finland
100.0%
100.0%
Silm\u00e4sairaala Pilke Oy
Finland
100.0%
100.0%
Suomen Hierojakoulut Oy
Finland
100.0%
100.0%
Suomen Terveystalo Oy
Finland
100.0%
100.0%
Terveystalo Estonia O\u00dc
Estonia
100.0%
100.0%
Terveystalo Healthcare Holding Oy
Finland
100.0%
100.0%
Terveystalo Healthcare Oy
Finland
100.0%
100.0%
Terveystalo Julkiset palvelut Oy
Finland
100.0%
100.0%
Company name
Domicile
Group's share
Group's voting rights
Terveystalo Kuntaturva Oy
Finland
100.0%
100.0%
Terveystalo Tactus Oy
Finland
100.0%
100.0%
TT \u00c5lands Tandl\u00e4karna AB
Finland
100.0%
100.0%
Turun Silm\u00e4laser Oy
Finland
100.0%
100.0%
* Evli Asset Management holds the ownership and voting rights of EAM TTALO Holding Oy by legal terms, but according to the agreement, Terveystalo has control over the company and acts as the principal, whereas EAM is an agent through the holding company. Based on this control arising from contractual terms, the holding company is consolidated into the Group's IFRS financial statements as a structured entity. Changes in the Group structure Financial year 2025 The following mergers took place during the financial year 2025: \u2022 1 Feb 2025 Feelgood Alna Sverige AB merged with Feelgood F\u00f6retagsh\u00e4lsov\u00e5rd AB. \u2022 1 Apr 2025 Feelgood L\u00e4nsh\u00e4lsan AB merged with Feelgood F\u00f6retagsh\u00e4lsov\u00e5rd AB. \u2022 31 Oct 2025 Veikkolan hammasl\u00e4\u00e4k\u00e4riasema Oy merged with Suomen Terveystalo Oy. \u2022 30 Nov 2025 Recuror Oy merged with Suomen Terveystalo Oy. Financial year 2024 The following mergers took place during the financial year 2024: \u2022 31 Dec 2024 Kajaanin Radiologikeskus Oy merged with Suomen Radiologikeskus Oy. \u2022 31 Dec 2024 Suomen Radiologikeskus Oy merged with SRK Group Oy. \u2022 31 Dec 2024 IRad Oy merged with SRK Group Oy. \u2022 31 Dec 2024 SRK Group Oy merged with Terveystalo Julkiset Palvelut Oy", "dimensions": { "concept": "ifrs-full:DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory", "language": "en", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00/2026-01-01T00:00:00" } }, "fact-385": { "value": "32. Assets held for sale On 19 December 2025, Terveystalo signed an agreement to sell child welfare services business (Sauma Lastensuojelupalvelut Oy) to Validia Oy. As of the balance sheet date on 31 December 2025, the sale of the child welfare services business has met the classification criteria of IFRS 5 and consequently Terveystalo classifies the assets and liabilities of the child welfare services business as assets held for sale. At the same time, the net assets of the business have been valued to reflect the fair value less costs to sell. As a result of the revaluation, an impairment of EUR 4.1 million was recorded against the goodwill allocated to child welfare services business. The child welfare services business has been reported as part of the Portfolio Businesses segment, to which the assets held for sale and liabilities belonged. The assets and liabilities of the child welfare services business are classified as held for sale and presented separately in the consolidated balance sheet. Their carrying values are as follows: Goodwill EUR 4.9 million, non-current assets EUR 3.7 million, current assets EUR 1.5 million, non-current liabilities EUR 2.4 million, and current liabilities EUR 2.1 million. The completion of the transaction was conditional upon approval from the Finnish Competition and Consumer Authority, which was obtained in January 2026. The transaction has been completed after the reporting period.", "dimensions": { "concept": "ifrs-full:DisclosureOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleExplanatory", "language": "en", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00/2026-01-01T00:00:00" } }, "fact-386": { "value": "33. Subsequent events Terveystalo Plc's Board of Directors has approved a new performance period covering years 2026\u20132028 of the long-term share-based incentive plan for key personnel Terveystalo Plc's Board of Directors has approved a new performance period covering the years 2026\u20132028 of the long-term share-based incentive plan for key personnel. The purpose of the programme is to align the objectives of shareholders and key personnel to increase the company's value in the long term, and to commit key personnel to implementing Terveystalo's strategy by offering them a competitive, share-based incentive programme. The Performance Share Plan is based on a rolling 3-year performance period structure, with a new performance period starting at the beginning of each year if so decided by the Board. The Board decides on the participants, performance measures, and targets as well as earning opportunities on an annual basis. Terveystalo published the establishment of the program and its main terms in a stock exchange release on 3 December 2020. Performance Period 2026\u20132028 of the Performance Share Plan (PSP) During the performance period 2026\u20132028, the participants are awarded for successful shareholder value creation. The performance indicators based on which share rewards may be paid to 90 percent of the participants are absolute and relative (compared to the OMX HKI benchmark CAP GI index) Total Shareholder Return. For 10 percent of the participants, the value creation is measured by EBITA (adjusted earnings before interest, taxes, and amortization) of the business area that they lead. Terveystalo's Board of Directors confirms the total amount of shares earned after the end of the performance period. The share rewards that may be paid based on the 2026\u20132028 earning period will be paid in Terveystalo Plc shares after the end of the performance period, provided that the performance targets set for the programme by the Board are achieved. The maximum number of shares to be paid based on this plan is 740,000 shares. Taxes and tax-like payments to the recipient are deducted from the reward, after which the remaining net amount is paid to the participants in shares. No more than approximately 90 people selected by the Board are eligible to participate in the programme, including members of Terveystalo's Executive Team. Terveystalo applies a share ownership requirement to the members of the Executive Team. Each member of the Executive Team is expected to retain at least 50 percent of the net shares received under the long-term incentive plan until his or her shareholding in Terveystalo is at least equal to his or her annual gross base salary. Performance Period 2026\u20132028 of the Restricted Share Plan (RSP) The purpose of the Restricted Share Plan is to function as a supplementary structure for separately selected key personnel of Terveystalo in special situations. The share rewards will be paid in Terveystalo Plc shares after the end of the performance period, provided that the individual participants are still employed by Terveystalo. The maximum number of shares to be paid based on this plan is 74,000 shares. Hilppa Rautpalo appointed Terveystalo's SVP, Human Resources and member of the Group Management Team Hilppa Rautpalo, Master of Laws (trained at the bench), born in 1974, has been appointed Senior Vice President of Human Resources and a member of the Group's Management Team. She will start in the position no later than 14 August 2026. Hilppa Rautpalo will report to President and CEO Ville Iho.", "dimensions": { "concept": "ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory", "language": "en", "entity": "scheme:7437001AEZHLL3UEX093", "period": "2025-01-01T00:00:00/2026-01-01T00:00:00" } } } }